



Appendix 4E

Preliminary final report

Lodged with the Australian Securities Exchange (ASX) under ASX Listing Rule 4.3A.

Sigma Healthcare Limited ABN 15 088 417 403

Reporting period

Year ended 30 June 2025

Comparative period

Year ended 30 June 2024

Impact of Merger on the presentation of results and financial report

On 12 February 2025, Sigma Healthcare Limited (Sigma) acquired 100% of the issued shares in CW Group Holdings Limited (Chemist Warehouse) by way of scheme of arrangement (Scheme).

In accordance with the Australian Accounting Standards, the merger has been accounted for as a reverse acquisition with Chemist Warehouse being deemed the acquirer for accounting purposes.

As a result of this, for the financial year ended 30 June 2025, Sigma's audited consolidated financial statements incorporates 12 months of financial information of Chemist Warehouse and its controlled entities and financial information of Sigma and its controlled entities for the period from the date of implementation of the scheme (12 February 2025) to 30 June 2025.

As a further result of this, the comparative results for the year ended 30 June 2024 reflect Chemist Warehouse results only.

Change in financial year-end, ASIC relief and ASX confirmations

Prior to the merger between Sigma and Chemist Warehouse on 12 February 2025, the companies had non-coterminous balance dates with Sigma's financial year ending on 31 January, and Chemist Warehouse's financial year ending on 30 June.

Following the implementation of the merger (Merged Group), ASIC has granted relief that will allow Sigma to meet its ongoing financial reporting obligations based on a notional financial year that runs to 30 June each year, enabling the Merged Group to report in accordance with Chemist Warehouse's financial year end of 30 June.

As a result of receiving this relief, Sigma will meet its financial reporting obligations under Part 2M.3 of the *Corporations Act 2001* in relation to notional financial years ending 30 June and notional half-years ending 31 December, as if those were Sigma's statutory financial years and half-years (notwithstanding that Sigma's statutory financial year end date will remain as 31 January).

In light of the ASIC relief, ASX provided confirmations to Sigma regarding the application of certain requirements in Chapter 4 of ASX Listing Rules that would otherwise require the lodgement of half and full year results based on a 31 January financial year end (and 31 July half-financial year end). ASX's confirmations provide that ASX will apply Listing Rules 4.2A, 4.2B, 4.3A, 4.3B, 4.5.1 and 4.7 as if Sigma's half year balance date is 31 December and not 31 July and its full year balance date is 30 June and not 31 January (subject to the satisfaction of certain conditions which require that the ASIC relief remain in force and Sigma complies with any conditions of that relief).

Statutory results for announcement to the market

Group results	30 June 2025 ¹ \$000	30 June 2024* \$000	Change %
Sales revenue from ordinary activities	6,001,835	3,294,402	82.3%
Net profit from ordinary activities after tax (NPAT)	525,455	539,657	(2.6%)
NPAT attributable to owners of the Company	529,914	541,013	(2.1%)

¹ The results for the year ended 30 June 2025 reflects 12 months of financial information of Chemist Warehouse and its controlled entities and financial information of Sigma and its controlled entities for the period from the date of implementation of the scheme (12 February 2025) to 30 June 2025.

* The comparative results for the year ended 30 June 2024 reflect Chemist Warehouse only.

Net tangible asset per security

	30 June 2025	30 June 2024*	Change %
Net tangible asset ¹ backing per ordinary share ² (cents per share)	6.9 cents	45.2 cents	(84.7%)

¹ Net tangible asset represents net assets excluding goodwill and other intangible assets.

² This calculation is based on number of ordinary shares at the end of the financial years, as disclosed in Note 18 to the consolidated financial statements.

* The comparative results for the year ended 30 June 2024 reflect Chemist Warehouse only.

Dividend information

Since the financial year ended 30 June 2025, the Directors have resolved to pay a fully franked final dividend of 1.3 cents per share. Accordingly, this dividend is not provided for in the balance sheet as at 30 June 2025. The ex-dividend date is 2 September 2025, the record date is 3 September 2025 and the dividend is expected to be paid on 18 September 2025.

Dividend	Amount per security ¹	Franking percentage
Final dividend – year ended 30 June 2025	1.3 cents	100%
Interim dividend – year ended 30 June 2025 [^]	21.5 cents	100%
Final dividend – year ended 30 June 2024 [^]	9.5 cents	100%

¹ The amount per security is as per disclosure in Note 21 to the consolidated financial statements.

[^] Chemist Warehouse dividends prior to the merger with Sigma.

Gain or loss of control over entities

On 12 February 2025, Sigma Healthcare Limited acquired 100% of the issued shares in CW Group Holdings Limited. A summary of all subsidiaries is included in the consolidated financial statements at Note 27.

Dividend reinvestment plans

The company does not currently have a dividend reinvestment plan in operation.

Other information

This report is based on the consolidated financial statements which have been audited by PricewaterhouseCoopers Australia (PwC). The financial report is not subject to a modified opinion. The audit report includes an emphasis of matter paragraph highlighting the Basis of Preparation for the disclosure of Key Management Personnel included in the Remuneration Report.

Additional information supporting the Appendix 4E disclosure requirements, including a brief explanation of the figures above, can be found in the Directors' Report, notes to the consolidated financial statements in this report and the Sigma year ended 30 June 2025 Full Year Media/ASX Release lodged with the ASX.

Shareholder information

Further information can be obtained from Gary Woodford (Head of Corporate Affairs):

+61 3 9215 9215

investor.relations@sigmahealthcare.com.au

Full Year Financial Report

For the year ended 30 June 2025

<u>Contents</u>	<u>Page</u>
Directors' Report	4
Operating and financial review	11
Remuneration Report	18
Auditor's independence declaration	57
<hr/>	
Consolidated financial statements	
• Consolidated statement of profit or loss and other comprehensive income	59
• Consolidated balance sheet	60
• Consolidated statement of changes in equity	61
• Consolidated statement of cash flows	63
• Notes to the consolidated financial statements	64
<hr/>	
Consolidated entity disclosure statement	122
Directors' declaration	124
Independent auditor's report	125

Directors' Report
For the year ended 30 June 2025

The directors present their report on Sigma Healthcare Limited (the Company or Sigma) and its controlled entities (the Group) for the year ended 30 June 2025.

Prior to the merger between Sigma and CW Group Holdings Limited (Chemist Warehouse) on 12 February 2025, the companies had non-coterminous balance dates with Sigma's financial year ending on 31 January and Chemist Warehouse's financial year ending on 30 June.

Given the complexity with reconciling conflicting legal and accounting requirements applying to the preparation of the Sigma and Chemist Warehouse accounts following the implementation of the merger (Merged Group), ASIC has granted relief that will allow Sigma to meet its ongoing financial reporting obligations based on a notional financial year that runs to 30 June each year, enabling the Merged Group to report in accordance with Chemist Warehouse's financial year end of 30 June.

As a result of receiving this relief, Sigma will meet its financial reporting obligations under Part 2M.3 of the *Corporations Act 2001* in relation to notional financial years ending 30 June and notional half-years ending 31 December, as if those were Sigma's statutory financial years and half-years (notwithstanding that Sigma's statutory financial year end date will remain as 31 January).

In light of the ASIC relief, ASX provided confirmations to Sigma regarding the application of certain requirements in Chapter 4 of ASX Listing Rules that would otherwise require the lodgement of half and full year results based on a 31 January financial year end (and 31 July half-financial year end). ASX's confirmations provide that ASX will apply Listing Rules 4.2A, 4.2B, 4.3A, 4.3B, 4.5.1 and 4.7 as if Sigma's half year balance date is 31 December and not 31 July and its full year balance date is 30 June and not 31 January (subject to the satisfaction of certain conditions which require that the ASIC relief remain in force and Sigma complies with any conditions of that relief).

Within this report whenever there is reference to the financial year ended 30 June 2025 or year ended 30 June 2025 it is referring to the notional financial year ended 30 June 2025 unless stated otherwise.

Directors

The names of the Directors and Company Secretary of the Company as at 30 June 2025 (unless otherwise stated) were:

Name	Particulars
Mr Michael Sammells <i>BBus (Acc), FCPA, GAICD</i> Independent Non-Executive Director	<p>Mr Sammells was appointed as a Director of Sigma in February 2020 and Chairman in August 2022. He is also the Chair of the Independent Board Committee (IBC), Member of the Audit Committee and Member of the Nomination and Remuneration Committee.</p> <p>Mr Sammells is currently a non-executive director at AMP Limited and a director at GMHBA. He has 35 years of broad experience in finance, corporate services and has held operational roles with expertise in finance, accounting, treasury, investor relations, capital developments, mergers and acquisitions and IPOs.</p> <p>Further, Mr Sammells is a former Chief Financial Officer of Healthscope Limited and Medibank Private.</p>
Mr Vikesh Ramsunder <i>B.Com Logistics, (MBL)</i> <i>Corporate Strategy</i> CEO and Managing Director	<p>Mr Ramsunder commenced as the Managing Director and CEO of Sigma on 1 February 2022.</p> <p>Mr Ramsunder has extensive experience in pharmacy retailing, wholesaling and logistics. He spent 28 Years with the Clicks Group in South Africa, a top-30 JSE listed company, and one of the largest pharmacy and retail operations in Africa. This included 18 years as part of the executive team.</p> <p>Before becoming Clicks Group Chief Executive Officer in January 2019, Mr Ramsunder held a number of roles within Clicks, including Chief Operating Officer from 2015 and Managing Director of the pharmaceutical wholesaler business, United Pharmaceutical Distributors from 2010.</p>

Directors' Report
For the year ended 30 June 2025

<p>Dr Chris Roberts (AO) <i>B. Eng (Honours), MBA, PhD</i> Independent Non-Executive Director</p>	<p>Dr Roberts was appointed as a Director of Sigma on 6 October 2023. He is the Chair of the Risk, Compliance and Sustainability Committee and Member of the Audit Committee.</p> <p>Dr Roberts has more than 40 years' experience in the medical device industry, including as the former Chief Executive Officer of Cochlear Limited (ASX:COH) from 2004 to 2015, Executive Vice President of ResMed Inc (NYSE:RMD) from 1992 to 2003 and as a director of ResMed Inc until November 2017.</p> <p>He is currently a non-executive director of HMC Capital Ltd (ASX:HMC). HMC Capital managed HealthCo Healthcare and Wellness REIT (ASX:HCW), HMC Capital Partners Fund 1, Clarity Pharmaceuticals Limited (ASX:CU6), Nutromics Pty Ltd, Atmo Biosciences Limited and the Cochlear Foundation Board. He is also a Governor of the Centenary Institute Cancer Medicine and Cell Biology.</p>
<p>Ms Annette Carey <i>LLB, BA</i> Independent Non-Executive Director</p>	<p>Ms Carey was appointed as a Director of Sigma in April 2023. She is the Chair of the Nomination and Remuneration Committee, Member of the IBC and Member of the Risk, Compliance and Sustainability Committee.</p> <p>Ms Carey is a current a non-executive director of the Kinetic bus group and, with effect from 1 November 2025, a non-executive director of Downer Group.</p> <p>Ms Carey previously held senior legal roles at two major commercial law firms and the Lend Lease group before joining Linfox Logistics and progressing from General Counsel and Company Secretary to Chief Executive Officer of Linfox Logistics ANZ and Linfox Armaguard. Ms Carey also held the position of Executive General Manager International with Australia Post.</p> <p>Ms Carey has held director roles within the Linfox group of companies and been Chair or Deputy Chair of Australia Post joint ventures in the UK and China.</p> <p>Ms Carey has a balance of technical expertise as well as legal, strategic and commercial intellect from over 30 years' experience in supply chain, logistics, cross border e-commerce and commercial law.</p>
<p>Mr Neville Mitchell <i>B.Com, CA</i> Independent Non-Executive Director</p>	<p>Mr Mitchell was appointed as a Director of Sigma in February 2023. He is the Chair of the Audit Committee, Member of the IBC and Member of the Nomination and Remuneration Committee.</p> <p>Mr Mitchell is a qualified Chartered Accountant with international healthcare and finance experience. He was Chief Financial Officer and Company Secretary at ASX-listed Cochlear Limited (until March 2017), a world leading medical device developer, manufacturer and seller of hearing devices.</p> <p>Mr Mitchell is currently the Chairman of ASX and NZX-listed Fisher & Paykel Healthcare Corporation (non-executive director from November 2018) and a non-executive director of Sonic Healthcare Limited from September 2017. He is Chair of the Sonic Audit Committee. He was formerly a non-executive director of ASX-listed Sirtex Healthcare, Osprey Medical Inc and Q'Biotics Group Limited.</p> <p>He has also performed roles with a number of industry and Government committees.</p>
<p>Mr Jack Gance <i>PhC MPS, MBA, GAICD,</i> <i>AFAIM</i> Non-Executive Director (appointed 12 February 2025)</p>	<p>Mr Gance was appointed as a Director of Sigma in February 2025 and is a Member of the Audit Committee, Member of the Nomination and Remuneration Committee and Member of the Risk, Compliance and Sustainability Committee.</p> <p>Mr Gance qualified as a pharmacist in 1967 and opened his first pharmacy store in Reservoir, Victoria, with Mr S Gance in 1972. In 1997, Messrs Gance and Mr Verrocchi, established MyChemist and opened the first MyChemist store. In 2000, they established the Chemist Warehouse chain and opened the first Chemist Warehouse store.</p> <p>Mr Gance also created the brands Le Specs, Le Tan and Colours of Australis.</p>

Directors' Report
For the year ended 30 June 2025

<p>Mr Mario Verrocchi <i>BPharm</i> Non-Executive Director (appointed 12 February 2025)</p>	<p>Mr Verrocchi was appointed as a Director of Sigma in February 2025. He is a Member of the Risk, Compliance and Sustainability Committee. He is also the Chief Executive Officer of Chemist Warehouse.</p> <p>Mr Verrocchi is a qualified pharmacist who joined Mr J Gance and S Gance's pharmacy group in 1982. Mr Verrocchi established MyChemist with Messrs Gance in 1997 and subsequently created the Chemist Warehouse chain with them in 2000.</p>
<p>Mr Damien Gance <i>BPharm, MBA, GAICD</i> Non-Executive Director (appointed 12 February 2025)</p>	<p>Mr Gance was appointed as a Director of Sigma in February 2025. He is a Member of the Risk, Compliance and Sustainability Committee.</p> <p>Mr Gance is a qualified pharmacist who joined MyChemist in 1998 and was the first Chemist Warehouse Franchisee opening the first Chemist Warehouse pharmacy in June 2000. He is currently the Chief Strategy and Business Development Officer of the Group.</p>
<p>Ms Danielle Di Pilla <i>BSc, BPharm</i> Non-Executive Director (appointed 12 February 2025)</p>	<p>Ms Di Pilla was appointed as a Director of Sigma in February 2025. She is a Member of the Risk, Compliance and Sustainability Committee.</p> <p>Ms Di Pilla is a qualified pharmacist who is the Chief People Officer of the Group.</p> <p>Ms Di Pilla established DPP Pharmaceuticals Pty Ltd (DPP) in 2000 and is the founder of brands such as Goat Soap, which has had international success.</p> <p>She also currently sits on the Board of Gotcha4Life.</p>
<p>Ms Kathryn Spargo <i>LLB (Honours), BA, FAICD</i> Independent Non-Executive Director (resigned 12 February 2025)</p>	<p>Ms Spargo was appointed as a Director of Sigma in December 2015 and resigned in February 2025.</p> <p>Ms Spargo is a non-executive director of the following listed entities: Sonic Healthcare Limited and Bapcor Ltd. In addition, Ms Spargo is also currently a non-executive director at CIMIC Ltd (now unlisted). Over the last three years, Ms Spargo was a non-executive director at Adairs Limited and Xenith IP Ltd. In September 2021, Ms Spargo retired from her position as Chairman of Colinvest and at the same time joined the board of the unlisted company Jellis Craig.</p> <p>Ms Spargo is also director at the Geelong Football Club and Future Fuels Cooperative Research Centre.</p>
<p>Ms Kara McGowan <i>LLB (Hons), BCom, BbusEc, ACIS, GAICD</i> General Counsel & Company Secretary</p>	<p>Ms McGowan was appointed as Sigma's General Counsel and Company Secretary in October 2021.</p> <p>Ms McGowan has been a Company Secretary for over 15 years for a broad range of corporate structures and businesses. Over the years she has held a variety of legal and commercial roles including General Counsel and Company Secretary at Transdev, Company Solicitor at Kmart and Head of Joint Ventures for Australian Unity Investments. She began her legal career at Clayton Utz as a competition lawyer.</p> <p>Ms McGowan is admitted as a Barrister & Solicitor of the Supreme Court of Victoria, holds a Graduate Diploma of Applied Corporate Governance and is a Graduate and Member of the Australian Institute of Company Directors. Ms McGowan also holds a Bachelor of Commerce and Bachelor of Business Economics.</p>

Note: former directorships mandatorily disclosed above are those held in the last 3 years for listed entities only. Directors' interest in shares are detailed in Table 4a of the Remuneration Report.

Directors' Report

For the year ended 30 June 2025

Principal activities

The principal activities of the Group during the financial year consist of:

- marketing, retailing, wholesaling and distributing pharmaceutical, medical, healthcare and beauty products;
- provision of support services to a network of franchised retail pharmacies; and
- provision of third and fourth party logistics services to pharmaceutical manufacturers and other supplier partners.

The Group has its principal place of business at 6 Albert Street, Preston, Victoria 3072, Australia.

Significant changes in the state of affairs

Merger between Sigma Healthcare Limited and CW Group Holdings Limited

On 12 February 2025, the implementation of the scheme of arrangement ("Scheme"), under which Sigma Healthcare Limited ("Sigma") would acquire 100% of the issued shares in CW Group Holdings Limited ("Chemist Warehouse"), was completed.

Under the Scheme, Sigma Healthcare Limited acquired 100% of the shares in Chemist Warehouse. The transaction resulted in the previous Chemist Warehouse shareholders receiving \$700.0 million cash and 9,906,180,588 Sigma shares.

Sigma is the legal acquirer of Chemist Warehouse. For financial reporting purposes, Chemist Warehouse has been identified as the accounting acquirer and Sigma as the accounting acquiree, known as a reverse acquisition, when applying AASB 3 *Business Combinations*.

Whilst Sigma Healthcare Limited is the legal acquirer and these accounts are represented as Sigma accounts, they have been prepared on the basis of Chemist Warehouse as the accounting acquirer, representing the continuing accounts.

The financial statements for the year ended 30 June 2025 have been prepared on the following basis:

- Chemist Warehouse continuing accounts at historical cost and is the accounting acquirer; and
- Sigma recognised at fair value on date of acquisition (12 February 2025) and is the accounting acquiree.

Operating and financial review

The operating and financial review, which forms part of this Directors' Report, is presented separately on pages 11 to 17.

Environmental regulations

The Group is not licensed or otherwise subject to conditions for the purposes of environmental legislation or regulation.

Dividends

Subsequent to 30 June 2025, the Directors have resolved to pay a fully franked final dividend of 1.3 cents per share. Accordingly, this dividend is not provided for in the balance sheet at 30 June 2025. The ex-dividend date is 2 September 2025, the record date is 3 September 2025 and is expected to be payable on 18 September 2025. The total amount expected to be payable is \$150.1 million.

Rounding of amounts

The Company is a Company of the kind referred to in the Australian Securities and Investments Commission (ASIC) Corporations (Rounding in Financials / Directors' Report) Instrument 2016/191, dated 24 March 2016, and in accordance with that Corporations Instrument amounts in the Directors' Report and the financial statements are rounded off to the nearest thousand dollars, unless otherwise indicated.

Proceedings on behalf of the Company

The Directors are not aware of any persons applying for leave under s.237 of the *Corporations Act 2001* to bring, or intervene in, proceedings on behalf of the Company.

Directors' Report

For the year ended 30 June 2025

Directors and officers' indemnities and insurance

As provided under the Constitution, the Company indemnifies Directors and Officers to the extent permitted by law for any liability incurred to persons other than the Company or its related bodies corporate in their capacity as directors or officers unless the liability arises out of conduct involving a lack of good faith.

During the year, the Company paid an insurance premium in respect of a contract insuring its Directors and Officers against a liability of this nature. In accordance with normal commercial practices, under the terms of the insurance contracts, the nature of the liabilities insured against and the amounts of premiums paid are confidential.

Non-audit services

Following the implementation of the Merger Implementation Agreement between Sigma and Chemist Warehouse on 12 February 2025, the Group appointed PricewaterhouseCoopers ("PwC") as its new independent auditor commencing for the financial year ended 30 June 2025, following the resignation of Deloitte Touch Tohmatsu. PwC were the appointed auditors of Chemist Warehouse prior to the Merger.

Details of the amounts paid to the auditor of the Company, PwC, and its related practices, for audit and other services provided during the year are set out in Note 33.

The Directors are aware of the issues relating to auditor independence and have in place policies and procedures to address actual, potential and perceived conflicts in relation to the provision of non-audit related services by the Company's auditor. Specifically, through the Audit Committee, the independence of the auditor is maintained by:

- Limiting the scope and nature of non-audit services that may be provided; and
- Requiring that permitted non-audit services must be pre-approved by the Chair of the Audit Committee.

The Directors are satisfied that the provision of non-audit services during the year by the auditor is compatible with, and do not compromise, the auditor independence requirements of the *Corporations Act 2001*. None of the services undermine the general principles relating to auditor independence as set out in the *APES 110 Code of Ethics for Professional Accountants* issued by the Australian Professional & Ethical Standards Board, including reviewing or auditing the auditor's own work, acting in a management or decision-making capacity for the Company, acting as advocate for the Company or jointly sharing economic risks and rewards.

A copy of the auditor's independence declaration as required under section 307C of the *Corporations Act 2001* is set out on page 57.

Environmental, social and governance

Sigma recognises the importance of environmental, social and governance matters to our shareholders, suppliers, customers and our team members. The Group also recognises it is important to support an efficient and sustainable supply chain, to encourage the wellbeing of its employees and the communities it interacts with to reduce the environment impact of its activities, and to conduct business in alignment with high standards of ethical behaviour and corporate governance principles.

Given the breadth and depth of the business combination between Sigma and Chemist Warehouse, the Group is undertaking a materiality assessment to ascertain materiality targets of the Merged Group to achieve key goals in areas of focus including climate change, emissions reductions and waste management.

The Group will comply with the new Australian Sustainability Reporting Standards (ASRS) which were issued by the Australian Accounting Standards Board (AASB), with mandatory reporting of climate-related disclosures for financial years beginning on or after 1 January 2025. This will apply to the Group for the first time for the year ending 30 June 2026.

Directors' Report
For the year ended 30 June 2025

Remuneration Report

Details of the Group's Remuneration Policy in respect of the Directors and Key Management Personnel are included in the Remuneration Report on pages 18 to 56, which forms part of this Directors' Report. Details of the remuneration paid to each Non-Executive Director, the CEO and Managing Director and other Key Management Personnel are also detailed in the Remuneration Report.

Directors' interests in share capital, options and performance rights of the Company

Details of the Directors' relevant interests in shares, options and performance rights of the Company at the date of this Report are as follows:

	Number of fully paid ordinary shares	Number of performance rights / options over fully paid ordinary shares
M Sammells	258,448	-
V Ramsunder	3,132,984	1,010,723
A Carey	21,212	-
C Roberts	12,014	-
N Mitchell	30,295	-
J Gance	1,579,052,263	-
D Gance	133,740,023	-
M Verrocchi	2,555,284,920	-
D Di Pilla	75,629,122	-

Board and committee meeting attendance

The following table sets out the number of Board and Committee meetings held during the year for Sigma Healthcare Limited as the legal entity and the number attended by each Director or Committee member while the Director was a member of the Board or relevant Committee.

Directors	Board of Directors		Audit Committee ¹		Independent Board Committee ²		Nomination and Remuneration Committee		Risk, Compliance and Sustainability Committee ¹	
	Held	Attended	Held	Attended	Held	Attended	Held	Attended	Held	Attended
M Sammells	8	8	4	4	2	2	3	3	-	-
V Ramsunder	8	8	-	-	-	-	-	-	-	-
K Spargo ⁴	5	5	-	-	-	-	-	-	-	-
A Carey	8	8	-	-	2	2	3	3	1	1
C Roberts	8	8	4	4	-	-	-	-	1	1
N Mitchell	8	8	4	4	2	2	3	3	-	-
J Gance ³	3	3	2	2	-	-	1	1	1	1
D Gance ³	3	3	-	-	-	-	-	-	1	1
M Verrocchi ³	3	3	-	-	-	-	-	-	1	-
D Di Pilla ³	3	3	-	-	-	-	-	-	1	1

¹ Prior to the merger on 12 February 2025, Sigma Healthcare Limited had in place a Risk Management and Audit Committee (RMAC). Upon implementation, two separate committees, being the Audit Committee (AC) and Risk, Compliance and Sustainability Committee (RCSC), were created. Meetings and attendance of the RMAC prior to the merger is included under 'Audit Committee' in the table above.

² Independent Board Committee was set up post-merger on 12 February 2025.

³ Appointed as a Director and member of the committee(s) in February 2025, subsequent to the implementation of the Merger.

⁴ Ms K Spargo retired as a Director and Chair of the Nomination and Remuneration Committee and member of the Audit Committee in February 2025.

Directors' Report
For the year ended 30 June 2025

Events since the end of the financial year

Subsequent to 30 June 2025, the Directors have resolved to pay a fully franked final dividend of 1.3 cents per share. Accordingly, this dividend is not provided for in the balance sheet as at 30 June 2025. The ex-dividend date is 2 September 2025, the record date is 3 September 2025 and is expected to be payable on 18 September 2025. The total amount expected to be payable is \$150.1 million.

In August 2025, the Group has also made the decision to close three distribution centres in Australia, following a comprehensive review.

Other than the matters discussed above, there have not been any other matters or circumstances that have arisen since 30 June 2025 that have significantly affected, or may significantly affect the operations of the Group, the results of those operations or the state of affairs of the Group in subsequent years not otherwise disclosed.

Signed in accordance with a resolution of the Directors made pursuant to section 306(3) of the *Corporations Act 2001*, dated 27 August 2025.



Michael Sammells
Chairman

Melbourne
27 August 2025



Vikesh Ramsunder
CEO and Managing Director

Operating and financial review For the year ended 30 June 2025

Operating review

The financial year ended 30 June 2025 was transformational for Sigma following the successful merger with Chemist Warehouse in February 2025. The merger has delivered a stronger, more integrated healthcare business, with greater scale, capability, and market reach.

The results for the financial year ended 30 June 2025 demonstrate the Group's momentum and potential for ongoing growth. Revenue for the year reached \$6.0 billion, with statutory Earnings before Interest and Tax (EBIT) up 32.0% to \$767.9 million. Normalised EBIT of \$834.5 million was up 41.4% compared to the prior corresponding period¹. Normalised EBIT is after adjusting for:

- a. Merger related costs of \$46.6 million
- b. Integration costs of \$12.7 million; and
- c. Non-cash P&L charges of \$7.3 million associated with merger purchase price accounting

During the year, the Company has:

- Successfully completed the merger with Chemist Warehouse, effective from 12 February 2025, bringing together retail and wholesale expertise;
- Upgraded our integration synergies target to \$100 million per annum, up from \$60 million per annum;
- Increased revenues to \$6.0 billion, which reflects the Chemist Warehouse revenue for the full 12-months and Sigma revenue for the period since merger completion;
- Added the Chemist Warehouse medicine supply agreement from 1 July 2024, which has increased annualised volume distributed by more than 29%;
- Expanded the Chemist Warehouse retail network with a total of 35 stores opened in Australia and internationally;
- Continued to successfully execute our own label product strategy to support margins.

We are committed to delivering excellence for our customers, partners and suppliers while strengthening our operations and driving ongoing efficiencies.

We have made good progress executing the integration plan and have upgraded the merger synergy target from \$60 million p.a. to \$100 million p.a. to be achieved within four years. The one-off costs anticipated to be progressively incurred to achieve the synergies has also been increased to \$95 – 105 million.

The performance of the Chemist Warehouse retail network was a standout. Total retail network sales² to customers for the 12-months were up 14.1% to \$10.3 billion. Like-for-like sales growth across the same store Chemist Warehouse network was up 11%. Sales growth was delivered in the franchise store network across the major product categories including beauty, vitamins and supplements, healthcare/medicines, baby/children, and fragrances.

During the year, we continued to expand our range of own label products, headlined by the launch of 269 lines of Wagner pharmaceuticals generics in November 2024, and achieved high pharmacy customer conversion rates and sell through.

Our value proposition and service offering are resonating with more customers. We opened a total of 35 new stores in Australia and internationally to bring our global network to 967 stores. Our international network also continues to grow across New Zealand, Ireland, and UAE demonstrating that the Chemist Warehouse model is transportable and scalable in other markets.

In addition, we are well advanced in executing our pharmacy brand strategy in Australia following the decision to convert the MyChemist pharmacies to Amcal and Discount Drug Stores. By 30 June 2025, 14 MyChemist stores have been converted to Amcal and DDS brands, with conversion of the remaining stores to be completed in the 2025 calendar year. In addition, the Ultra Beauty retail offering has now been made available to select stores across the Amcal network, providing a compelling retail experience for customers and a competitive advantage for Amcal franchisees.

Meanwhile, with a focus on delivering profitable growth, since year end, we have taken the decision to progressively close the Chemist Warehouse bricks and mortar stores in China, with the China market to be serviced through our online channel.

¹ Prior corresponding period refers to the results for Chemist Warehouse only for the period 1 July 2023 to 30 June 2024.

² Based on Chemist Warehouse management information (unaudited). Includes a combination of in-store and online sales across the Chemist Warehouse retail network, as well as online sales fulfilled directly by Chemist Warehouse.

Operating and financial review For the year ended 30 June 2025

Supply chain reliability and efficiencies are keys to our success. Our distribution centre network has successfully absorbed the significant volume increase during the period. With a combined 14 distribution centres across Australia, we now deliver around 530 million units on an annualised basis, with the benefit of scale resulting in a lower cost to serve per unit. At the same time, we have maintained our commitment to delivering service excellence to our customers, with the average delivery in full metric maintained above 99.5%.

We remain focused on optimising the network to improve service delivery, reduce cost and open new business opportunities. Since year end, we have made the decision to close our ePharmacy distribution centre in Victoria, with fulfilment to occur from store. We have also announced the intention to close our distribution centre in South Guildford in Western Australia by May 2026, and the Port Adelaide distribution centre in South Australia over the coming years. Volumes will be absorbed in our existing infrastructure.

Operating free cash flow was robust at \$546.3 million. At 30 June 2025, we reported net debt of \$752.2 million, well below the starting net debt range of \$1.0 to \$1.3 billion set out in the merger prospectus. We are well placed to self-fund our organic growth strategy and reward shareholders with dividends.

Financial performance

Highlights:

- Sales revenue of \$6.0 billion
- Statutory EBIT of \$767.9 million
- Statutory NPAT attributable to owners of the Company of \$529.9 million
- Final dividend of 1.3 cents per share, fully franked.

\$'000	Group		
	2025 ¹	2024 ¹	Change (%) ³
Sales revenue	6,001,835	3,294,402	82.3%
Gross profit	1,440,288	1,042,952	38.1%
Gross margin	24.0%	31.7%	(24.2%)
Cost of doing business (CODB) ²	(717,701)	(490,298)	46.4%
EBIT	767,883	581,536	32.0%
Normalised EBIT	834,527	590,142	41.4%
EBIT margin	12.8%	17.7%	(27.5%)
Normalised EBIT margin	13.9%	17.9%	(22.4%)
NPAT attributable to the owners of the Company	529,914	541,013	(2.1%)
Statutory earnings per share (EPS) (cents per share)	5.1	5.5	(8.1%)

¹ As set out in the Financial Statements, as a result of the reverse acquisition of Sigma Healthcare Limited (Sigma) by CW Group Holdings Limited (Chemist Warehouse) on 12 February 2025, these financial statements represent the continuing accounts of Chemist Warehouse. The comparative information for the financial year ended 30 June 2024 represents results for Chemist Warehouse only for the period 1 July 2023 to 30 June 2024. The income statement for the financial year ended 30 June 2025 represents the results of Chemist Warehouse for the period from 1 July 2024 to 11 February 2025 and the consolidated results of Chemist Warehouse and Sigma from 12 February 2025 to 30 June 2025.

² CODB includes \$66.6 million of merger related items.

³ Percentage change figures are calculated using underlying data prior to rounding and as such, recalculations based on displayed values may result in differences.

Sales revenue

As disclosed in Note 25 Business Combinations in the Financial Statements, the acquired business (Sigma) contributed revenue of \$2.4 billion (before intercompany eliminations) to the group for the period 12 February to 30 June 2025. Excluding the acquired business, group sales revenue was \$3.6 billion, which was 8.5% up on the prior corresponding period (pcp), reflecting continuous growth in the Australian retail network performance.

Gross margin

Gross profit of \$1.4 billion (margin of 24.0%) is up 38.1% on the pcp. This includes Sigma's contribution to the Group from merger date of \$159.4 million (before intercompany eliminations). Excluding the acquired business, gross profit has increased by \$237.9 million, which represents an improvement in gross margin by 4.2 percentage point.

Operating and financial review For the year ended 30 June 2025

Cost of doing business (CODB)

CODB includes:

- Warehouse and delivery expenses were \$225.8 million, 51.6% up on pcp. This reflects the inclusion of Sigma's costs from acquisition date, growth in costs from launch of the Wagner generics range and overall increase in sales activities.
- Sales and marketing expenses were \$107.9 million, 22.3% up YoY. The increase in costs is driven by the acquisition of Sigma and growth in employee costs from new overseas stores opening in Ireland and UAE.
- Administrative expenses were \$384.0 million, 51.7% up on pcp. This includes \$46.6 million (2024: \$8.6 million) of transaction costs in relation to the merger between Sigma and Chemist Warehouse. The overall increase is also attributable to acquisition of Sigma and an increase in employee costs for corporate functions, as a result of growth in business operations.

Earnings

Reported statutory EBIT (attributable to owners) was \$767.9 million, which represents a 32.0% increase from prior year, and includes merger related items of \$66.6 million and statutory EBIT contribution of \$18.8 million (before intercompany eliminations) from the acquired business (Sigma) between 12 February to 30 June 2025, as set out in Note 25 Business Combinations.

Normalised EBIT was \$834.5 million, which represents a 41.4% increase from prior period.

Reconciliation of Normalised EBIT to Statutory EBIT

\$'000s	2025	2024	Change % ⁴
Normalised EBIT	834,527	590,142	41.4%
Merger related costs ¹	(46,624)	(8,606)	441.7%
Integration costs ²	(12,707)	-	
Impact from PPA ³	(7,313)	-	
Statutory EBIT	767,883	581,536	32.0%

¹ Non-recurring costs incurred by the Group in association with the Merger between Sigma and Chemist Warehouse. These costs include financial advisory, legal, regulatory, accounting, tax and other costs and do not relate to the ongoing operations of the Group.

² Costs incurred to integrate the Sigma and Chemist Warehouse businesses, post-merger. These include consulting and employee costs, compliance costs and impacts from alignment of accounting policies.

³ Non-cash charges related to the merger purchase price allocation (PPA) accounting.

⁴ Percentage change figures are calculated using underlying data prior to rounding and as such, recalculations based on displayed values may result in differences.

Excluding the merger related items and contribution from the acquisition, like-for-like EBIT increased by \$244.4 million, demonstrating a strong performance for the year.

Financial position

The Group has a strong financial position with total net assets at the end of the financial year were \$4.7 billion, which was \$3.9 billion higher than at the year ended 30 June 2024, driven by the acquisition of Sigma. The Group has total assets of \$8.3 billion (2024: \$2.9 billion), of which \$3.8 billion related to intangible assets (including goodwill) recognised from the acquisition of Sigma in February 2025. The remaining being comprised primarily of trade and other receivables, inventory and right-of-use assets. The Group's cash reserves of \$138.8 million, as well as its available bank facilities, ensures that the Group is well placed to invest in business initiatives and support working capital requirements.

As at 30 June 2025, the Group has total drawn bank facilities of \$865.0 million (\$575.0 million undrawn). The Group has total borrowings of \$890.9 million at 30 June 2025, with transactions costs of \$9.7 million incorporated into the carrying value presented at Note 22.

Operating cash flow in the financial year ended 30 June 2025 was \$598.8 million, representing a strong cash conversion of 113% on NPAT. Net working capital has increased by \$722.2 million to \$1,271.3 million at 30 June 2025 as a result of the acquisition of Sigma.

The Board will continue to regularly monitor and review the Group's capital structure with a focus on maintaining balance sheet strength and its capacity to respond to strategic growth opportunities.

**Operating and financial review
For the year ended 30 June 2025**

Material risks

The Group's activities expose it to a number of economic and business risks. Sigma's risk management policy recognises that risk management is an essential element of good corporate governance and fundamental in achieving its strategic and operational objectives. Sigma accepts that risk is a part of doing business, therefore, this policy is not designed to promote risk avoidance, rather to create a risk conscious culture that encourages the systematic identification, management and control of risks whilst ensuring we do not enter into unnecessary risks or enter into risks unknowingly.

The Group's risk management approach is supported by:

- A risk governance framework overseen by the Risk, Compliance and Sustainability Committee (RCSC);
- A strong and experienced management team;
- Clearly articulated levels of authority and approval processes;
- Established risk identification tools including a Group Risk Register that is reported to the RCSC quarterly; and
- Adequate external insurance cover.

The following, in no particular order, is a summary of material risks facing the Group that are currently reported to the RSC Committee and are under active management. Our material risks are defined as risks that would have the most significant impact on the Group. We have included in the table examples of mitigations in place to assist in managing these risks:

Risk	Mitigation
<p>Regulatory environment, reform and / or legislative changes The Group operates in a highly regulated environment and business operations may be affected by changes in government policies and legislation, including those relating to the Pharmaceutical Benefits Scheme (PBS), Community Service Obligation (CSO), the pharmacy sector (to which the Group supplies products and services) and other Government initiatives, regulation and legislation.</p>	<ul style="list-style-type: none"> • Monitoring and review of PBS and CSO changes • Active agenda and timetable of engagement with identified industry and political stakeholders and membership of industry groups • Dedicated and experienced compliance teams to manage all regulatory matters, including pharmacy ownership arrangements • Ongoing investment in systems and processes to ensure compliance with regulatory requirements
<p>Strategy execution and business integration Post-merger, the Group has undertaken a detailed strategic review of the business and developed a growth strategy plan, which includes prioritisation of the integration of the two businesses. An integration of this size and nature carries inherent risk, including delays, talent retention, unplanned costs and difficulties in integrating various operations. Compromised delivery of key strategic initiatives and the integration plan could result in increased costs, inability to meet shareholder expectations and loss of market share.</p>	<ul style="list-style-type: none"> • Detailed planning and budgeting process • Structured program governance including oversight from board and management • Executive sponsorship and responsibility of all key strategic projects including structured project management for all material projects • Regular review and monitoring of strategic projects and programs, including costs and benefits tracking and resource allocation • Development and implementation of detailed integration plan, including establishing dedicated integration team and obtaining external expert support when required
<p>Change in competitive landscape The Group operates in highly competitive markets which could become more competitive due to actions from both new and existing competitors. The environment can be significantly affected by macro-economic conditions, general competitive dynamics and consumer behaviour changes. Increased competition could impact the Group's ability to generate sales, leading to a loss of market share and a decline in profitability.</p>	<ul style="list-style-type: none"> • Closely monitor and respond to competitor activity. These include but are not limited to pricing strategies, product launches, market entries and marketing activities • Monitor and prepare for external economic shifts that could impact demand, costs and overall competitiveness. Track key indicators across key markets • Capitalise on the Group's competitive advantage such as breadth of offerings for franchisees, brand awareness and in-house media and marketing capabilities

Operating and financial review
For the year ended 30 June 2025

Risk	Mitigation
<p>Financial risk Effective liquidity management is imperative to meet the Group's ongoing funding requirements in executing the capital expenditure program, investment in systems, management of working capital and overall strategy.</p>	<ul style="list-style-type: none"> • Cash forecasting and monitoring of financial ratios, cash conversion metrics and funding covenants • Regular review of the appropriateness of the Group's debt facilities and funding sources • Standard trading terms for trade debtors and creditors and governance of the approval of variations to these terms • Robust working capital management • Structured process to review funding and debt needs overseen by the CFO
<p>Operations risk The Group is exposed to several risks that have the potential to materially impact operations or result in business interruptions. This includes industrial action, workplace health and safety incidents and the loss or outage of critical infrastructure.</p>	<p>Various controls in place to address risks to operations. Specific examples include:</p> <ul style="list-style-type: none"> • Enterprise agreement strategies and site-specific planning • Business continuity plans and disaster recovery capability and technology for core systems • Established contracts and strong partnerships with critical business partners • Capital investment in distribution centre network infrastructure • Robust health and safety management system and dedicated health and safety resources
<p>Sourcing and third-party supply chain The Group relies on securing competitively priced arrangements with third-party suppliers. Inability to acquire products at competitive prices could lead to reduced margin and profitability for the business. Sigma is also subject to supply chain vulnerabilities of the suppliers which could be caused by extreme weather events, environmental policy changes and wide-scale product shortage.</p>	<ul style="list-style-type: none"> • Actively maintaining relationships and communications with key suppliers • Implementation of joint supplier business plans with key suppliers • Active monitoring of stock levels to manage risk of stock shortage where practicable • Increasing the diversification of sourcing operations • Ongoing investment in supply chain capabilities and technologies
<p>Talent retention and attraction The Group's ability to attract, retain and develop team members is critical to the execution of our strategies and delivery of strong operating and financial performance.</p>	<ul style="list-style-type: none"> • Talent development programs in place to retain and develop employees • Ongoing investments to strengthen employee value propositions to ensure the right talent is attracted and retained by the Group • Continuation of Women in Leadership program to support development of our female leaders and strengthen our talent pipeline

Risk	Mitigation
<p>Related party dealings The Group receives a material proportion of its revenue from related party franchisees and there are a number of interrelationships between related parties and the Group, such as certain leasing and supply arrangements. Where there is misalignment of interest between the Group and the related persons, there is a risk this may impact the financial and operational performance of the Group.</p>	<p>Sigma has established processes for the oversight and management of transactions between the Group and its related parties. The Board has established a committee comprised of independent directors (Independent Board Committee or IBC) to oversee the existing related party arrangements and the future related party dealings.</p> <p>The IBC is governed by a set of Board-approved protocols (IBC Protocols). Key responsibilities of the IBC include:</p> <ul style="list-style-type: none"> • considering, negotiating, entering into, making any changes or amendments to, and taking any actions (including exercising any rights) under the related party arrangements, and all matters in connection with or related to the related party arrangements • overseeing and monitoring compliance of the related party arrangements with the requirements of the related party arrangements approval, the IBC protocols, the Board-approved manual containing the framework for administering the related party arrangements in accordance with the requirements of the related party arrangements approval (Related Party Manual), Listing Rule 10.1 and Chapter 2E of the Corporations Act • ensuring that, at all times, the related party arrangements are in the best interests of the Company's shareholders including having regard to the principles set out in the Related Party Manual
<p>Data governance and cyber security There is a risk that the Group may be exposed to an event or events which may result in Sigma's or Sigma's customers information being unavailable, lost, stolen or otherwise compromised with adverse consequences for the business, which could result in damage to its brand, impact operations and cause a loss of customer trust.</p>	<p>Sigma has an information security and data governance strategy and framework in place, which includes tools, training, systems and processes to address data collection, data governance and protection.</p> <ul style="list-style-type: none"> • Alignment of information security strategy to the National Institute of Standards and Technology ("NIST") Cybersecurity Framework 2.0 • IT security function in place across security architecture, security operations, security engineering, identity management, cyber program management and security engagement • Enterprise Vulnerability Management solution established and implemented • Next-gen firewalls deployed at all Sigma and subsidiary sites • Training and awareness programmes established • Internal Assessments conducted to improve controls across the Merged Group • Maintaining a Security Operations Centre (SOC) • Periodic penetration testing performed, augmented by Vulnerability Disclosure Program and Bug Bounty Program • Weekly reporting on cyber incidents, cyber uplift and cyber matters to operational teams, with material updates provided to the Executive Leadership Team

Operating and financial review
For the year ended 30 June 2025

Risk	Mitigation
<p>Social and environmental sustainability risk Sigma is committed to delivering sustainable outcomes for investors, customers, communities and the environment, today and for the future. There is a risk to our reputation and operations from not delivering on this commitment.</p>	<ul style="list-style-type: none"> • Establishment of environment, social and governance (ESG) strategy and reporting with support of external experts • Identifying, managing and mitigating environmental risks from our operations, particularly our distribution centre network • Commitment to the Australian Packaging Covenant (APCO) sustainable packaging guidelines • Active community engagement in various charity organisations and other targeted programs • Ongoing commitment of the ESG Steering Committee and Modern Slavery working group to monitor and report on activities • Supply chain review, changes to the procurement process and amendment of standard contracts in response to Modern Slavery legislation
<p>Climate risks and opportunities Climate change presents an evolving risk for Sigma. This includes potential disruption to operations from extreme weather events, but also due to such things as changes to laws and regulations and not meeting stakeholder expectations, resulting in reputational damage.</p>	<ul style="list-style-type: none"> • Establishment of the Risk, Compliance and Sustainability Board Committee with a mandate covering climate-related reporting • Inclusion of climate risks and opportunities as a key matter in the Group's ESG reporting • Identifying major business inputs that contribute to our overall environmental footprint and implementing actions to help reduce this footprint (e.g., waste, packaging, energy efficiency) • Establishment of processes to measure, track and report energy use and greenhouse gas (GHG) emissions • Climate related risks and potential financial impacts assessed in line with the Group's risk management framework • Business continuity plans in place to respond to disruption to operations

Remuneration Report – year ended 30 June 2025 (2024/25)

- 1. Introduction**
- 2. Response to the ‘first strike’ at the 2024 AGM**
- 3. Executive Remuneration Snapshot for the Financial Year ended 30 June 2025**
 - 3.1 Our remuneration framework supports our strategy and transformation
 - 3.2 A transitional year for the remuneration framework
 - 3.3 Post-merger executive remuneration framework updates
 - 3.4 Merger impacts on in-flight awards
 - 3.5 Service agreements
- 4. Link between performance and remuneration outcomes**
- 5. Executive Remuneration Framework**
 - 5.1 Fixed Remuneration
 - 5.2 2024/2025 Short Term Incentive
 - 5.3 2024/2025 Long Term Incentive
 - 5.4 KMP Retention Arrangements
- 6. Remuneration governance**
 - 6.1 Use of external advisors
 - 6.2 Minimum Shareholding Policy
 - 6.3 Share Trading Policy
 - 6.4 Clawback arrangements
 - 6.5 Change of Control Event
- 7. Non-Executive Director Remuneration**
 - 7.1 Service Agreements
- 8. Statutory Remuneration Tables**
- 9. Related Party Disclosures**
 - 9.1 Independent Board Committee
 - 9.2 Related Parties who are not KMPs
 - 9.3 Differences in disclosure between Disclosure Documents and Remuneration Report
- 10. Transactions with KMPs and other Related Parties**
- 11. Other related party transactions with KMP occurring in the financial year ended 30 June 2025**

TABLE 3A: LTI loan funded shares: details of movement during the financial year ended 30 June 2025

TABLE 3B: Rights: details of movement during the financial year ended 30 June 2025

TABLE 4A: Shareholdings of KMP for financial year ended 30 June 2025

TABLE 4B: Performance rights and options (loan funded shares) holdings of KMP for financial year ended 30 June 2025

TABLE 4C: Restricted shareholdings of KMP for the financial year ended 30 June 2025

TABLE 5A: Inputs used in determination of fair value of share-based payments schemes

Abbreviation	Item
AGM	Annual General Meeting
ASX	Australian Securities Exchange
CAGR	Compound Annual Growth Rate
CEO	Chief Executive Officer
CFO	Chief Financial Officer
CW	Chemist Warehouse
EBIT	Earnings Before Interest and Tax
EEG	Executive Equity Grant
EPS	Earnings per Share
FR	Fixed Remuneration
IBC	Independent Board Committee
KMP	Key Management Personnel
LTI	Long Term Incentive
NPAT	Net Profit After Tax
NRC	Nomination and Remuneration Committee
STI	Short Term Incentive
TSR	Total Shareholder Return
VWAP	Volume Weighted Average Price

Remuneration Report For the year ended 30 June 2025

Message from our Chair of the Nomination and Remuneration Committee

Dear Shareholders

I am pleased to present Sigma Healthcare's Remuneration Report for the financial year reporting period 1 July 2024 to 30 June 2025 (FY25).

The Group delivered strong financial and non-financial performance in FY25 across all aspects of our business. These results were achieved against the backdrop of a truly transformational time for our business, including commencing the 5-year supply contract to serve the Chemist Warehouse pharmacy network on 1 July 2024, and subsequently the merger with Chemist Warehouse (CW) by way of a scheme of arrangement (Scheme) implemented on 12 February 2025. Through the merger we brought together a leading Australian retail pharmacy franchisor with a full-line wholesaler and distributor, to fulfill our vision to make pharmacy services and medicines accessible to all Australians. We are confident that the Company, in its new form, will achieve profitable growth and continue to deliver sustainable returns to shareholders.

With effect from the date of the Scheme, there were several changes to our Board and executive leadership. We welcomed four new directors to the Board, Mr Jack Gance, as a non-executive director, and Mr Mario Verrocchi, Mr Damien Gance and Ms Danielle Di Pilla as executive directors. Ms Kate Spargo resigned from the Board with effect from the date of the Scheme. Mr Mark Conway served as the Chief Financial Officer of Sigma Healthcare prior to the Scheme, and following this, Mr Mark Davis, CFO of CW, was appointed as the CFO. Mr Mark Conway remains with the Merged Group in a new finance role reporting through to Mr Mark Davis.

This Remuneration Report covers the Key Management Personnel (KMP) of the newly merged Sigma Healthcare from the date of the Scheme, that is 12 February 2025 to 30 June 2025. Prior to this, for the period from 1 July 2024 to 11 February 2025, the KMP detailed includes those of Sigma Healthcare (pre-merger) and does not include any KMP of CW (pre-merger).

Overview of performance and 2024/2025 remuneration decisions

Performance for the financial year ended 30 June 2025 was as follows:

- Normalised EBIT was \$834.5m
- Normalised NPAT was \$579.1m.

Normalised EBIT and NPAT are key operational metrics. As disclosed in the Directors' Report, Normalised EBIT and NPAT are after adjusting for merger related costs, integration costs and non-cash P&L charges associated with merger purchase price accounting.

As a result of the merger, the Group's market capitalisation increased significantly, placing Sigma Healthcare firmly within the ASX top-30 companies and delivering significant value to Sigma shareholders.

I would like to thank our executive and leadership team for their hard work this year in contributing to the growth of our business, through delivering on our operational performance commitments and driving the completion of a complex merger. We believe that the newly merged Sigma Healthcare is well placed to deliver significant long-term value to our shareholders.

As previously disclosed in the Scheme, which was approved by shareholders, the Board and Nomination and Remuneration Committee (NRC) undertook a market benchmarking review of peers in the ASX 20-100. As a result, and to position the CEO/Managing Director's remuneration levels at the median of the peer group, the Board determined to increase the fixed remuneration to \$1,600,000 and variable remuneration opportunity such that the target STI opportunity is 100% of fixed remuneration, maximum STI opportunity is 150% of fixed remuneration and LTI is 150% of fixed remuneration.

For the year ended 31 January 2025 (pre-merger), reward outcomes for Sigma Healthcare Limited were as follows:

- **STI outcomes:** The STI scorecard outcome was achieved at maximum. This is an exceptional result and reflects all scorecard metrics being exceeded. Full details for performance against STI targets are provided in Section 4 of the Remuneration Report. As previously disclosed, and in the context of the merger, the total STI awards were paid in cash for the 2024/2025 award only.

Remuneration Report For the year ended 30 June 2025

- **LTI outcomes:**
 - The 2022 LTI vested in full. As previously disclosed, and under the Loan Funded Share Plan rules, upon a change of control event occurring, the Sigma Board is required to make a determination that the shares vest. In relation to the merger with CW, the Sigma Board considered the continued employment of LTI participants, the significant value delivered to Sigma Shareholders through the merger and the key roles executives have performed in relation to the merger in making the determination to vest the Loan Funded Shares.
 - The 2023 Executive Equity Grant (EEG) was converted to a mix of cash and shares, conditional on ongoing service, following support from shareholders at the Extraordinary General Meeting. The first of these cash payments vested in February 2025.
- Initial KMP retention arrangements were delivered in December 2024, aligned with previous disclosures. The Board believes that these payments were important to secure the services of the CEO/Managing Director and CFO regardless of whether the merger occurred. Refer to Section 5.4 for further details.

Furthermore, in relation to in-flight awards applicable to Mr Ramsunder for the period following merger completion until 30 June 2025:

- The 2025/2026 STI performance period will be extended to align with the 30 June 2026 notional financial year end. That is, for the 2025/2026 STI award only, performance will be assessed over a 17-month performance period, being 1 February 2025 to 30 June 2026. This change will allow for performance to be assessed annually, aligned to the financial year going forward. Additionally, the Board determined that a greater portion of the STI would be delivered in equity (50% of the STI opportunity, up from 25%) and for a longer deferral period, with 50% deferred for 12 months, and the remaining 50% now deferred for 24 months).
- Similarly, the 2024/2025 LTI award's performance period will be extended from 31 January 2027 to 30 June 2027, to align with the financial year going forward. That is, performance will be assessed over the period 1 February 2024 to 30 June 2027. The two performance conditions remain (EPS and absolute TSR), with a single EPS CAGR target to cover the remainder of the performance period, rather than progressive annual targets. This change allows for a longer-term focus, alignment of the target with post-merger stretch objectives, and a measurement approach more aligned with market practice. Given the significant movement in the share price post-merger, the absolute TSR performance will be assessed by reference to the share price post-merger.

Understanding reasons and responding to the 'first strike'

At the 2024 AGM, Sigma Healthcare received a 'first strike' against its Remuneration Report for the period ended 31 January 2024. We engaged with key investors and proxy advisors leading up to and following the AGM. Of the concerns raised, the main concern appeared to be the retention awards that were offered. As a Board, we believe these were necessary to retain key executives leading up to the merger, and were important in the context of a complex merger which may or may not have completed as planned. These are 'once off' awards and do not represent any ongoing structural concerns with our remuneration framework.

Incentives review to support our strategy and transformation

Our current remuneration arrangements have served us well in attracting, retaining and motivating high performing executives by driving business growth and aligning with shareholder interest. However, because of the transformation of our business, our strategy has evolved, so has the need for our remuneration framework to support it. As such the Board and NRC have commenced a comprehensive review of all aspects of the Remuneration Framework. We note that some changes have already been flagged for 2025/2026 that are outlined further in the report.

We welcome your feedback on our remuneration framework and look forward to your support at our 2025 AGM.

Ms Annette Carey

Chair, Nomination and Remuneration Committee

**Remuneration Report
For the year ended 30 June 2025**

Remuneration Report

1. Introduction

The Directors of Sigma Healthcare Limited (Company or Sigma) are pleased to present the Remuneration Report (Report) for the Company and its subsidiaries (Group) for the financial year ended 30 June 2025 (financial year). This Report has been prepared on a statutory basis and audited in accordance with the requirements of the *Corporations Act 2001*.

On 12 February 2025, Sigma acquired 100% of the issued shares in CW Group Holdings Limited (Chemist Warehouse). This transaction is considered a reverse acquisition under AASB 3 *Business Combinations*, that is, a reverse acquisition of Sigma by Chemist Warehouse. Prior to the merger, Chemist Warehouse was not required to prepare a Remuneration Report in accordance with the *Corporations Act 2001*.

Basis of preparation

In considering the application of KMP remuneration disclosures required under the *Corporations Act* and *Corporations Regulations*, the Group has adopted the following approach:

- From the merger date of 12 February 2025 to 30 June 2025, KMP include all directors and certain executives of the consolidated Group.
- From 1 July 2024 to 11 February 2025, KMP refer to all directors and select executives of Sigma Healthcare Limited (pre-merger) and does not include KMP of Chemist Warehouse (pre-merger).
- Sigma Healthcare Limited was a disclosing entity and prepared a remuneration report for the year ended 31 January 2025 and 31 January 2024. Therefore, comparative information related to KMP in this report refers to those KMP of Sigma Healthcare Limited's prior year Annual Reports for the year ended 31 January 2025 and 31 January 2024 reporting periods.

ASIC has granted relief that will allow Sigma to meet its financial reporting obligations based on a notional financial year that runs to 30 June each year, enabling the Merged Group to report in accordance with Chemist Warehouse's financial year of 30 June.

Key Management Personnel (KMP)

KMP are defined as persons having authority and responsibility for planning, directing and controlling the major activities of the Group, and include all Non-Executive Directors of the Company and Executives as listed in the table below.

Current Non-Executive Directors		Term
Mr M Sammells	Chairman	Full year
Mr N Mitchell	Non-Executive Director	Full year
Ms A Carey	Non-Executive Director	Full year
Dr C Roberts	Non-Executive Director	Full year
Mr J Gance	Non-Executive Director	Part year – from 12 February 2025 ¹
Former Non-Executive Directors who served during the financial year		
Ms K Spargo	Non-Executive Director	Part year – to 12 February 2025 ²
Current Executive Directors		
Mr V Ramsunder	CEO/Managing Director	Full year
Mr M Verrocchi	Executive Director and CEO of Chemist Warehouse	Part year – from 12 February 2025 ¹
Mr D Gance	Executive Director and Chief Strategy and Business Development Officer	Part year – from 12 February 2025 ¹
Ms D Di Pilla	Executive Director and Chief People Officer	Part year – from 12 February 2025 ¹
Current Executives		
Mr M Davis	Chief Financial Officer	Part year – from 12 February 2025 ³

**Remuneration Report
For the year ended 30 June 2025**

Former Executives who served during the financial year	
Mr M Conway	Chief Financial Officer
Part year – to 12 February 2025 ³	

1. Appointed to the Board of Sigma Healthcare Limited with effect from the implementation of the merger between Sigma and Chemist Warehouse on 12 February 2025.
2. Ms K Spargo resigned from the Board of Sigma with effect from the implementation of the merger.
3. Mr M Conway served as the Chief Financial Officer of Sigma Healthcare Limited prior to the merger between Sigma and Chemist Warehouse. With effect from the implementation of the merger, Mr. M Davis, CFO of CW Group Holdings Limited, was appointed as the CFO of the Merged Group. Mr Mark Conway remains with the Merged Group in a new finance role reporting through to Mr Davis.

2. Response to the ‘first strike’ at the 2024 AGM

Following the strike against the Remuneration Report for the period ended 31 January 2024, the Board engaged with key investors and proxy advisers to understand the key concerns. Set out below is a summary of the key concerns we heard, and our Board’s response:

Concern	Our response
Retention awards to the CEO/Managing Director and CFO prior to merger, with a provision for an increase to the award if the merger didn’t proceed	<p>As a Board, we believe that these were necessary to retain key executives leading up to the proposed merger. These awards were important to secure key executive talent in the context of the complexity of the proposed merger, which may or may not have completed as planned.</p> <p>The retention awards were made as ‘once off’ awards and do not represent any ongoing structural concerns with our remuneration framework.</p> <p>The final cash payment of the retention awards will be made in December 2025 (subject to continuous service and satisfactory performance) and will be disclosed in the next reporting period’s Remuneration Report.</p> <p>No further retention awards were made to KMP during the reporting period.</p>
CEO/Managing Directors’ fixed pay is above the market	<p>During the year, we conducted a review of the CEO/Managing Directors’ remuneration levels. In the context of the merger, remuneration was benchmarked to the ASX 20-100 companies. The Board approved an adjustment to the CEO/Managing Director’s fixed remuneration with effect from implementation of the merger, to reflect the remit and deliverables of the CEO/Managing Director of the newly Merged Group. The CEO/Managing Director’s fixed remuneration is positioned at the median of the market data for the comparator group.</p>
The use of absolute TSR as a LTI performance condition	<p>The Board and the Nomination and Remuneration Committee (NRC) have commenced a comprehensive review of the executive remuneration framework to ensure it aligns with our evolving business strategy as a newly Merged Group. The LTI performance conditions have been considered as part of this review. For the 2025/2026 LTI, the absolute TSR performance measure will change to relative TSR to ensure it reflects performance against other suitable companies and is appropriately challenging.</p>
Quantum of potential termination benefits	<p>At the 2024 AGM, we sought approval from shareholders as to the potential retirement benefits to the CEO/Managing Director in a range of leaver scenarios. We believe that the proposals are fair and aligned to market. While there were some concerns raised regarding the potential quantum, the majority of shareholders supported this resolution and it was carried.</p>

**Remuneration Report
For the year ended 30 June 2025**

3. Executive Remuneration Snapshot for the Financial Year ended 30 June 2025

3.1 Our remuneration framework supports our strategy and transformation

Sigma's remuneration framework supports business strategy and transformation, by attracting, retaining, motivating and rewarding high-performing employees. It aims to deliver sustainable value for shareholders, serve community and customer interests and provide fair and reasonable rewards for achieving high performance. Our vision is clear – to be a leading pharmacy franchisor, wholesaler and distribution business in Australia and internationally.

Our purpose and strategy				
Deliver sustained growth in Australia	Cultivate emerging growth in international markets	Expand our portfolio of differentiated brands	Support our customer network through excellence in operational execution	Deliver shareholder value and disciplined governance

Our remuneration principles	
Competitive remuneration	Enabling the Company to attract, retain, motivate and reward high calibre employees and Non-Executive Directors.
Incentives linked to Company performance	Rewards are linked to delivery of the Company's financial and strategic goals which deliver value for shareholders.
Equality of remuneration	Ensuring that remuneration principles are applied fairly and consistently across the business.
Drive community and customer interests	Ensuring rewards are only paid where outcomes have been achieved in the interests of the community and customers.
Foster a partnership between employees and shareholders	Reinforcing an ownership mindset through ownership of Company shares.

3.2 A transitional year for the remuneration framework

Prior to the merger, Sigma's executive remuneration framework was implemented for executive KMP (Mr V Ramsunder and Mr M Conway) for the financial year ended 31 January 2025. Further detail on the pre-merger remuneration framework is provided below in Section 5.

For the remainder of the reporting period (i.e. 1 February 2025 to 30 June 2025), a revised remuneration framework is being considered by the NRC and Board. Only some changes have been determined, including the extension to STI and LTI performance periods to align with the 30 June financial year reporting period. Refer to section 3.3 for details on updates to the executive remuneration framework.

An overview of the remuneration structure and time horizons for the reporting period is shown below.

**Remuneration Report
For the year ended 30 June 2025**

Remuneration structure for the current reporting period ended 30 June 2025

	1 Feb 2024 to 30 June 2024	Financial year 1 July 2024 to 30 June 2025 (FY25)	FY26	FY27	FY28	FY29
Sigma's current executive remuneration framework		Fixed Remuneration (base salary + super)				
		2024/2025 STI performance period (1 Feb 2024 to 31 Jan 2025) Assessed against a scorecard over 12-months, subject to a financial gateway and meeting financial and non-financial criteria	100% STI cash for the 2024/2025 award only, in the context of the merger ¹			
		2024/2025 LTI performance period (1 Feb 2024 to 30 Jun 2027) Assessed against two equally weighted performance criteria (absolute TSR and EPS) ² over an extended period of 3 years and 5 months (period extended from the usual 3 years to align with the financial year reporting period)			100% LTI rights vest	

¹ Delivery of STI would have been 75% cash and 25% share rights deferred for 12 months. However, in the context of the merger, the Board determined that 100% of the STI be awarded in cash for the 2024/2025 STI only.

² There will be a single EPS CAGR target to cover the remainder of the performance period rather than progressive annual targets. The absolute TSR performance will be assessed by reference to the share price post-merger. For more information see section 3.4

An overview of the maximum potential remuneration mix for the current reporting period is shown below.

Current executives

CEO/Managing Director	FR 33.4%	Maximum STI 33.3% (100% of FR) ³	Maximum LTI 33.3% (100% of FR)
CFO¹	FR 100%		
Executive Directors²	FR 100%		

Former executives

CFO	FR 50.0%	Maximum STI 25.0% (50% of FR)	Maximum LTI 25.0% (50% of FR)
------------	----------	-------------------------------	-------------------------------

¹ Mr M Davis was not a participant in the 2024/2025 STI or LTI, however will be a participant in the 2025/2026 STI and LTI.

² Mr M Verocchi, Mr D Gance and Ms D Di Pilla were not participants in the 2024/2025 STI or LTI, however will participate in future LTI awards, subject to shareholder approval of equity grants.

³ This relates to the 2024/2025 STI plan for Mr Ramsunder which had a performance period of 1 February 2024 to 31 January 2025. The performance period for the 2025/2026 STI plan is set out in Section 3.3.

**Remuneration Report
For the year ended 30 June 2025**

Proposed CEO/Managing Director remuneration structure for the next reporting period ending 30 June 2026

The illustration below is proposed only. Some changes have been confirmed and disclosed (see Section 3.3 below). The full framework is still being developed and will be detailed in the next Remuneration Report.

	FY25	Financial year 1 July 2025 to 30 June 2026 (FY26)	FY27	FY28	FY29
Sigma's proposed future executive remuneration framework		Fixed Remuneration (base salary + super)			
		2025/2026 STI performance period (1 February 2025 to 30 June 2026) Assessed against a scorecard over 17-months, subject to meeting financial and non-financial criteria	50% STI cash	25% STI rights (vest 30 June 2027) ¹	25% STI rights (vest 30 June 2028) ²
		2025/2026 LTI performance period (1 July 2025 to 30 Jun 2028) Subject to EPS and relative TSR performance criteria over a 3-year period			100% LTI rights vest

¹ Represents the STI deferred equity for 12 months.

² Represents the STI deferred equity for 24 months.

For the purposes of the above illustrations, the retention arrangements for the CEO/Managing Director and former CFO associated with the proposed merger, as disclosed in the prior reporting period, are not shown. Refer to Section 5.4 for further details.

3.3 Post-merger executive remuneration framework updates

The Board and NRC have commenced a comprehensive review of the executive remuneration framework to ensure it aligns with our evolving business strategy as a newly Merged Group. While some changes have been confirmed and disclosed, the full framework is still being developed and will be detailed in the next Remuneration Report.

Fixed Remuneration	As disclosed in the Scheme, effective from implementation of the merger, the fixed remuneration levels were determined as: <ul style="list-style-type: none"> • Mr Ramsunder: \$1,600,000 • Mr Davis: \$1,200,000 • Mr Verrocchi: \$995,565 • Mr Gance: \$673,652 • Ms Di Pilla: \$673,652 <p>The Board and NRC believe that the remuneration levels for the CEO/Managing Director and CFO are competitively positioned and appropriately reflect the increased remit and accountabilities for the newly merged entity.</p> <p>The pre-merger fixed remuneration for executive directors remains unchanged.</p>											
Short Term Incentive (STI)	The STI opportunities have been determined as follows: <table border="1" style="margin-left: 20px;"> <thead> <tr> <th>Executive</th> <th>Target STI opportunity (% fixed remuneration)</th> <th>Maximum STI opportunity (% fixed remuneration)</th> </tr> </thead> <tbody> <tr> <td>Mr Ramsunder</td> <td>100%</td> <td>150%</td> </tr> <tr> <td>Mr Davis</td> <td>80%</td> <td>120%</td> </tr> </tbody> </table>			Executive	Target STI opportunity (% fixed remuneration)	Maximum STI opportunity (% fixed remuneration)	Mr Ramsunder	100%	150%	Mr Davis	80%	120%
Executive	Target STI opportunity (% fixed remuneration)	Maximum STI opportunity (% fixed remuneration)										
Mr Ramsunder	100%	150%										
Mr Davis	80%	120%										

**Remuneration Report
For the year ended 30 June 2025**

	<p>Mr Verrocchi, Mr Gance and Ms Di Pilla will not participate in the 2025/2026 STI.</p> <p>The 2025/2026 STI performance period for Mr Davis will be from 1 July 2025 to 30 June 2026.</p> <p>The 2025/2026 STI performance period for Mr Ramsunder will cover the period 1 February 2025 to 30 June 2026. This one-off change will allow for performance to be assessed annually in future awards, aligned to the financial year reporting period going forward.</p> <p>Mr Ramsunder's STI opportunity for the 2025/2026 financial year only will be 141.67% at target and 212.50% at maximum or 'stretch', based on the extended 17-month period (being 1 February 2025 to 30 June 2026).</p> <p>The STI deferred equity component will be increased to 50% (with 50% deferred for 12 months and the remaining 50% deferred for 24 months).</p>
<p>Long Term Incentive (LTI)</p>	<p>The maximum LTI opportunities have been determined as follows:</p> <ul style="list-style-type: none"> • Mr Ramsunder: 150% of fixed remuneration • Mr Davis: 120% of fixed remuneration • Mr Verrocchi: 90% of fixed remuneration • Mr Gance: 60% of fixed remuneration • Ms Di Pilla: 60% of fixed remuneration

3.4 Merger impacts on in-flight awards

As previously disclosed, and in the context of the merger, the Board considered the 'change of control' provisions under the in-flight LTI awards. In making its determination, it also factored the continued employment of the LTI participants, the significant value delivered to Sigma shareholders through the merger and the key roles executives have performed in relation to the merger. The Board determined the following treatment of in-flight LTI awards:

- **2022 Loan Funded Share Plan** – Under the Plan Rules, upon a change of control event, the Board is required to make a determination that the loan plan shares vest. The Board determined that all Loan Funded Shares vested, with participants being required to satisfy the outstanding loan balance to exercise the shares.
- **2023 Executive Equity Grant (“EEG”)** – The Board determined to restructure the award of Performance Rights to strike an appropriate balance between recognising the efforts and key role of participants in delivering the merger, with encouraging retention. Following shareholder approval at the Extraordinary General Meeting on 29 January 2025, the award was restructured as follows:
 - 37.5% of the Performance Rights were lapsed upon implementation of the merger, and a cash bonus of an equal amount paid;
 - 37.5% of the Performance Rights vested upon implementation of the merger, and the corresponding shares subject to disposal restrictions and continued employment up to 31 January 2026; and
 - 25% of the Performance Rights were lapsed upon implementation of the merger and to be paid as a cash bonus of an amount equal to 25% of the Performance Rights, subject to continued employment, on 31 January 2026.
- **2024 LTI** – The Board determined that the award's performance period be extended to 30 June 2027, to align with the financial year going forward, and that while the two performance conditions remain (EPS and absolute TSR), a new single EPS CAGR target has been set to cover the remaining performance period (rather than progressive annual targets). The targets for both measures will be divided into two components: (a) pre-merger: 1 February 2024 – 31 January 2025 where the previously disclosed targets remain unchanged and (b) post-merger: 1 February 2025 – 30 June 2027. This ensures that participants are appropriately incentivised with targets that are reflective of the structure of the Group, sufficiently stretching and aligned to the shareholder experience. Given the significant movement in the share price post-merger, the absolute TSR performance will be assessed by reference to the share price post-merger.

**Remuneration Report
For the year ended 30 June 2025**

Year 1	Year 2	Year 3	Year 1	Year 2	Year 3
100% Maximum of at risk LTI award					
50% EPS			50% absolute TSR		
15%	35%		15%	35%	
achieved	at risk		achieved	at risk	

Up to 50% of shares will vest in accordance with an Earnings per Share (EPS) measure, whereby the targets pre-merger (1 February 2024 to 31 January 2025) remains unchanged and the target for the post-merger period (1 February 2025 to 30 June 2027) is per the vesting schedule set out below:

Performance (CAGR)	% of EPS component that vest
Less than 7.5%	0%
> 7.5% and < 15%	Straight-line pro rata vesting between 50% to 100%
>= 15%	100%

Prior to the merger with Chemist Warehouse, Sigma's Board and shareholders approved the modification to existing performance rights in the context of the merger and the change of control provisions within the incentive schemes. The inputs used in the measurement of the fair values of the share-based payments schemes at the modification date are set out in Table 5A.

3.5 Service agreements

The employment conditions and remuneration of the executives are formalised in individual contracts of employment. No fixed terms are specified within these employment contracts and the following termination provisions apply:

Executives	Notice Period by Company	Notice Period by Employee
Mr V Ramsunder	12 months	12 months
Mr M Verrocchi	6 months	6 months
Mr D Gance	6 months	6 months
Ms D Di Pilla	6 months	6 months
Mr M Davis	6 months	6 months

The Company may terminate an employment contract without cause by providing written notice or making a payment in lieu of the notice period based on the individual's fixed annual remuneration. Each employment contract provides for termination of employment without notice in circumstances sufficient to warrant summary termination.

**Remuneration Report
For the year ended 30 June 2025**

4. Link between performance and remuneration outcomes

Sigma's incentive awards have historically been aligned with short-term and long-term financial outcomes. Prior year performance and remuneration outcomes (pre-merger and based on its former 31 January year-end), are shown below. The current period reflects Sigma's statutory results for the year ended 30 June 2025.

12-month period	Financial Year					
	Current period 2024/25 ¹	Sigma results pre-merger ²				
		2024/25	2023/24	2022/23	2021/22	
STI outcomes (% of maximum)	100%	100%	92.5%	75%	0%	
LTI outcomes (% of maximum)	N/A	N/A	100% ¹¹	100% ¹¹	50%	
Share price (\$) ³	3.133	2.869	0.963	0.607	0.468	
Dividends paid in the financial year (cps)	0.5	1.0	1.0	1.5	2.0	
Earnings per share (cps)	Basic	5.1	(0.9)	0.4	0.2	(0.7)
	Diluted	5.1	(0.9)	0.4	0.2	(0.7)
TSR ⁴	152.0%	78.4%	64.63%	34.28%	(20.4%)	
Pre-tax ROIC ⁵	17.9%	7.9% ⁹	5.6% ⁸	11.2% ⁷	7.9% ⁶	
EBIT (\$m) – Normalised ¹⁰	\$834.5	\$68.0 ⁹	\$30.7 ⁸	\$65.0 ⁷	\$47.6 ⁶	
NPAT (\$m) – Reported (attributable to owners of the company)	\$529.9	\$(13.8)	\$4.5	\$1.8	\$(7.2)	

- Figures are prepared on a statutory basis and consistent with Sigma's Financial Report for the 12 months ended 30 June 2025. The results reflect 12 months of financial information of Chemist Warehouse and its controlled entities and financial information of Sigma and its controlled entities for the period from the date of implementation of the Scheme (12 February 2025) to 30 June 2025.
- Refers to Sigma Healthcare Limited figures for 12 months ended 31 January.
- Share price is the volume weighted average price of the Company's shares traded on the ASX for the 20 trading days up to and including year-end date.
- TSR = (share price appreciation + dividends + value of franking credits)/Sigma share price at the start of financial year.
- Pre-tax ROIC = EBIT/ (Total Shareholder Funds + Net Debt).
- Adjusted for a number of one-off items including SaaS change in accounting policy and restructuring costs.
- Adjusted for a number of one-off items including losses associated with the cessation of Cura service contract and loss on the disposal of WholeLife, and inventory adjustments.
- Adjusted for non-operating transaction costs associated with the proposed merger.
- Adjusted for non-operating transaction costs associated with the proposed merger as well as CW onboarding costs.
- EBIT (\$m) – Normalised, metric excludes contribution from non-controlling interest for determining ROI.
- Refer section 3.4 for additional information.

Remuneration Report For the year ended 30 June 2025

STI Outcomes

The table below shows the STI scorecard outcomes for Sigma Healthcare Limited's 2024/25 financial year ended 31 January 2025, applicable to the CEO/Managing Director and CFO prior to merger. These outcomes align with the previous Remuneration Report disclosure for the period ended 31 January 2025 given this is the performance result that has determined incentive outcomes.

Category	Metric	Meets stretch objectives (50%)	Exceeds expectations (100%)	Actual result
Finance	Normalised NPAT (\$)	21.4m	22.4m	41.9m
Operations	Delivered in Full	96%	97.5%	99.5%
	Dispatched on Time	96%	98%	99%
Health & Safety	TRIFR	16	14.3	12
	Positive Performance Indicators	95.5%	97%	99.4%
Customer Metric	Voice of Customer	36	40	43.6

<p>FINANCE</p> <p>Weighting 60% % Achieved 100% Weighted Outcome 60%</p> <p>The Company achieved adjusted NPAT of \$41.9m, exceeding the target financial measure for the year's STI program.</p>	OBJECTIVE	METRIC			
	Improve Profitability (50%)	Budget Net Profit After Tax			
	Achievement			\$41.9m	
		Significantly below	Below	Achieved	
				Exceeded	
<p>OPERATIONS</p> <p>Weighting 20% % Achieved 100% Weighted Outcome 20%</p> <p>Our Logistics Operations performed exceptionally well, continuing to deliver market-leading operational results. This was particularly pleasing given the onboarding of the Chemist Warehouse Supply Contract which increased volume by almost 60% and exiting of Eastern Creek DC whilst maintaining very high service levels.</p>	OBJECTIVE	METRIC			
	Improve Core Operations (10%)	Delivered in Full			
	Achievement			99.55%	
		Significantly below	Below	Achieved	Exceeded
	Improve Core Operations (10%)	Dispatched on Time			
Achievement			99.00%		
		Significantly below	Below	Achieved	Exceeded
<p>HEALTH AND SAFETY</p> <p>Weighting 10% % Achieved 100% Weighted Outcome 10%</p> <p>The stretch TRIFR target was exceeded. This was an important milestone for the business in light of the increase in volume through our Distribution network and the additional number of new team members in our Distribution Centres upon the onboarding of the Chemist Warehouse Supply Contract. Our PPI measure captures proactive actions and events used to prevent injury and accidents.</p>	OBJECTIVE	METRIC			
	Improve Health & Safety Performance (5%)	TRIFR			
	Achievement			12.6	
		Significantly below	Below	Achieved	Exceeded
	Improve Health & Safety Performance (5%)	Positive Performance Indicators (PPIs)			
Achievement			99.4%		
		Significantly below	Below	Achieved	Exceeded
<p>CUSTOMER</p> <p>Weighting 10% % Achieved 100% Weighted Outcome 10%</p> <p>A number of improvements were made throughout the year to enhance Sigma Connect, our online ordering platform. This ongoing solution development work combined with improved operational performance has resulted in the Company exceeding its target on Voice of Customer.</p>	OBJECTIVE	METRIC			
	Increase customer satisfaction (10%)	Voice of Customer (NPS)			
Achievement			43.6		
		Significantly below	Below	Achieved	Exceeded

Remuneration Report For the year ended 30 June 2025

The table below shows the STI award outcomes for Sigma's 2024/25 Financial Year ended 31 January 2025, applicable to the CEO/Managing Director and CFO prior to merger, as approved by the Board. These outcomes align with the previous Remuneration Report disclosure for the period ended 31 January 2025.

KMP	2024/25 ¹							2023/24						
	Maximum STI	Target Opportunity \$	Stretch Opportunity \$	Total STI Awarded \$	Cash STI Paid \$	Performance Rights Issued ² #	Deferral period	Maximum STI	Target Opportunity \$	Stretch Opportunity \$	Total STI Awarded \$	Cash STI Paid \$	Performance Rights Issued ³ #	Deferral period ³
Mr V Ramsunder	100%	534,319	1,088,637	1,088,637	1,088,637	n/a	n/a	100%	516,250	1,032,500	955,063	716,297	242,994	1/2/24 - 31/1/25
Mr M Conway	50%	148,625	297,250	297,250	297,250	n/a	n/a	50%	37,923	75,846	70,158	52,618	17,850	1/2/24 - 31/1/25
TOTAL		682,944	1,385,887	1,385,887	1,385,887	n/a	n/a		554,173	1,108,346	1,025,221	768,915	260,844	

1. Refers to Sigma Healthcare Limited figures for 12 months ended 31 January.
2. 100% of the STI awarded in cash for the 2024/2025 plan only.
3. The number of rights was calculated based on the volume weighted average price of a Share for the 5 trading days immediately preceding the end of the performance period.

5. Executive Remuneration Framework – pre-merger

5.1 Fixed Remuneration

The fixed remuneration consists of base salary and statutory superannuation contributions. Fixed remuneration is reviewed annually, however there are no guaranteed increases in any contracts of employment for the CEO/Managing Director or Executive team members.

5.2 2024/2025 Short Term Incentive

The STI component of an executive's total reward is an annual at-risk incentive reward. The STI links a portion of executive reward opportunity to specific financial and non-financial measures. The 2024/2025 STI award relates to the period ended 31 January 2025, prior to the merger and is detailed below. This arrangement is applicable to Mr Ramsunder and Mr Conway only.

Component	Commentary
Maximum STI Reward Value	100% of fixed remuneration for the CEO/Managing Director (Mr Ramsunder). 50% of fixed remuneration for the CFO (Mr Conway).
Gateway Requirement	A NPAT gateway must be achieved to trigger any STI payment opportunity. The NPAT gateway is determined by the Board prior to the commencement of the financial year, taking into account the NPAT result for the concluding financial year and the budgeted NPAT target for the new financial year. The NPAT gateway is based on the normalised figure, and excludes any significant uncontrollable or one-off events, initial impacts from business development initiatives, and any material costs associated with the merger as approved by the Board. Normalised NPAT was selected as an appropriate gateway at the time given it was reflective of the generation of shareholder value, and is a measure readily recognised by and reported to shareholders.
Performance Measures	60% of maximum STI reward relate to normalised NPAT.
Financial	Budgeted NPAT has been set to strike an appropriate balance between being ambitious and achievable, such that the target is challenging yet deliverable. Budget must be met for the first threshold level of STI payments and stretch targets are required to be achieved to deliver the full outcome under the STI Plan. Rationale for adopting normalised NPAT as a performance measure Normalised NPAT was selected as an appropriate performance measure as it assesses overall Company performance and the generation of shareholder value. It is a key operational metric used internally. Adjustments from statutory figures are made for material, one-off or extraordinary items, as approved by the Board. Group financial calculations under the STI plan exclude significant uncontrollable or one-off events, the initial impacts from business development initiatives, and any material costs associated with the merger as approved by the Board.

**Remuneration Report
For the year ended 30 June 2025**

Performance Measures	40% of maximum STI reward relate to non-financial measures, specifically:		
Non-financial	Customer (10%)	Operations (20%)	Health and Safety (10%)
	Voice of Customer	Key delivery indicators including Delivered in Full and Dispatched on Time	Health and Safety metrics, including Total Recordable Injury Frequency Rate (TRIFR) and Positive Performance Indicators (PPIs)
	Each non-financial measure is selected based on its alignment with core values and key strategic priorities that lead to improved and sustainable shareholder value.		
Governance	All performance measures under the STI are clearly defined and measurable.		
	The Board, on recommendation from the NRC, approves the targets and assesses the performance outcome under the STI plan.		
	The Board, on recommendation from the NRC, approves STI outcomes for the CEO/Managing Director and the CFO.		
	Under the STI plan, the Board has discretion to adjust STI outcomes based on the achievements which are consistent with the Group's strategic priorities and in the opinion of the Board, enhance shareholder value.		
Reward Mechanism	STI reward is to be delivered in a combination of cash and deferred equity for the CEO/Managing Director and the CFO as determined by the Board. In the context of the merger, the Board approved payment of the 25% deferred equity component to be delivered in cash for the 2024/2025 financial year ended 31 January 2025. Board approval was obtained on 29 January 2025 and the Company's closing share price on the date immediately preceding the Board's approval was \$3.03 per share.		

5.3 2024/2025 Long Term Incentive

The LTI component of an executive's total reward is an at-risk equity incentive designed to focus executives on key performance drivers that underpin sustainable growth in shareholder value. The LTI facilitates share ownership by executives and links a significant proportion of their at-risk remuneration to the Company's ongoing share price and returns to shareholders over the performance period.

The 2024/2025 LTI plan was delivered through a Rights Plan. This arrangement is applicable to Mr Ramsunder and Mr Conway only.

Component	Commentary
Maximum LTI Reward Value	100% of fixed remuneration for the CEO/Managing Director (Mr Ramsunder) 50% of fixed remuneration for the CFO (Mr Conway).
Performance Period	Three financial years commencing on 1 February in the year of the grant. However, in the context of the merger and to align with the 30 June financial year reporting period, the 2024/2025 LTI performance period will be extended from a current vesting date of 31 January 2027 to 30 June 2027 (i.e. the award will cover 3 years and 5 months). The maximum LTI opportunity remains unchanged. The performance period reflects the business cycle of the Company. As a wholesaler, strategic, operational and financial initiatives translate to a short to medium term impact on the financial performance of the Company. The performance period also reflects the competitive market practice in attracting, retaining and rewarding high-calibre executives.

**Remuneration Report
For the year ended 30 June 2025**

Delivery Mechanism	<p>Executives are provided with the opportunity to acquire Rights subject to the vesting conditions being met. The vesting period is 3 years and 5 months from the grant date, and Rights must be exercised before the expiry of the term, which is 5 years and 5 months from the grant date.</p> <p>The maximum number of Rights is determined by dividing the agreed maximum incentive opportunity by the 10-day volume weighted average price (VWAP) commencing on the start of the performance period.</p>
Vesting Conditions	<p>Up to 50% of shares will vest in accordance with the absolute TSR vesting schedule set out below:</p> <ul style="list-style-type: none">i. 12.5% of the performance rights will vest if a minimum absolute TSR of 8% CAGR is achieved during the performance period;ii. this will increase in a straight line to 25% of the performance rights vesting if an absolute TSR of 10% CAGR is achieved during the performance period; andiii. this will increase in a straight line to a maximum vesting of this component at 12% CAGR. <p>Absolute TSR = (Sigma share price appreciation + dividends + value of franking credits)/Sigma share price at the start of the performance period.</p> <p>Up to 50% of shares will vest in accordance with an Earnings per Share (EPS) measure as set out below:</p> <ul style="list-style-type: none">i. EPS will be progressively tested in years 1, 2 and 3 of the performance period against an EPS performance measure with any earned rewards only released at the end of Year 3;ii. The EPS performance measure will be set at the beginning of each year based on the outlook following the preceding year; andiii. The vesting range is to be agreed and advised by the Board. <p>The EPS target for the 2024/2025 financial year was 1.3 cents.</p> <p>The Board has reviewed the targets associated with the performance measures to ensure these are appropriate for the merged entity. The two performance conditions remain (EPS and absolute TSR), with a single EPS CAGR target to cover the remainder of the performance period, rather than progressive annual targets. The vesting schedule is set out in section 3.4.</p> <p>This change allows for a longer-term focus, alignment of the target with post-merger stretch objectives, and a measurement approach more aligned with market practice. Given the significant movement in the share price post-merger, the absolute TSR performance will be assessed by reference to the share price post-merger.</p> <p>Performance Measures for the 2025/2026 LTI</p> <p>The use of absolute TSR was appropriate pre-merger as it is not limited by the challenges associated with selecting a fair and appropriate comparator group given the size of the industry in which the Company operates. Post-merger, the Board has decided that relative TSR is a more appropriate performance measure for the 2025/2026 LTI plan.</p> <p>EPS was selected as a suitable vesting condition as it is a universal standard measure on Company performance.</p>
Re-testing	<p>No re-testing applies - shares that do not vest after testing lapse.</p>

**Remuneration Report
For the year ended 30 June 2025**

Forfeiture Conditions	<p>In the event of resignation, unvested shares are typically forfeited (subject to Board discretion) and vested shares are retained.</p> <p>In the event of summary dismissal, unvested rights are forfeited.</p> <p>In the event of death or redundancy, the Board has discretion to determine an appropriate outcome.</p>
Governance	<p>All performance measures under the LTI are clearly defined and measurable.</p> <p>The Board, on recommendation from the NRC, approves each LTI grant, including the performance targets, and assesses the performance outcome of each LTI grant. In doing so, it reviews a range of factors including business circumstances on an annual basis.</p> <p>The Board, on recommendation from the NRC, approves LTI vesting for each plan. Confirmation of vesting only occurs once the audited year-end accounts have been approved by the Board.</p>

Table 3a on page 51 sets out the movements of loan funded shares during the financial year.

5.4 KMP Retention Arrangements

As indicated in Sigma’s Remuneration Report for year ended 31 January 2025, retention arrangements were considered important to secure the services of the Mr Ramsunder in light of the proposed merger. These arrangements involved a cash payment in December 2024 of \$1,000,000 and another payment of \$500,000 payable in December 2025.

6. Remuneration Governance

The diagram below illustrates the interaction between the Board, NRC, management and external advisers, in overseeing the executive remuneration framework and its implementation.



6.1 Use of external advisers

During the reporting period, the NRC received remuneration benchmarking data, market practice information and advice on the remuneration framework from SW Corporate and Korn Ferry. No remuneration recommendations were made by remuneration consultants during the reporting period.

6.2 Minimum Shareholding Policy

A minimum shareholding policy has been implemented to align the interest of the directors and senior executives with the long-term interest of the Company’s shareholders. The CEO/Managing Director is required to accumulate and maintain a minimum shareholding of 200% of annual fixed pay, and 100% of annual fixed pay for the CFO within a five-year period. The policy can be viewed on the Company’s website at www.sigmahealthcare.com.au.

Remuneration Report For the year ended 30 June 2025

6.3 Share Trading Policy

Unvested equity under the LTI plan are personal to the executive and cannot be sold, transferred, mortgaged, charged, hedged, made subject to any margin lending arrangement or otherwise disposed of, dealt with or encumbered in any way. Breach of this provision will result in the immediate forfeiture of any unvested equity.

Dealing in Sigma shares by directors, officers and employees is subject to the Company's Share Trading Policy, which is published on the Company's website at www.sigmahealthcare.com.au.

6.4 Clawback arrangements

The Board has discretion to adjust or cancel unvested LTI, unexercised LTI, vested LTI that is subject to an outstanding loan balance, or clawback acquired shares on exercise of Rights, should the Board determine the specific circumstance warrants such action.

6.5 Change of Control Event

Generally, if the Company becomes, or in the opinion of the Board is likely to become, subject to a Change of Control, the Board may at its absolute discretion make a determination that some or all of a participant's equity vests. As noted in section 3.2, the performance period for the 2024/2025 LTI will be extended to align with the Group's 30 June financial year end, and vesting will remain subject to the vesting conditions.

7. Non-Executive Director Remuneration

Remuneration for the Company's Non-Executive Directors reflects the complexity of the Company's operations as well as the responsibilities, accountabilities and time commitments of the Non-Executive Directors. It consists of base fees, committee fees and superannuation within the current maximum aggregate fee limit of \$2.5 million, as approved by shareholders at the Company's 2025 Extraordinary General Meeting.

The remuneration of Non-Executive Directors is not incentive based and Non-Executive Directors do not participate in employee share plans or receive performance shares, rights or options over the Company's shares.

Prior to merger Sigma had in place a Non-Executive Director Share Plan. This was designed to ensure the interests of Non-Executive Directors were aligned with those of shareholders. In accordance with the rules of the Non-Executive Directors Share Plan (Plan), 25% of each Non-Executive Director's post-tax fees were used to purchase Sigma shares on market every three months. Shares purchased under the Plan could not be transferred or sold until the Non-Executive Director ceases being a director of the Company, or the first day of the financial year following the third anniversary of the purchase date, or a change of control of the Company, whichever occurs first.

During the period of discussion with Chemist Warehouse in relation to the merger, the Plan was suspended from the September 2024 quarter until 12 February 2025 and the 25% of fees that would ordinarily be directed toward a share purchase was paid in cash to directors. Following the merger this Non-Executive Director Share Plan was discontinued and all Non-Executive Directors are now remunerated solely in cash.

As noted in Sigma's Remuneration Report for year ended 31 January 2025, with effect from the merger an updated Minimum Shareholding Policy applies to Executive and Non-Executive Directors. The updated Minimum Shareholding Policy requires that Executive and Non-Executive directors accumulate and maintain for the duration of their position, a minimum shareholding equivalent to 100% of their Fixed Pay. The minimum shareholding is to be achieved by the 5th anniversary of the date they are appointed.

Non-Executive Director share holdings and movements under the Plan for the financial year are set out in Table 4a on page 53.

Total fees and superannuation actually paid to the Non-Executive Directors for the financial year ended 30 June 2025 was \$1,368,784, as set out in Table 1 in Section 8.

Remuneration Report For the year ended 30 June 2025

The table below shows the structure and level of Non-Executive Director fees from 1 July 2024 to 11 February 2025 as approved by the Board.

Role	Annual Fee Structure ¹
Chair of the Board	\$310,300
Non-Executive Director	\$128,400
Risk Management and Audit Committee - Chair	\$42,800
Nomination and Remuneration Committee - Chair	\$42,800
Risk Management and Audit Committee - Member	\$16,050
Nomination and Remuneration Committee - Member	\$16,050

¹ Includes the 25% of Non-Executive Director fees used for share acquisition under the Non-Executive Director Share Plan and excludes Superannuation Guarantee contributions.

Fees for Non-Executive Directors are designed to be set at levels that fairly reflect the complexity of operations as well as the responsibilities, accountabilities and time commitments of the Directors and Committee members. Market capitalisation is also a determinant of fees. The Board and Committee structure on implementation of the merger from 12 February 2025 is set out below.

Role	Annual Fee Structure*
Chair of the Board	\$550,000
Non-Executive Director	\$200,000
Independent Board Committee – Chair	\$50,000
Audit Committee – Chair	\$50,000
Nomination and Remuneration Committee – Chair	\$50,000
Risk, Operations, Compliance and Sustainability – Chair	\$50,000
Independent Board Committee – Member	\$25,000
Audit Committee – Member	\$25,000
Nomination and Remuneration Committee – Member	\$25,000
Risk, Operations, Compliance and Sustainability – Member	\$25,000

7.1 Service Agreements

On appointment to the Board, all Non-Executive Directors enter into a service agreement with the Company in the form of a letter of appointment which summarises the policies and terms, including remuneration, relevant to the office of Non-Executive Director.

Remuneration Report
For the year ended 30 June 2025

8. Statutory Remuneration Tables

TABLE 1: Statutory remuneration disclosure for Key Management Personnel of the Sigma Healthcare Limited: financial year 1 July 2024 to 30 June 2025

	Short Term Benefits				Post-employment Benefits	Other Long Term Benefits ³	Termination Payments	Total Remuneration excluding Value in Share-Based Plans	Value in Share-Based Plans			Total Remuneration including Value in Share-Based Plans	Performance Based Payments as Proportion of Remuneration ⁵
	Salary and Base Fees ¹	Committee Fees	Short-term Incentive ²	One-off Awards ⁶	Superannuation Benefits				Equity-settled Rights ⁴	Cash-settled Rights ⁴	Loan Funded Shares ⁴		
	\$	\$	\$	\$	\$				\$	\$	\$		
NON-EXECUTIVE DIRECTORS													
Ms A Carey	156,145	48,581	n/a	n/a	22,021	n/a	-	226,747	n/a	n/a	n/a	226,747	-
Mr N Mitchell	156,145	64,965	n/a	n/a	23,905	n/a	-	245,015	n/a	n/a	n/a	245,015	-
Dr C Roberts	156,145	38,893	n/a	n/a	21,865	n/a	-	216,903	n/a	n/a	n/a	216,903	-
Mr M Sammells	403,184	-	n/a	n/a	29,932	n/a	-	433,116	n/a	n/a	n/a	433,116	-
Mr J Gance ⁷	77,500	29,063	n/a	n/a	11,690	n/a	-	118,253	n/a	n/a	n/a	118,253	-
Ms K Spargo ⁸	79,180	36,291	n/a	n/a	13,279	n/a	-	128,750	n/a	n/a	n/a	128,750	-
Subtotal for Non-Executive Directors	1,028,299	217,793	n/a	n/a	122,692	n/a	-	1,368,784	n/a	n/a	n/a	1,368,784	-
EXECUTIVES													
Mr V Ramsunder	1,207,467	n/a	1,127,153	696,237	29,932	13,166	-	3,073,955	1,404,993	956,398	271,032	5,706,378	66
Mr M Verrocchi ⁷	385,182	n/a	-	-	11,397	319	-	396,898	-	-	-	396,898	-
Mr D Gance ⁷	265,694	n/a	-	-	11,397	212	-	277,303	-	-	-	277,303	-
Ms D Di Pilla ⁷	265,694	n/a	-	-	11,397	212	-	277,303	-	-	-	277,303	-
Mr M Davis ⁷	488,118	n/a	-	-	11,397	14,950	-	514,465	-	-	-	514,465	-
Mr M Conway ⁸	338,692	n/a	174,665	218,739	19,354	1,383	-	752,833	43,986	-	-	796,819	27
Subtotal for Executives	2,950,847	n/a	1,301,818	914,976	94,874	30,242	-	5,292,757	1,448,979	956,398	271,032	7,969,166	50
TOTAL	3,979,146	217,793	1,301,818	914,976	217,566	30,242	-	6,661,541	1,448,979	956,398	271,032	9,337,950	43

1. For Non-Executive Directors, includes base fees paid in cash and shares as per the Non-Executive Directors Share Plan. For the Executives, includes base salary and amounts in respect to annual leave expense movement.
2. Represents the reward under the 2024/25 STI plan. For the 2024/25 plan only, 100% of the STI was awarded in cash.
3. Includes amounts in respect to long service leave expense movement.
4. The value of the rights and loan funded shares determined using the Black-Scholes option and Monte Carlo simulation pricing models is expensed over the vesting period, therefore the amount disclosed above for the current year includes loan funded shares allocated in prior years.
5. Includes amounts expensed in relation to rights, loan funded shares and short-term incentives. Excludes share purchases under the Non-Executive Directors Share Plan.
6. Represents retention arrangements associated with the merger.
7. Commenced as Key Management Personnel upon implementation of merger on 12 February 2025.
8. Ceased as Key Management Personnel from 12 February 2025.

Remuneration Report
For the year ended 30 June 2025

TABLE 2A: Statutory remuneration disclosure for Key Management Personnel of Sigma Healthcare Limited: financial year 1 February 2024 to 31 January 2025

	Short Term Benefits				Post-employment Benefits	Other Long Term Benefits ³	Termination Payments	Total Remuneration excluding Value in Share-Based Plans	Value in Share-Based Plans			Total Remuneration including Value in Share-Based Plans	Performance Based Payments as Proportion of Remuneration ⁵
	Salary and Base Fees ¹	Committee Fees	Short-term Incentive ²	One-off Awards	Superannuation Benefits				Equity-settled Rights ⁴	Cash-settled Rights ⁴	Loan Funded Shares ⁴		
	\$	\$	\$	\$	\$				\$	\$	\$		
NON-EXECUTIVE DIRECTORS													
Ms A Carey	126,300	15,788	n/a	n/a	16,051	n/a	-	158,139	n/a	n/a	n/a	158,139	-
Mr N Mitchell	126,300	42,100	n/a	n/a	19,023	n/a	-	187,423	n/a	n/a	n/a	187,423	-
Dr C Roberts	126,300	15,788	n/a	n/a	16,051	n/a	-	158,139	n/a	n/a	n/a	158,139	-
Mr M Sammells	305,225	-	n/a	n/a	28,877	n/a	-	334,102	n/a	n/a	n/a	334,102	-
Ms K Spargo	126,300	57,888	n/a	n/a	20,807	n/a	-	204,995	n/a	n/a	n/a	204,995	-
Subtotal for Non-Executive Directors	810,425	131,564	n/a	n/a	100,809	n/a	-	1,042,798	n/a	n/a	n/a	1,042,798	-
EXECUTIVES													
Mr V Ramsunder	1,028,260	-	1,068,637	1,110,959 ⁶	28,877	5,281	-	3,242,014	405,051	298,872	417,361	4,363,298	50
Mr M Conway	571,867	-	297,250	394,887 ⁶	28,877	1,517	-	1,294,398	62,788	-	-	1,357,186	27
Subtotal for Executives	1,600,127	-	1,365,887	1,505,846	57,754	6,798	-	4,536,412	467,839	298,872	417,361	5,720,484	45
TOTAL	2,410,552	131,564	1,365,887	1,505,846	158,563	6,798	-	5,579,210	467,839	298,872	417,361	6,783,282	38

1. For Non-Executive Directors, includes base fees paid in cash and shares as per the Non-Executive Directors Share Plan. For the Executives, includes base salary and amounts in respect to annual leave expense movement.
2. Represents the reward under the 2024/25 STI plan. For the 2024/25 plan only, 100% of the STI was awarded in cash.
3. Includes amounts in respect to long service leave expense movement.
4. The value of the rights and loan funded shares determined using the Black-Scholes option and Monte Carlo simulation pricing model is expensed over the vesting period, therefore the amount disclosed above for the current year includes loan funded shares allocated in prior years.
5. Includes amounts expensed in relation to rights and loan funded shares. Excludes share purchases under the Non-Executive Directors Share Plan.
6. Represents retention arrangements associated with the merger

Remuneration Report
For the year ended 30 June 2025

TABLE 2B: Statutory remuneration disclosure for Key Management Personnel of Sigma Healthcare Limited: financial year 1 February 2023 to 31 January 2024

	Short Term Benefits				Post-employment Benefits			Total Remuneration excluding Value in Share-Based Plans	Value in Share-Based Plans		Total Remuneration including Value in Share-Based Plans Short-term	Share Based Payments as Proportion of Remuneration ⁷ One-off Awards ¹⁰
	Salary and Base Fees ¹	Committee Fees	Short-term Incentive ²	One-off Awards ¹⁰	Superannuation Benefits	Other Long Term Benefits ³	Termination Payments		Rights ⁵	Loan Funded Shares ⁵		
	\$	\$	\$	\$	\$	\$	\$		\$	\$		
NON-EXECUTIVE DIRECTORS												
Ms C Bartlett	102,308	34,103	n/a	n/a	14,672	n/a	-	151,083	n/a	n/a	151,083	-
Ms A Carey	100,000	12,500	n/a	n/a	12,206	n/a	-	124,706	n/a	n/a	124,706	-
Mr D Manuel	36,000	9,000	n/a	n/a	4,725	n/a	-	49,725	n/a	n/a	49,725	-
Mr N Mitchell	119,538	35,776	n/a	25,000 ¹⁰	19,224	n/a	-	199,538	n/a	n/a	199,538	-
Dr C Roberts	38,154	4,773	n/a	n/a	4,725	n/a	-	47,680	n/a	n/a	47,680	-
Mr M Sammells	290,000	(5,436) ⁴	n/a	150,000 ¹⁰	26,521	n/a	-	461,085	n/a	n/a	461,085	-
Ms K Spargo	120,000	37,853	n/a	n/a	17,030	n/a	-	174,883	n/a	n/a	174,883	-
Subtotal for Non-Executive Directors	806,000	128,569	n/a	175,000	99,103	n/a	-	1,208,700	n/a	n/a	1,208,700	-
EXECUTIVES												
Mr V Ramsunder	943,121	-	716,297	174,658 ¹¹	26,521	2,267	-	1,862,864	1,169,972	351,196	3,384,032	45
Mr M Conway ⁸	148,059	-	52,618	260,781 ⁹	6,850	104	-	468,412	17,850	-	486,262	4
Mr N Simonsz ⁶	345,660	-	-	-	15,105	(186)	-	360,579	-	-	360,579	0
Subtotal for Executives	1,436,840	-	768,915	435,439	48,476	2,185	-	2,691,855	1,187,822	351,196	4,230,873	36
TOTAL	2,242,840	128,569	768,915	610,439	147,579	2,185	-	3,900,555	1,187,822	351,196	5,439,573	28

1. For Non-Executive Directors, includes base fees paid in cash and shares as per the Non-Executive Directors Share Plan. For the Executives, includes base salary and amounts in respect to annual leave expense movement.
2. Represents the reward under the 2023/24 STI plan. Of the STI payment made to Mr Ramsunder, \$716,297 was paid in cash, with the remaining payment made by way of rights. Of the STI payment made to Mr Conway, \$52,618 was paid in cash, with the remaining payment made by way of rights.
3. Includes amounts in respect to long service leave expense movement.
4. Represents an adjustment to Committee Fees paid to Mr Sammells in FY2022/2023 while being acting Chairman.
5. The value of the rights and loan funded shares determined using the Black-Scholes option and Monte Carlo simulation pricing model is expensed over the vesting period, therefore the amount disclosed above for the current year includes loan funded shares allocated in prior years.
6. Chief Financial Officer until 31 August 2023.
7. Includes amounts expensed in relation to rights and loan funded shares. Excludes share purchases under the Non-Executive Directors Share Plan.
8. Appointed as Chief Financial Officer from 30 October 2023.
9. Represents a sign on payment for Mr Conway upon commencement.
10. Represents a one-off fee approved for the Board Chair and Chair of the Risk Management and Audit Committee in recognition of the significant work associated with the proposed merger.
11. Represents value of retention arrangements associated with the proposed merger.

Remuneration Report For the year ended 30 June 2025

9. Related Party Disclosures

9.1 Independent Board Committee

Sigma has established processes for the oversight and management of transactions between the Group and its Related Parties. Following the merger in February 2025, the Board established a committee comprised of independent directors (Independent Board Committee or IBC) to oversee the Existing Related Party Arrangements and the Future Related Party Dealings (each as defined in the Notice of Meeting issued to the Company's shareholders on 18 December 2024 in connection with the Merger and collectively, the Related Party Arrangements). As at 30 June 2025 the Independent Board Committee members are:

- Mr M Sammells;
- Ms A Carey; and
- Mr N Mitchell.

The Independent Board Committee is governed by a set of Board-approved protocols (IBC Protocols). Key responsibilities of the IBC include:

- considering, negotiating, approving the entry into, making any changes or amendments to, and taking any actions (including exercising any rights) under the Related Party Arrangements, and all matters in connection with or related to the Related Party Arrangements;
- overseeing and monitoring compliance of the Related Party Arrangements with the requirements of the Related Party Arrangements Approval (defined below), the IBC Protocols, the Board-approved manual containing the framework for administering the Related Party Arrangements in accordance with the requirements of the Related Party Arrangements Approval (Related Party Manual), Listing Rule 10.1 and Chapter 2E of the Corporations Act; and
- ensuring that, at all times, the Related Party Arrangements are in the best interests of the Company's shareholders including having regard to the principles set out in the Related Party Manual.

During the period 12 February 2025 to 30 June 2025, two Independent Board Committee meetings were held. The following table sets out the number of IBC meetings held during the financial year and the number attended by each Director while the Director was a member of the IBC.

Name of Director	Number of IBC meetings the Director was eligible to attend	Number of IBC meetings attended by the Director
M Sammells	2	2
A Carey	2	2
N Mitchell	2	2

The IBC has also overseen the formation of a related party working group of senior management of the Group (which acts on authority delegated by the Independent Board Committee) (Related Party Working Group), consistent with the Related Party Arrangements Approval. Refer to the "New related party arrangements entered into in the year ended 30 June 2025 following the Implementation Date" section of this Report below for further details in relation to arrangements approved by the related party working group.

During the year ended 30 June 2025, following its establishment, the IBC also oversaw the implementation and operation of the Group's related party transaction processes in accordance with the IBC Protocols. The IBC will review the processes in place so that they continue to remain fit for purpose, and where the IBC considers that amendments are required, the IBC will recommend those changes to the Board for approval. The IBC is empowered to obtain external advice to assist the committee with its oversight responsibilities and utilises the expertise of external advisors when necessary.

9.2 Related Parties who are not KMPs

In connection with the acquisition of CW Group Holdings Limited (Chemist Warehouse) by the Company (Merger), which completed on 12 February 2025 (Implementation Date), certain related party arrangements of Chemist Warehouse became related party arrangements of Sigma. These arrangements were approved by the Company's shareholders on 29 January 2025 under Listing Rule 10.1 (Related Party Arrangements Approval).

In addition to the usual requirements under accounting standards and the Corporations Act and its associated regulations (Corporations Regulations), and as a condition of certain confirmations provided by ASX in respect of the Listing Rules in connection with the Merger (ASX Confirmations), ASX required the Company to include in the Group's annual report disclosure regarding these related party transactions (ASX Confirmation Conditions).

Remuneration Report For the year ended 30 June 2025

These disclosures are required for related parties, including those who are not KMP. As such, while Mr S Gance (an executive director of Chemist Warehouse before the Implementation Date) is not KMP of the Group, he is a related party about whom disclosure is required under the ASX Confirmation Conditions because he holds over 10% of the Sigma Shares.

9.3 Differences in disclosure between Disclosure Documents and Remuneration Report

The related party disclosure in this Remuneration Report is governed by the Corporations Act, Corporations Regulations and AASB124 *Related Party Disclosures* (AASB124) as well as the ASX Confirmation Conditions discussed above. These requirements are similar, but not identical, to the disclosure required in the prospectus, scheme booklet and notice of meeting (Disclosure Documents) despatched in connection with the Merger. For example:

- **Scheme Booklet and Prospectus:** quantitative and qualitative materiality thresholds applied to disclosure in the prospectus and scheme booklet do not apply to disclosure in this remuneration report as a result of the requirements of Part 2M.3 of the Corporations Regulations;¹ and
- **Notice of Meeting:** The disclosures included in the Notice of Meeting were the result of ASX Listing Rule requirements and therefore focused on transactions requiring shareholder approval, which were those that exceeded the 'substantial asset threshold' set out in Listing Rule 10.2 (set at \$204.6 million at the time the Related Party Arrangements Approval was sought). In the Notice of Meeting in accordance with accounting standard requirements, in situations where Chemist Warehouse wholesale sales were directly delivered by Sigma to stores, Chemist Warehouse recognised revenue as the consideration received from the customer, net of amounts payable to Sigma (these were recognised in "Fees and other revenue"). Following Implementation, under such scenarios the revenue is recognised as the consideration received from the customer, without netting the amounts payable (these are now recognised in "Sale of goods"), in line with the accounting standards for revenue as outlined in Note 2 of the Consolidated Financial Statements.

Furthermore, the definitions of 'related party' are slightly different between the Corporations Act, ASX Listing Rules and AASB124, with the result that in certain cases disclosure is required for different persons.

For similar reasons, there are differences in the related party disclosure required in this Remuneration Report and Note 32 to the consolidated financial statements. As the merger between Chemist Warehouse and Sigma is accounted for as a reverse acquisition under *AASB 3 Business Combinations*, Chemist Warehouse is assessed to be the accounting acquirer and the consolidated financial statements represent the continuing accounts of Chemist Warehouse. Under the *Corporations Act*, this Remuneration Report is prepared on the basis that Sigma Healthcare Limited is the disclosing entity.

10. Transactions with KMPs and other Related Parties

Background

This section sets out the transactions between the Group and KMPs, their close family members or entities they control (either directly, indirectly or jointly) (Related Parties) as well as information on the governance processes required by the Related Party Arrangements Approval. As referred to above, while Mr S Gance is not a KMP, he is deemed to be a Related Party for the purposes of this section for compliance with the ASX Confirmation Conditions.

¹ Matters considered 'trivial or domestic' are not required to be disclosed under the Corporations Regulations (for example, a Related Party purchasing an item from a Group Entity for their personal use).

**Remuneration Report
For the year ended 30 June 2025**

There were transactions between the Group and the following Related Parties for the financial year:

Related Party	Relevant relationship	Category of transaction(s)
Mr M Verrocchi and his related entities	KMP	Franchise, lease and supply arrangements – see 'Value of transactions in the financial year' section.
Mr J Gance and his related entities	KMP	
Mr D Gance and his related entities	KMP	Other related party transactions as applicable – see 'Other related party transactions with KMPs occurring in the financial year ended 30 June 2025' section.
Ms D Di Pilla and her related entities	KMP	
Mr S Gance and his related entities	Disclosure required by ASX Confirmation Conditions	Employment arrangements for current KMPs are included in the Remuneration Report.
Ms S Robertson and her related entities	Close family member (spouse) of Mr D Gance	
Ms E Verrocchi and her related entities	Close family member (child) of Mr M Verrocchi	Employment arrangements – see 'Close family members employed by the Group' section.
Ms V Schena and her related entities	Close family member (child) of Mr M Verrocchi	
Mr Madison Verrocchi and his related entities	Close family member (child) of Mr M Verrocchi	

Related Party franchisees

As at 30 June 2025, the Group is the franchisor to 881 franchised stores in Australia. In total, there are 182 franchised stores in Australia either wholly or partly owned by a Related Party.

The table below sets out the number of franchised stores in Australia in which a Related Party currently has an ownership interest. The Related Parties do not wholly or partly own any franchised stores outside of Australia.

Related Party	Number of franchised retail stores as at 30 June 2025 ¹
Mr M Verrocchi ²	79
Mr J Gance ²	66
Mr D Gance	20
Ms D Di Pilla	18
Mr S Gance	37
Ms S Robertson	19
Eliminations ³	(57)
Total	182

¹ Each franchised retail store may have an associated occupancy license(s) with the Group.

² The disclosures included in the Notice of Meeting included a line item for East Yarra Friendly Society Pty Ltd (a friendly society jointly owned-by Mr M Verrocchi and Mr J Gance) (EYFS). In the Remuneration Report franchised stores wholly or partly owned by EYFS have been separately allocated to both Mr M Verrocchi and Mr J Gance.

³ Eliminations have been made to avoid double counting and overstating the total number of franchised stores owned by Related Parties to reflect franchised stores that are partly owned by two or more Related Parties.

**Remuneration Report
For the year ended 30 June 2025**

Related Party leases

There are 143 properties owned or controlled (either directly, indirectly or jointly) by a Related Party that are leased to the Group. The table below sets out the number of leases between the Group and the relevant Related Party as at 30 June 2025. The amount paid by the Group to the Related Party that owns or controls the relevant property in the year ended 30 June 2025 following the Implementation Date is set out in the “Value of transactions in the financial year” section below.

Related Party	Number of leases as at 30 June 2025¹
Mr M Verrocchi	139
Mr J Gance	141
Mr D Gance	112
Ms D Di Pilla ²	1
Mr S Gance	141
Ms S Robertson	-
Eliminations ³	(391)
Total	143

¹ The number of leases excludes a small number of properties where the Group has access to the premises however has not yet executed a formal lease agreement. This is typically for a short period of time whilst the lease agreement is prepared, and a valuation undertaken.

² This includes leases in relation to properties owned by Ms D Di Pilla’s parents.

³ Eliminations have been made to avoid double counting of the same leases where multiple Related Parties have an interest in the one premise or store.

**Remuneration Report
For the year ended 30 June 2025**

Value of transactions in the financial year following Implementation Date

The following table sets out the value of transactions with each Related Party (excluding Ms E Verrocchi, Ms V Schena and Mr Madison Verrocchi as they are not party to any of the arrangements set out below) in the financial year following the Implementation Date related to the Group's franchise, supply and leasing arrangements. For more information on the arrangements below, please see Note 32 to the consolidated financial statements.

Type of transaction	Ms D Di Pilla	Mr D Gance	Mr J Gance	Mr M Verrocchi	Mr S Gance	Ms S Robertson	Eliminations ¹	Total
<p>Revenue from sales of goods under supply arrangements to Related Parties</p> <p>Revenue derived by the Group from the supply of goods to Related Party franchisees.</p> <p>These arrangements with Related Party franchisees are on terms and conditions no more favourable to the Related Party than those that it is reasonable to expect the Group to have adopted if dealing at arms-length with an unrelated person.</p> <p>Revenue from sales of goods under supply arrangements to Related Parties is recognised on the same accounting policy outlined in Note 2 to the consolidated financial statements.</p>	\$83,053,310	\$102,942,428	\$248,511,396	\$321,133,032	\$170,785,751	\$85,062,026	(\$206,251,227)	\$805,236,716
<p>Rendering of services to Related Parties</p> <p>Revenue derived predominantly by the Group from:</p> <ul style="list-style-type: none"> franchise fees and administration fees under the franchise or service arrangements; and separate licence fees paid in relation to the use of the Group's intellectual property. <p>These arrangements with Related Party franchisees are on terms and conditions no more favourable to the Related Party than those that it is reasonable to expect the Group to have adopted if dealing at arms-length with an unrelated person.</p> <p>Revenue from rendering of services to related parties is recognised on the same accounting policy outlined in Note 2 to the consolidated financial statements.</p>	\$3,207,512	\$3,447,166	\$4,216,082	\$6,147,972	\$4,525,449	\$2,525,655	(\$2,057,960)	\$22,011,876

¹ Where franchised stores or properties are partly owned by two or more Related Parties, the full transaction value has been included in the individual's balance. Eliminations have been made to ensure there is no double counting in the total.

**Remuneration Report
For the year ended 30 June 2025**

Type of transaction	Ms D Di Pilla	Mr D Gance	Mr J Gance	Mr M Verrocchi	Mr S Gance	Ms S Robertson	Eliminations ¹	Total
Fees revenue from Related Parties	\$564,979	\$962,834	\$1,977,184	\$2,545,956	\$2,256,471	\$922,864	(\$1,350,398)	\$7,879,890
Revenue derived predominantly by the Group from:								
<ul style="list-style-type: none"> management fees paid by Related Party franchisees under the supply arrangements for the Group securing and managing arrangements between the franchisees and certain third-party suppliers and wholesalers; and wholesale sales under the supply arrangements delivered directly by suppliers, revenue recognised represents consideration received from the Related Party net of amounts payable to third parties. 								
<p>These arrangements with Related Party franchisees are on terms and conditions no more favourable to the Related Party than those that it is reasonable to expect the Group to have adopted if dealing at arms-length with an unrelated person.</p>								
<p>Fees revenue from Related Parties is recognised on the same accounting policy outlined in Note 2 to the consolidated financial statements.</p>								

¹ Where franchised stores or properties are partly owned by two or more Related Parties, the full transaction value has been included in the individual's balance. Eliminations have been made to ensure there is no double counting in the total.

**Remuneration Report
For the year ended 30 June 2025**

Type of transaction	Ms D Di Pilla	Mr D Gance	Mr J Gance	Mr M Verrocchi	Mr S Gance	Ms S Robertson	Eliminations ¹	Total
Lease charges from Related Parties	(\$86,773)	(\$15,158,294)	(\$18,753,789)	(\$18,533,133)	(\$18,753,789)	-	\$52,411,429	(\$18,874,349)
<p>There are properties owned or controlled (either directly, indirectly or jointly) by a Related Party that are rented to the Group, which include retail properties that are sub-licensed to stores (see row immediately below), warehouses and offices. Under these arrangements, rent is paid by the Group to the Related Party that owns or controls the relevant property.</p> <p>Lease charges represent the rent and outgoings paid by the Group to the Related Party under each lease and is either:</p> <ul style="list-style-type: none"> • 'inherited' from the third-party prior owner of the property from which the Related Party acquired the property, in which case they have been negotiated on an arms' length basis by parties that are not related; or • set by reference to terms of a pro forma lease used by Chemist Warehouse with an independent valuation. Typically, key terms include an initial term of 6 years and 2 x 5-year options, with annual fixed percentage increases and a market rent review at the end of each term. <p>The leases are on terms and conditions no more favourable than those that it is reasonable to expect the Group to have adopted if dealing at arms-length with an unrelated person.</p>								

¹ Where franchised stores or properties are partly owned by two or more Related Parties, the full transaction value has been included in the individual's balance. Eliminations have been made to ensure there is no double counting in the total.

Remuneration Report
For the year ended 30 June 2025

Type of transaction	Ms D Di Pilla	Mr D Gance	Mr J Gance	Mr M Verrocchi	Mr S Gance	Ms S Robertson	Eliminations ¹	Total
Lease income from Related Parties under the franchise arrangements (occupancy license)	\$2,569,527	\$2,555,048	\$8,836,308	\$10,291,615	\$4,225,720	\$2,516,812	(\$7,423,747)	\$23,571,283
<p>The Group has leased retail properties from Related Parties (as noted in the row immediately above). The Group in turn licences these properties to franchisees under the franchise arrangements, including Related Parties, pursuant to occupancy licences.</p> <p>Lease income represents the amount paid to the Group under these occupancy licences.</p> <p>The occupancy licences with Related Parties are on terms and conditions no more favourable than those that it is reasonable to expect the Group to have adopted if dealing at arms-length with an unrelated person.</p>								

¹ Where franchised stores or properties are partly owned by two or more Related Parties, the full transaction value has been included in the individual's balance. Eliminations have been made to ensure there is no double counting in the total.

Remuneration Report
For the year ended 30 June 2025

Amounts recognised as assets and liabilities

At the end of the financial year ended 30 June 2025, the following are related party balances in the Group's balance sheet. These balances are in relation to the transactions identified in the above table:

	Ms D Di Pilla	Mr D Gance	Mr J Gance	Mr M Verrocchi	Mr S Gance	Ms S Robertson	Eliminations ¹	Total
Current assets	40,970,672	47,872,839	124,808,811	155,404,907	81,501,501	44,241,226	(101,080,313)	393,719,643
Trade receivables	37,101,839	43,308,305	107,941,009	136,581,775	74,574,709	39,930,606	(86,852,453)	352,585,790
Lease receivables	3,868,833	4,564,534	16,867,802	18,823,132	6,926,792	4,310,620	(14,227,860)	41,133,853
Current liabilities	2,776,338	25,363,465	35,543,902	36,982,945	33,405,115	1,933,864	(85,321,603)	50,684,026
Trade payables	2,643,843	2,150,581	7,087,557	8,921,334	4,948,770	1,933,864	(5,642,676)	22,043,273
Lease liabilities	132,495	22,789,667	27,858,128	27,513,394	27,858,128	-	(78,109,276)	28,042,536
Provision for makegood	-	423,217	598,217	548,217	598,217	-	(1,569,651)	598,217
Non-current assets	25,069,228	26,575,518	95,422,485	110,957,491	38,379,411	23,509,657	(82,708,640)	237,205,150
Lease receivables	25,069,228	26,575,518	95,422,485	110,957,491	38,379,411	23,509,657	(82,708,640)	237,205,150
Non-current liabilities	1,325,988	175,763,563	213,335,815	211,629,544	213,335,815	-	(600,323,621)	215,067,104
Lease liabilities	1,300,988	173,462,926	210,504,695	208,776,127	210,504,695	-	(592,363,447)	212,185,984
Provision for makegood	25,000	2,300,637	2,831,120	2,853,417	2,831,120	-	(7,960,174)	2,881,120

¹ Where franchised stores or properties are partly owned by two or more Related Parties, the full related party balance has been included in the individual's balance. Eliminations have been made to ensure there is no double counting in the total.

Remuneration Report For the year ended 30 June 2025

11. Other related party transactions with KMPs occurring in the financial year ended 30 June 2025

My Beauty Spot

My Beauty Spot (MBS) and its associated kiosks are currently in run-down, with all kiosks in the process of being closed and the underlying leases terminated with the final MBS store expected to be closed permanently in the next financial year. MBS is jointly owned by Mr M Verrocchi and Mr J Gance.

In the year ended 30 June 2025, from the Implementation Date, MBS paid \$17,500 in administration fees to the Group and \$956,103 in revenue for the supply of stock by the Group.

At 30 June 2025, the Group had \$144,903 of current trade receivables owing from MBS.

AMS Constructions Pty Ltd

AMS Constructions Pty Ltd (AMS) is partly owned (less than 50%) by several related parties being Mr D Gance, Mr J Gance, Mr M Verrocchi and Mr S Gance. Following the Implementation Date in the year ended 30 June 2025, the aggregate fees charged by AMS to entities in the Group were \$581,116 and the aggregate fees charged to AMS by the Group was \$22,811.

At 30 June 2025, the Group had \$105,227 of current trade receivables owing from AMS and \$124,326 of current trade payables owing to AMS. The Group also had \$32,645 of current lease liability and \$317,336 of non-current lease liability owing to AMS.

Fit-out leases

The Group has entered into arrangements with a number of franchise stores in the Group to finance their establishment, expansion or relocation costs (Fit-out Leases). This includes both Related Party and non-related party stores. The financing includes equipment & fit-out lease agreements between the Group and franchise stores in the Group. In some instances, the Group acquires the fit-out from the store and leases it back to the store. The value of equipment and fit-out purchased by the Group from Related Parties since the Implementation Date under the Fit-out Leases is equal to \$315,139.

There are currently Fit-out Leases in place with Mr M Verrocchi, Mr J Gance, Mr D Gance, Mr S Gance, Ms D Di Pilla and Ms S Robertson. The aggregate amount charged by the Group to Related Parties under the Fit-out Leases in the year ended 30 June 2025 following the Implementation Date was \$929,346.

Close family members employed by the Group

Since the Implementation Date to 30 June 2025, three close family members of the KMP were employed by the Group and total employment benefit of \$35,562 was incurred in aggregate to these close family members by the Group. Subsequent to the financial year ended 30 June 2025, an additional close family member (Mr Matthew Verrocchi) entered into an employment arrangement with the Group. Mr Matthew Verrocchi's employment benefits will be included in the financial year ending 30 June 2026 aggregated close family members employment benefits disclosure.

Loans to KMP

The Group provides loans to Chemist Warehouse franchisees, including Related Party franchisees. In the year ended 30 June 2025 following the Implementation Date, there were no new loans made to the franchises owned or controlled (directly, indirectly or jointly) by Ms D Di Pilla and Mr S Gance in addition to historical and pre-existing loans that were made by Chemist Warehouse prior to the Implementation Date.

**Remuneration Report
For the year ended 30 June 2025**

Item	Ms D Di Pilla	Mr S Gance
1 Amount outstanding as at the Implementation Date	\$4,772,000	\$500,000
2 Interest paid and payable in the year ended 30 June 2025 following the Implementation Date to Sigma or its subsidiaries	\$124,536	\$13,338
3 Loans advanced in the year ended 30 June 2025 following the Implementation Date by Sigma or its subsidiaries	-	-
4 Difference between amount disclosed under item 2 and the amount that would have been charged on arm's length terms	-	-
5 Each write-down and each allowance for doubtful receivables recognised by Sigma or its subsidiaries	-	-
6 Settlement in the year ended 30 June 2025 following the Implementation Date to Sigma or its subsidiaries	(\$3,059,000)	(\$500,000)
7 The amount outstanding at 30 June 2025	\$1,713,000	-
8 The highest amount of the KMP's indebtedness during the year ended 30 June 2025	\$4,772,000	\$500,000

There were no other loans to KMP or any of their close family members during the financial year ended 30 June 2025.

Terms of transactions in the financial year

Refer to Sigma's Notice of Meeting released to ASX on 18 December 2024 in connection with the Merger for further details on the terms and conditions of certain transactions discussed above in this Report.

New related party arrangements entered into in the financial year ended 30 June 2025 following the Implementation Date

During the financial year and after the Implementation Date, the Group entered into the following arrangements that were approved by the Related Party Working Group under the Related Party Arrangements Approval:

- 2 new franchise and supply arrangements, representing \$3,114,923 in aggregate sales, service and fee revenue earned during the financial year ended 30 June 2025;
 - 1 new arrangement for Ms D Di Pilla
 - 1 new arrangement for Mr M Verrocchi
- 6 new occupancy licenses representing \$441,816 in aggregate rent earned during the financial year ended 30 June 2025:
 - 4 new occupancy licenses jointly with Mr M Verrocchi and Mr J Gance
 - 1 new occupancy license with Mr M Verrocchi
 - 1 new occupancy license with Mr S Gance
- 6 new lease arrangements representing \$607,943 in aggregate rent paid during the financial year ended 30 June 2025;
 - 5 new leases jointly with Mr M Verrocchi, Mr J Gance, Mr S Gance and Mr D Gance
 - 1 new lease jointly with Mr M Verrocchi, Mr J Gance and Mr S Gance
- 0 new loan arrangements
- 2 new fit-out arrangements representing \$708,721 in aggregate fit-out leases during the financial year ended 30 June 2025:
 - 1 new fit out arrangement with Ms D Di Pilla
 - 1 new fit out arrangement jointly with Mr M Verrocchi and Mr J Gance

These arrangements were approved by the related party working group (acting on authority delegated by the Independent Board Committee), consistent with the Related Party Arrangements Approval.

**Remuneration Report
For the year ended 30 June 2025**

Changes to existing related party arrangements entered into in the financial year ended 30 June 2025 following the Implementation Date

Changes to existing related party arrangements includes, for example, renewal of an existing lease, entry into a revised franchise or occupancy agreement to include a further non-related party partner or to update the franchise agreement for regulatory reasons.

Following the Implementation Date the following changes to existing related party arrangements have been made: 1 lease renewal, 7 revised franchise agreements to include a further non-related party partner and 6 revised occupancy arrangements to include a further non-related party partner. These arrangements remain on terms and conditions no more favourable to the Related Party than those that it is reasonable to expect the Group to have adopted if dealing at arms-length with an unrelated person.

The Group is in the process of rebranding 24 MyChemist franchised stores to Amcal or Discount Drug Stores (DDS), of which 13 are related party franchises. In the financial year ended 30 June 2025 following the Implementation Date, a total of 14 franchises have been rebranded, of which 6 are Related Party pharmacies. In all instances the rebranding of these franchises has not changed the existing commercial arrangements.

The above changes to existing related party arrangements were approved by the related party working group (acting on authority delegated by the Independent Board Committee), consistent with the Related Party Arrangements Approval.

This disclosure is required by the ASX Confirmation Conditions.

Remuneration Report
For the year ended 30 June 2025

TABLE 3A: LTI loan funded shares: details of movement during the financial year 1 July 2024 to 30 June 2025

Executive	Grant Date	Share Price at Grant \$	Fair Value Per Share Grant Date ¹ \$	Exercise Price \$	Exercise Date ²	Number of Loan Funded Shares						Loan Value and Balance ³			
						Balance at 01/07/24	Granted During the Year	Vested During the Year	Forfeited During the Year	Exercised During the Year	Balance at 30/06/25	Loan Value at Grant Date \$	Loan Balance at 01/07/24 ⁶ \$	Loan Repayments During the Year ⁴ \$	Loan Balance at 30/06/25 \$
Mr V Ramsunder	01/02/2022	0.4650	0.1100	0.4650	01/02/2025	10,179,605	-	10,179,605	-	(10,179,605)	-	4,733,516	4,585,149	4,585,149	-
Mr M Verrocchi ⁶	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Mr D Gance ⁶	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Ms D Di Pilla ⁶	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Mr M Davis ⁶	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Mr M Conway ^{5,7}	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

1. For accounting purposes, the fair value of the loan funded shares was calculated using the Black-Scholes option pricing model with Monte Carlo simulations.
2. Loan funded shares will only vest after satisfying the specific vesting conditions and will expire at the end of the five-year loan period subject to forfeiture conditions.
3. Loan value and balance are rounded to the nearest whole number.
4. Represents loan repayment through forfeited shares and/or dividend payment.
5. Mr M Conway was not eligible to participate in the 2022 LTI plan.
6. Commenced as Key Management Personnel upon implementation of merger on 12 February 2025.
7. Ceased as Key Management Personnel from 12 February 2025.

**Remuneration Report
For the year ended 30 June 2025**

TABLE 3B: Rights: details of movement during the financial year 1 July 2024 to 30 June 2025

Executive	Grant Date	Fair Value Per Right at Grant ¹ \$	Exercise Price \$	Exercise Date ²	Number of Rights								Vesting Date	Expiry Date
					Balance at 01/07/24	Granted during the Year	Vested during the Year	Vested %	Lapsed during the Year	Exercised during the Year	Balance – vested at 30/06/25	Balance – unvested at 30/06/25		
Mr V Ramsunder	01/02/2022	0.4200	-	01/02/2024	1,482,422	-	-	-	-	(1,482,422)	-	-	31/01/2024	31/01/2026
	01/02/2023	0.4150	-	01/02/2026	3,112,283	-	-	-	(3,112,283)	-	-	-	31/01/2026	31/01/2028
	01/02/2023	0.6200	-	01/02/2024	240,462	-	-	-	-	(240,462)	-	-	31/01/2024	31/01/2027
	01/02/2024	0.6700	-	01/02/2027	1,010,723	-	-	-	-	-	-	1,010,723	30/06/2027	31/01/2029
	01/02/2024	0.6200	-	01/02/2025	242,994	-	242,994	100%	-	(242,994)	-	-	31/01/2025	31/01/2028
Mr M Conway ³	01/02/2024	0.6700	-	01/02/2027	281,141	-	-	-	-	-	-	281,141	30/06/2027	31/01/2029
	01/02/2024	0.6200	-	01/02/2025	17,850	-	17,850	100%	-	(17,850)	-	-	31/01/2025	31/01/2028

1. For accounting purposes, the fair value of the rights have been valued using the Monte Carlo simulation option pricing model for market hurdle rights and Black-Scholes option pricing model for the non-market hurdle.
2. Rights will only vest after satisfying the specific vesting conditions and are subject to forfeiture conditions.
3. Ceased as Key Management Personnel from 12 February 2025.

Remuneration Report
For the year ended 30 June 2025

TABLE 4A: Shareholdings of Key Management Personnel for financial year 1 July 2024 to 30 June 2025

2025	Number of Shares at 01/07/2024	Number of Shares acquired through Share Plans during the year	Interest in Sigma Shares on Implementation of the merger on 12 February 2025 ³	Number of Shares purchased during the year	Number of Shares sold during the year	Number of Share on date of ceasing to be a KMP	Number of shares at 30/06/2025 ⁴
NON-EXECUTIVE DIRECTORS							
Ms K Spargo ²	714,932	4,747	719,679	-	-	719,679	n/a
Ms A Carey	17,550	3,662	21,212	-	-	-	21,212
Mr N Mitchell	25,955	4,340	30,295	-	-	-	30,295
Dr C Roberts	8,353	3,661	12,014	-	-	-	12,014
Mr M Sammells	250,582	7,866	258,448	-	-	-	258,448
Mr J Gance ¹	n/a	-	1,579,052,263	-	-	-	1,579,052,263
Subtotal for Non-Executive Directors	1,017,372	24,276	1,580,093,911	-	-	719,679	1,579,374,232
EXECUTIVES							
Mr V Ramsunder	1,482,423	13,312,589	14,795,012	-	(11,662,028)	-	3,132,984
Mr M Verrocchi ¹	n/a	-	2,555,284,920	-	-	-	2,555,284,920
Mr D Gance ¹	n/a	-	400,240,023	-	(266,500,000)	-	133,740,023
Ms D Di Pilla ¹	n/a	-	105,471,272	-	(29,842,150)	-	75,629,122
Mr M Davis ¹	n/a	-	11,938,067	-	(9,238,067)	-	2,700,000
Mr M Conway ²	17,850	-	17,850	-	-	17,850	n/a
Subtotal for Executives	1,500,273	13,312,589	3,087,747,144	-	(317,242,245)	17,850	2,770,487,049
TOTAL	2,517,645	13,336,865	4,667,841,055	-	(317,242,245)	737,529	4,349,861,281

1. Commenced as Key Management Personnel upon implementation of merger on 12 February 2025.
2. Ceased as Key Management Personnel from 12 February 2025.
3. Any shares held prior to implementation is included in the "Interest in Sigma Shares on Implementation" column, in addition to any shares received on 12 February 2025.
4. Includes some restricted shareholdings. For details relating to restricted shareholdings of Key Management Personnel, refer to Table 4C.

Remuneration Report
For the year ended 30 June 2025

TABLE 4B: Performance rights and options (loan funded shares) holdings of Key Management Personnel for financial year 1 July 2024 to 30 June 2025

2025	Number of Rights/Options at 01/07/2024	Number of Rights/Options granted through Share Plans during the year	Number of Rights/Options Exercised during the year	Number of Rights/Options Lapsed/Forfeited during the year	Number of Rights/Options on date of ceasing to be a KMP	Number of Rights/Options at 30/06/2025
NON-EXECUTIVE DIRECTORS						
Ms K Spargo ²	n/a	n/a	n/a	n/a	n/a	n/a
Ms A Carey	n/a	n/a	n/a	n/a	n/a	n/a
Mr N Mitchell	n/a	n/a	n/a	n/a	n/a	n/a
Dr C Roberts	n/a	n/a	n/a	n/a	n/a	n/a
Mr M Sammells	n/a	n/a	n/a	n/a	n/a	n/a
Mr J Gance ¹	n/a	n/a	n/a	n/a	n/a	n/a
Subtotal for Non-Executive Directors	n/a	n/a	n/a	n/a	n/a	n/a
EXECUTIVES						
Mr V Ramsunder	16,268,489	-	(12,145,483)	(3,112,283)	-	1,010,723
Mr M Verrocchi ¹	-	-	-	-	-	-
Mr D Gance ¹	-	-	-	-	-	-
Ms D Di Pilla ¹	-	-	-	-	-	-
Mr M Davis ¹	-	-	-	-	-	-
Mr M Conway ²	298,991	-	(17,850)	-	281,141	n/a
Subtotal for Executives	16,567,480	-	(12,163,333)	(3,112,283)	281,141	1,010,723
TOTAL	16,567,480	-	(12,163,333)	(3,112,283)	281,141	1,010,723

1. Commenced as Key Management Personnel upon implementation of merger on 12 February 2025.
2. Ceased as Key Management Personnel from 12 February 2025.

Remuneration Report
For the year ended 30 June 2025

TABLE 4C: Restricted shareholdings of Key Management Personnel for financial year 1 July 2024 to 30 June 2025

2025	Number of Restricted Shares at 01/07/2024	Number of Restricted Shares granted through Share Plans during the year	Number of Restricted Shares on Implementation of the merger on 12 February 2025	Number of Restricted Shares Vested during the year	Number of Restricted Shares Forfeited during the year	Number of Restricted Shares on date of ceasing to be a KMP	Number of Restricted Shares at 30/06/2025
NON-EXECUTIVE DIRECTORS							
Ms K Spargo ²	-	-	-	-	-	-	n/a
Ms A Carey	-	-	-	-	-	-	-
Mr N Mitchell	-	-	-	-	-	-	-
Dr C Roberts	-	-	-	-	-	-	-
Mr M Sammells	-	-	-	-	-	-	-
Mr J Gance ¹	-	-	1,579,050,058 ⁴	-	-	-	1,579,050,058
Subtotal for Non-Executive Directors	-	-	1,579,050,058	-	-	-	1,579,050,058
EXECUTIVES							
Mr V Ramsunder	-	1,167,106 ³	1,167,106	-	-	-	1,167,106
Mr M Verrocchi ¹	-	-	2,555,284,920 ⁴	-	-	-	2,555,284,920
Mr D Gance ¹	-	-	-	-	-	-	-
Ms D Di Pilla ¹	-	-	-	-	-	-	-
Mr M Davis ¹	-	-	-	-	-	-	-
Mr M Conway ²	-	-	-	-	-	-	n/a
Subtotal for Executives	-	1,167,106	2,556,452,026	-	-	-	2,556,452,026
TOTAL	-	1,167,106	4,135,502,084	-	-	-	4,135,502,084

1. Commenced as Key Management Personnel upon implementation of merger on 12 February 2025.
2. Ceased as Key Management Personnel from 12 February 2025.
3. 37.5% of the 2023 EEG Rights vested upon the merger completion, and the corresponding shares granted are subject to disposal restrictions until, and forfeiture for ceasing employment before 31 January 2026. The fair value of these restricted shares at the date of acquisition was \$2.62 per share.
4. Mr M Verrocchi and Mr J Gance entered into voluntary escrow arrangements regarding the Sigma shares allotted to them in connection with the merger.

**Remuneration Report
For the year ended 30 June 2025**

TABLE 5A: Inputs used in determination of fair value of share-based payments schemes

Prior to the merger with Chemist Warehouse, Sigma's Board and shareholders approved the modification to existing performance rights in the context of the merger and the change of control provisions within the incentive schemes.

The inputs used in the measurement of the fair values of the share-based payments schemes at the modification date are set out below:

	2022 LTI LFS		2023 LTI EEG			2024 LTI	
	ROIC	TSR	Tranche A	Tranche B	Tranche C	EPS	TSR
	Non-market	Market	Non-market	Non-market	Market	Non-market	Market
Grant date	1-Feb-22	1-Feb-22	1-Feb-23	1-Feb-23	1-Feb-23	1-Feb-24	1-Feb-24
Share price at grant date	\$0.47	\$0.47	\$0.65	\$0.65	\$0.65	\$1.01	\$1.01
Fair value at grant date	\$0.13	\$0.09	\$0.57	\$0.57	\$0.26	\$0.93	\$0.41
Modification date	29-Jan-25	29-Jan-25	29-Jan-25	29-Jan-25	29-Jan-25	29-Jan-25	29-Jan-25
Share price pre-modification	\$3.03	\$3.03	\$3.03	\$3.03	\$3.03	\$3.03	\$3.03
FV (pre-modification)	N/A	N/A	\$2.95	\$3.03	\$2.95	\$2.88	\$2.84
Share price post-modification	N/A	N/A	\$3.10	\$3.10	\$3.10	\$3.10	\$3.10
FV (post-modification)	N/A	N/A	\$3.02	\$3.10	N/A	\$2.85	\$2.79
Vesting life from grant date	3 Years	3 Years	3 Years	3 Years	3 Years	3 Years	3 Years
Option life from grant date	5 Years	5 Years	5 Years	5 Years	5 Years	5 Years	5 Years

On implementation of the merger on 12 February 2025, in accordance with AASB 3 *Business Combinations*, Chemist Warehouse was identified as the accounting acquirer of Sigma, known as a reverse acquisition. Under AASB 3, the purchase consideration includes replacement employee share awards issued by the accounting acquirer for existing awards issued by the acquiree to its employees, to the extent that the market-based measure of the replacement awards is attributed to pre-merger services rendered by the employees. Whilst Chemist Warehouse did not issue replacement awards to Sigma's employees, the effects of the merger resulting in modification to the employee share awards are assessed to be in substance replacements issued by the Merged Group. The Terms & Conditions of these awards remained unchanged since the initial modification on 29 January 2025.

The fair value of these replacement awards on the date of acquisition (12 February 2025) is disclosed below:

	2022 LTI LFS		2023 LTI EEG			2024 LTI	
	ROIC	TSR	Tranche A	Tranche B	Tranche C	EPS	TSR
	Non-market	Market	Non-market	Non-market	Market	Non-market	Market
Modification date	12-Feb-25	12-Feb-25	12-Feb-25	12-Feb-25	12-Feb-25	12-Feb-25	12-Feb-25
Share price at modification date	\$2.76	\$2.76	\$2.76	\$2.76	\$2.76	\$2.76	\$2.76
Acquisition date fair value	N/A	N/A	\$2.69	\$2.76	\$2.62	\$2.60	\$2.54



Auditor's Independence Declaration

As lead auditor for the audit of Sigma Healthcare Limited for the year ended 30 June 2025, I declare that to the best of my knowledge and belief, there have been:

- a. no contraventions of the auditor independence requirements of the *Corporations Act 2001* in relation to the audit; and
- b. no contraventions of any applicable code of professional conduct in relation to the audit.

This declaration is in respect of Sigma Healthcare Limited and the entities it controlled during the period.

Alison Tait Milner

Alison Tait Milner
Partner
PricewaterhouseCoopers

Melbourne
27 August 2025

PricewaterhouseCoopers, ABN 52 780 433 757
2 Riverside Quay, SOUTHBANK VIC 3006,
GPO Box 1331, MELBOURNE VIC 3001
T: 61 3 8603 1000, F: 61 3 8603 1999, www.pwc.com.au

Sigma Healthcare Limited
Contents
30 June 2025

Consolidated statement of profit or loss and other comprehensive income	59
Consolidated balance sheet	60
Consolidated statement of changes in equity	61
Consolidated statement of cash flows	63
Notes to the consolidated financial statements	
About this report	65
Section 1: Group performance	69
Section 2: Group balance sheet	77
Section 3: Capital and risk management	90
Section 4: Group structure	100
Section 5: Other disclosures	117
Consolidated entity disclosure statement	122
Directors' declaration	124
Independent auditor's report	125

Sigma Healthcare Limited
Consolidated statement of profit or loss and other comprehensive income
For the year ended 30 June 2025

	Note	2025 \$'000	2024 \$'000
Revenue	2	6,001,835	3,294,402
Cost of sales		<u>(4,561,547)</u>	<u>(2,251,450)</u>
Gross profit		1,440,288	1,042,952
Share of profits of associates and joint ventures accounted for using the equity method	28	30,211	23,059
Other income		15,085	5,823
Expenses			
Warehousing and distribution expenses		(225,752)	(148,946)
Marketing and sales expenses		(107,907)	(88,259)
Administration and general expenses		(384,042)	(253,093)
Net finance costs	4	<u>(24,391)</u>	<u>(7,415)</u>
Profit before income tax expense		743,492	574,121
Income tax expense	5	<u>(218,037)</u>	<u>(34,464)</u>
Profit after income tax expense for the year		525,455	539,657
Other comprehensive income / (loss)			
<i>Items that will not be reclassified subsequently to profit or loss</i>			
Gain / (loss) on the revaluation of financial assets at fair value through other comprehensive income	24	20,217	1,314
Income tax impact		(6,035)	(394)
<i>Items that may be reclassified subsequently to profit or loss</i>			
Foreign currency translation	19	4,405	(1,144)
Income tax impact		<u>(1,754)</u>	<u>343</u>
Other comprehensive income/(loss) for the year, net of tax		16,833	119
Total comprehensive income for the year		<u>542,288</u>	<u>539,776</u>
Profit/(loss) for the year is attributable to:			
Non-controlling interests		(4,459)	(1,356)
Owners of the parent		<u>529,914</u>	<u>541,013</u>
		<u>525,455</u>	<u>539,657</u>
Total comprehensive income/(loss) for the year is attributable to:			
Non-controlling interests		(4,459)	(1,356)
Owners of the parent		<u>546,747</u>	<u>541,132</u>
		<u>542,288</u>	<u>539,776</u>
		cents	cents
Basic earnings per share	6	5.1	5.5
Diluted earnings per share	6	5.1	5.5

The above consolidated statement of profit or loss and other comprehensive income should be read in conjunction with the accompanying notes

Sigma Healthcare Limited
Consolidated balance sheet
As at 30 June 2025

	Note	2025 \$'000	2024 \$'000
Assets			
Current assets			
Cash and cash equivalents	17	138,774	273,124
Trade and other receivables	7	1,575,136	695,012
Inventories	8	1,019,778	599,903
Financial assets at amortised cost	9	512	3,808
Lease receivables	16	139,656	118,628
Other assets	10	34,573	26,144
Total current assets		<u>2,908,429</u>	<u>1,716,619</u>
Non-current assets			
Investments accounted for using the equity method	28	43,099	45,020
Financial assets at amortised cost	9	22,948	9,693
Financial assets at fair value through other comprehensive income	24	31,986	59,454
Financial assets at fair value through profit or loss	24	4,708	2,262
Property, plant and equipment	11	320,438	73,065
Right-of-use assets	16	238,729	113,020
Intangible assets	12	3,860,481	13,300
Deferred tax assets	5	28,535	87,332
Lease receivables	16	821,668	741,823
Other assets	10	6,781	-
Total non-current assets		<u>5,379,373</u>	<u>1,144,969</u>
Total assets		<u>8,287,802</u>	<u>2,861,588</u>
Liabilities			
Current liabilities			
Trade and other payables	13	1,323,603	745,824
Other liabilities	14	16,462	20,011
Borrowings	22	35,643	32,776
Lease liabilities	16	157,975	131,325
Current tax liabilities		124,906	2,777
Provisions	15	44,276	25,897
Total current liabilities		<u>1,702,865</u>	<u>958,610</u>
Non-current liabilities			
Other liabilities	14	17,104	14,777
Borrowings	22	855,292	300,000
Lease liabilities	16	1,021,846	849,598
Provisions	15	30,100	21,712
Total non-current liabilities		<u>1,924,342</u>	<u>1,186,087</u>
Total liabilities		<u>3,627,207</u>	<u>2,144,697</u>
Net assets		<u>4,660,595</u>	<u>716,891</u>
Equity			
Contributed equity	18	4,403,299	553,699
Reserves	19	(6,023)	(54,187)
Retained profits/(Accumulated losses)	20	273,263	222,906
Equity attributable to the owners of the Group		<u>4,670,539</u>	<u>722,418</u>
Non-controlling interests	29	(9,944)	(5,527)
Total equity		<u>4,660,595</u>	<u>716,891</u>

The above consolidated balance sheet should be read in conjunction with the accompanying notes

Sigma Healthcare Limited
Consolidated statement of changes in equity
For the year ended 30 June 2025

	Note	Contributed equity \$'000	Reserves \$'000	Retained earnings \$'000	Non-controlling interests \$'000	Total equity \$'000
Balance at 1 July 2024		553,699	(54,187)	222,906	(5,527)	716,891
Profit /(loss) after income tax expense		-	-	529,914	(4,459)	525,455
Other comprehensive income/(loss), net of tax		-	16,833	-	-	16,833
Total comprehensive income/(loss)		-	16,833	529,914	(4,459)	542,288
Transfer of gain/(loss) on disposal of equity investment at FV through OCI to retained profits, net of tax		-	(11,304)	11,304	-	-
<i>Transactions with owners in their capacity as owners:</i>						
Issue of new shares, pre-acquisition	18	47,900	-	-	-	47,900
Issue of shares on merger, net of transaction costs	18	4,489,968	-	-	-	4,489,968
Issuance of in-substance replacement equity compensation plans on merger	19	-	40,901	-	-	40,901
Cash distribution on merger	18	(700,000)	-	-	-	(700,000)
Employee shares exercised	18	7,182	-	-	-	7,182
Transfers related to share-based payments transactions	18	4,550	-	(4,550)	-	-
Share based payments		-	1,980	-	-	1,980
Transactions with non-controlling interests	29	-	-	-	42	42
Dividends provided for or paid	21	-	-	(486,036)	-	(486,036)
Other		-	(246)	(275)	-	(521)
Balance at 30 June 2025		4,403,299	(6,023)	273,263	(9,944)	4,660,595

The above consolidated statement of changes in equity should be read in conjunction with the accompanying notes

Sigma Healthcare Limited
Consolidated statement of changes in equity (continued)
For the year ended 30 June 2025

	Note	Contributed equity \$'000	Reserves \$'000	Retained earnings \$'000	Non-controlling interests \$'000	Total equity \$'000
Balance at 1 July 2023		549,391	(64,752)	(101,348)	(3,578)	379,713
Profit after income tax expense		-	-	541,013	(1,356)	539,657
Other comprehensive income/(loss), net of tax		-	119	-	-	119
Total comprehensive income		-	119	541,013	(1,356)	539,776
Transfer of gain/(loss) on disposal of equity investments at FV through OCI to retained profits, net of tax			(942)	942	-	-
<i>Transactions with owners in their capacity as owners:</i>						
Issue of new shares	18	4,308	-	-	-	4,308
Employee share schemes – value of employee service	36	-	15,513	-	-	15,513
Common control transactions		-	(4,125)	-	(183)	(4,308)
Dividends provided for or paid	21, 29	-	-	(217,701)	(410)	(218,111)
Balance at 30 June 2024		553,699	(54,187)	222,906	(5,527)	716,891

The above consolidated statement of changes in equity should be read in conjunction with the accompanying notes

Sigma Healthcare Limited
Consolidated statement of cash flows
For the year ended 30 June 2025

	Note	2025 \$'000	2024 \$'000
Cash flows from operating activities			
Receipts from customers (inclusive of GST)		6,448,080	3,291,324
Payments to suppliers and employees (inclusive of GST)		<u>(5,731,414)</u>	<u>(2,928,743)</u>
		716,666	362,581
Interest and other finance costs paid		(91,715)	(64,227)
Interest and other finance income received		67,566	56,812
Income taxes paid		<u>(93,689)</u>	<u>(81,989)</u>
Net cash from operating activities	17	<u>598,828</u>	<u>273,177</u>
Cash flows from investing activities			
Payments for property, plant and equipment		(52,562)	(32,838)
Payments for financial assets at fair value through other comprehensive income		-	(2,874)
Payments for financial assets at fair value through profit or loss		(2,762)	-
Proceeds from acquisition of subsidiaries, net of acquired cash		158,359	-
Payment for acquisition of associates		(3,988)	-
Acquisition of intangibles		(5,000)	(8,500)
Loans provided to other entities		(26,946)	(10,072)
Loan repayments from other entities		15,795	-
Proceeds from sale of investments		55,756	3,974
Distribution from associates		153	121
Principal elements of lease receipts		<u>127,661</u>	<u>109,478</u>
Net cash earned from investing activities		<u>266,466</u>	<u>59,289</u>
Cash flows from financing activities			
Proceeds from employee shares exercised		7,182	-
Payment for issuance of shares		(6,416)	-
Repayments of loans		(2,678,916)	(778,039)
Proceeds from loans		3,002,803	855,919
Principal elements of lease payments		(139,784)	(124,957)
Dividends paid to members of the company	21	(486,036)	(217,701)
Cash distribution to Chemist Warehouse shareholders	18	(700,000)	-
Dividends paid to non-controlling interests	29	-	(410)
Transactions with non-controlling interests	29	<u>42</u>	<u>-</u>
Net cash used in financing activities		<u>(1,001,125)</u>	<u>(265,188)</u>
Net increase /(decrease) in cash and cash equivalents		(135,831)	67,278
Cash and cash equivalents at the beginning of the financial year		273,124	206,647
Effects of exchange rate changes on cash and cash equivalents		<u>1,481</u>	<u>(801)</u>
Cash and cash equivalents at the end of the financial year	17	<u>138,774</u>	<u>273,124</u>

The above consolidated statement of cash flows should be read in conjunction with the accompanying notes

Sigma Healthcare Limited
Notes to the consolidated financial statements
30 June 2025

Contents of the notes to the consolidated financial statements

About this report

Group performance

- 1 Segment information
- 2 Revenue
- 3 Expenses
- 4 Finance income and expenses
- 5 Income tax
- 6 Earnings per share

Group balance sheet

- 7 Trade and other receivables
- 8 Inventories
- 9 Financial assets at amortised cost
- 10 Other assets
- 11 Property, plant and equipment
- 12 Intangible assets
- 13 Trade and other payables
- 14 Other liabilities
- 15 Provisions
- 16 Leases

Capital and risk management

- 17 Notes to the statement of cash flows
- 18 Issued capital
- 19 Reserves
- 20 Retained earnings
- 21 Dividends
- 22 Borrowings
- 23 Financial risk management
- 24 Fair value measurement

Group structure

- 25 Business combinations
- 26 Results of Sigma Consolidated Group pre-transaction
- 27 Interest in other entities
- 28 Investments accounted for using the equity method
- 29 Non-controlling interests
- 30 Deed of cross guarantee
- 31 Parent entity financial information
- 32 Related party transactions

Other disclosures

- 33 Remuneration of auditors
- 34 Commitments
- 35 Key management personnel
- 36 Share-based payments
- 37 Events after the reporting period

Sigma Healthcare Limited
Notes to the consolidated financial statements
30 June 2025

About this report

Sigma Healthcare Limited (referred to as “Sigma” or the “Company”) is a for-profit company limited by shares incorporated and domiciled in Australia whose shares are publicly traded on the Australian Securities Exchange (“ASX”). The financial report was authorised for issue by the Directors on 27 August 2025.

Basis of preparation

The consolidated financial statements are general purpose financial statements which:

- have been prepared in accordance with the requirements of the *Corporations Act 2001*, Australian Accounting Standards and other authoritative pronouncements of the Australian Accounting Standards Board (“AASB”) and International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”);
- have been prepared on a historical basis, except for investments which have been measured at fair value;
- are presented in Australian dollars (Sigma’s functional and presentation currency) with all values rounded to the nearest thousand dollars unless otherwise stated, in accordance with *ASIC Corporations (Rounding in Financial/Directors’ Reports) Instrument 2016/191*;
- presents reclassified comparative information where required for consistency with current financial year disclosures;
- applies relevant new Accounting Standards and Interpretations which are effective for the reporting period commencing 1 July 2024, as listed below; and
- does not early adopt Accounting Standards and Interpretations that have been issued or amended but are not yet effective.

Reverse acquisition

On 12 February 2025, the implementation of the scheme of arrangement (“Scheme”), under which Sigma Healthcare Limited (“Sigma”) would acquire 100% of the issued shares in CW Group Holdings Limited (“Chemist Warehouse” or “CW”), was completed.

Under the Scheme, Sigma Healthcare Limited acquired 100% of the shares in Chemist Warehouse. The transaction resulted in the previous Chemist Warehouse shareholders receiving \$700.0 million cash and 9,906,180,588 Sigma shares.

Sigma is the legal acquirer of Chemist Warehouse. For financial reporting purposes, Chemist Warehouse will be identified as the accounting acquirer, known as a reverse acquisition, when applying AASB 3 *Business Combinations*. Chemist Warehouse is identified as the accounting acquirer, and Sigma the accounting acquiree, because the shareholders of Chemist Warehouse obtained control of the combined Group (85.8% shareholdings), the change in Board composition with four Chemist Warehouse shareholders appointed as directors and the relative size of the two businesses.

Under AASB 3, the purchase consideration is determined with reference to the value of shares that Chemist Warehouse would have needed to issue in order to acquire Sigma at the acquisition date, being \$4,494.5 million. The \$700.0 million cash payment is a capital distribution to the previous Chemist Warehouse shareholders, and therefore is accounted for separately to the business combination.

Whilst Sigma Healthcare Limited is the legal entity and these financial statements are represented as Sigma financial statements, they have been prepared on the basis of Chemist Warehouse being the accounting acquirer, representing the continuing financial statements.

The financial statements of the Group for the year ended 30 June 2025 have been prepared on the following basis:

- Chemist Warehouse continuing accounts at historical cost and is the accounting acquirer; and
- Sigma recognised at fair value on date of acquisition and is the accounting acquiree.

The comparative information presented in the financial statements is that of Chemist Warehouse for the year ended 30 June 2024, unless otherwise stated.

Refer to Note 25 Business Combinations for further details of the reverse acquisition and Note 18 Issued Capital for accounting treatment of the \$700.0 million cash distribution.

Sigma Healthcare Limited
Notes to the consolidated financial statements
30 June 2025

Financial reporting obligations – ASIC relief

Pre-implementation of the Scheme, Sigma and Chemist Warehouse had different balance dates. Sigma's financial year ends on 31 January, whilst Chemist Warehouse's financial year ends on 30 June.

Given the complexity with reconciling conflicting legal and accounting requirements applying to the preparation of the Sigma and Chemist Warehouse accounts following the implementation of the merger (Merged Group), ASIC has granted relief that will allow Sigma to meet its financial reporting obligations based on a notional financial year that runs to 30 June each year, enabling the Merged Group to report in accordance with Chemist Warehouse's financial year end of 30 June.

As a result of receiving this relief, Sigma will meet its financial reporting obligations under Part 2M.3 of the *Corporations Act 2001* in relation to notional financial years ending 30 June and notional half-years ending 31 December, as if those were Sigma's statutory financial years and half-years.

In light of the ASIC relief, ASX has provided confirmation that it will apply certain ASX Listing Rules under Chapter 4 which require the lodgement of half-year and full year results, as if Sigma's half-year and full year balance dates at 31 December and 30 June respectively.

Within this report whenever there is reference to the financial year ended 30 June 2025 or year ended 30 June 2025, it is referring to the notional financial year ended 30 June 2025 unless stated otherwise.

Basis of consolidation

The consolidated financial statements are of the consolidated entity consisting of the Company and its subsidiaries (together referred to as the "Group").

Subsidiaries are all entities over which the Group has control. The Group controls an entity when the Group has power over the investee, is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power to direct the activities of the entity. Subsidiaries are fully consolidated from the date on which control is transferred to the Group. They are de-consolidated from the date that control ceases.

Inter-company transactions, balances and unrealised gains on transactions between Group companies are eliminated. Unrealised losses are also eliminated unless the transaction provides evidence of an impairment of the transferred asset. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the Group.

Non-controlling interests in the results and equity of subsidiaries are shown separately in the consolidated statement of profit or loss and other comprehensive income, balance sheet and statement of changes in equity respectively.

Notes to the financial statements

The notes included in the financial statements contain information which is required to understand the consolidated financial statements and is material and relevant to the operations, financial performance and position of the Group.

Information is considered material and relevant if, for example:

- the amount in question is significant because of its size or nature
- it is important for understanding the results of the Group
- it helps explain the impact of significant changes in the Group's business
- it relates to an aspect of the Group's operations that is important to its future performance

The notes in these financial statements have been organised into the following sections to help users find and understand the information they need to know:

- **Group Performance:** focuses on the results and performance of the Group;
- **Group Balance Sheet:** provides information on individual line items in the balance sheet that the directors consider most relevant;
- **Capital and Risk Management:** outlines how the Group manages its capital and various financial risks;
- **Group Structure:** provides information relating to subsidiaries and other material investments and divestments of the Group, as well as disclosing related party transactions and balances; and
- **Other Disclosures:** provides information on items which require disclosure to comply with Australian Accounting Standards and other regulatory pronouncements.

Sigma Healthcare Limited
Notes to the consolidated financial statements
30 June 2025

Key accounting judgements and estimates

Preparation of the financial report requires management to make judgements, estimates and assumptions about future events. Information on material estimates and judgements used in applying the accounting policies can be found in the following notes:

Judgement area	Note
Revenue – variable consideration	2
Inventory net realisable value	8
Impairment of goodwill and other intangible assets	12
Leases	16
Fair value of assets and liabilities	24
Business combinations	25
Consolidation assessment of franchisees	27
Investments accounted for using the equity method	28

Foreign currency translation

Items included in the financial statements of each of the Group in the financial statements are presented in Australian dollars, which is Sigma Healthcare Limited's functional and presentation currency.

Foreign currency transactions are translated into functional currency using the exchange rates at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation of monetary assets and liabilities denominated in foreign currencies at year end exchange rates are generally recognised in profit or loss.

The results and financial position of foreign operations (none of which has the currency of a hyperinflationary economy) that have a functional currency different from the presentation currency are translated into the presentation currency as follows:

- assets and liabilities for each balance sheet presented are translated at the closing rate at the date of that balance sheet
- income and expenses for each statement of profit or loss and statement of comprehensive income are translated at average exchange rates (unless this is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, in which case income and expenses are translated at the dates of the transactions), and
- all resulting exchange differences are recognised in other comprehensive income.

New Accounting Standards and Interpretations adopted by the Group

The Group has applied the following standards and amendments for the first time for its annual reporting period commencing 1 July 2024:

- AASB 2020-1 *Amendments to Australian Accounting Standards – Classification of Liabilities as Current or Non-current [AASB 101]*
- AASB 2022-6 *Amendments to Australian Accounting Standards – Non-current Liabilities with Covenants [AASB 101]*

The amendments listed above did not have any material impact on the amounts recognised in prior periods and are not expected to significantly affect the current or future period.

Sigma Healthcare Limited
Notes to the consolidated financial statements
30 June 2025

New Accounting Standards and Interpretations not yet adopted

Certain new accounting standards and amendments to accounting standards have been published that are not mandatory for 30 June 2025 reporting periods and have not been early adopted by the Group. Other than the below standards, these are not considered relevant to the activities of the Group, nor are they expected to have a material impact on the financial statements of the Group:

- AASB 18 *Presentation and Disclosure in Financial* (effective for annual periods commencing on or after 1 January 2027) – AASB 18 will replace AASB 101 *Presentation of financial statements*, introducing new requirements that will help achieve comparability of the financial performance of similar entities and provide more relevant information and transparency to users.
- AASB 2024-2 *Amendments to Australian Accounting Standards – Classification and Measurement of Financial Instruments [AASB 7 & AASB 9]* (effective for annual periods commencing on or after 1 January 2026) – this amendment clarifies that a financial liability is derecognised on the 'settlement date' and introduce an accounting policy choice to derecognise financial liabilities settled using an electronic payment system before the settlement date, along with some other clarifications and additional disclosures.

Management is currently assessing the impact of applying the new standards above.

Other accounting policies

The principal accounting policies adopted in the preparation of the financial statements are set out in the respective notes. These policies have been consistently applied to all the years presented, unless otherwise stated.

Group Performance

Note 1. Segment information

Description of segments

Management has determined the operating segments based on the reports reviewed and used by the Group's chief operating decision makers (CODM) to make strategic and operating decisions. The CODM has been identified as the Chief Executive Officer and Managing Director (CEO) and Executive Directors as disclosed in the Remuneration Report. The Group operates in one operating segment, being the Healthcare segment.

Notwithstanding the merger of Sigma and Chemist Warehouse, given the integration of the two businesses, the CODM views the business from a consolidated perspective and assesses the performance of the merged business on the same basis.

The CODM primarily uses statutory Profit before Tax (PBT), Normalised PBT and Normalised Earnings Before Interest and Tax (EBIT) to assess the operating performance of the business.

Reconciliation of Normalised EBIT to Statutory EBIT

	2025 \$'000	2024 \$'000
Normalised EBIT	834,527	590,142
Merger related costs ¹	(46,624)	(8,606)
Integration costs ²	(12,707)	-
Impact from PPA ³	(7,313)	-
Statutory EBIT	767,883	581,536

¹ Non-recurring costs incurred by the Group in association with the merger between Sigma and Chemist Warehouse. These costs include financial advisory, legal, regulatory, accounting, tax and other costs and do not relate to the ongoing operations of the Group.

² Costs incurred to integrate the Sigma and Chemist Warehouse businesses, post-merger. These include consulting and employee costs, compliance costs and impacts from alignment of accounting policies.

³ Non-cash charges related to the merger purchase price allocation (PPA) accounting.

Geographical regions

The Group operates in Australia, New Zealand, China, Ireland and UAE.

Disaggregation of revenue by geographic region

	2025 \$'000	2024 \$'000
Australia	5,654,168	3,005,482
International	347,667	288,920
	<u>6,001,835</u>	<u>3,294,402</u>

Sigma Healthcare Limited
Notes to the consolidated financial statements
30 June 2025

Note 1. Segment Information (continued)

Disaggregation of non-current assets by geographic region

	2025	2024
	\$'000	\$'000
Australia	4,365,135	168,601
International	54,512	30,784
	<u>4,419,647</u>	<u>199,385</u>

The disaggregation of non-current assets by geographic region excludes investments, financial instruments and deferred tax assets.

Information on Major Customers

The Group does not rely on any one customer for a significant component of revenue.

Accounting policy for operating segments

Operating segments are reported in a manner consistent with the internal reporting to the CODM.

The CEO and Executive Directors, as CODM, monitors the operating results on a consolidated basis, and accordingly, the Group has concluded that it has one reportable segment.

Note 2. Revenue

	2025	2024
	\$'000	\$'000
<i>Sales revenue</i>		
Sale of goods	5,130,246	2,424,772
Fees and other revenue	184,226	212,303
	<u>5,314,472</u>	<u>2,637,075</u>
<i>Services revenue</i>		
Franchise and related fees	204,747	168,316
Marketing, advertising and other	482,616	489,011
	<u>687,363</u>	<u>657,327</u>
Total revenue	<u>6,001,835</u>	<u>3,294,402</u>

Revenue recognised in relation to other liabilities

The following table shows how much of the revenue recognised in the current reporting period relates to carried-forward other liabilities:

	2025	2024
	\$'000	\$'000
<i>Revenue recognised that was included in the other liability balance at the beginning of the period</i>		
Sales revenue	5,378	2,232
Marketing, advertising and other	18,800	32,673
	<u>24,178</u>	<u>34,905</u>

Recognition and measurement

The Group derives its revenue from contracts with customers for the transfer of goods and services over time and at a point in time in the revenue streams summarised above and below.

The presentation of revenue is consistent with the segment reporting (refer to Note 1) as the Group has one reportable segment.

Sigma Healthcare Limited
Notes to the consolidated financial statements
30 June 2025

Note 2. Revenue (continued)

The Group generates a significant portion of its revenue from the following:

Sales revenue

Revenue stream	Description	Performance obligation	Timing of recognition
Sale of goods	Sale of goods, either to wholesale or retail customers. Consideration is recognised based on the price specified in the contract, net of estimated discounts and rebates. In recognising revenue from the sales of goods, the Group considers its historical experience with sales returns to determine if it is “highly probable” that a significant reversal of revenue will arise in the future.	Delivery of goods to customer	Point in time
Fees	(i) Management fees from franchisees for the Group securing and managing arrangements between the franchisees and certain third-party suppliers and wholesalers; (ii) revenue received from customers for wholesale sales delivered directly by suppliers, where the Group acts as an agent. Revenue recognised represents the consideration received from the customer, net of amounts payable to third parties.	Delivery of goods to customer	Point in time
Other – Community service obligation (CSO) income	Income earned from the Government to fulfil minimum delivery requirements for specified medicines to pharmacies in accordance with the Pharmaceutical Wholesaler Agreement (‘1PWA’).	Compliance with the obligations of the 1PWA	Over time

Services revenue

Revenue stream	Description	Performance obligation	Timing of recognition
Franchise and related fees	(i) Franchise fees and administration fees under the franchise or service arrangements; (ii) separate licence fees paid by franchisees in relation to the use of the Group intellectual property.	Over the term of the arrangements	Over time
Marketing, advertising and other	(i) Fees generated for promotional and advertising services rendered and other supplier income; (ii) Fees for services performed by the Group, including administration of discounts on products sold and packaging fees.	Completion of services to be rendered	Over time

Refund liability

A refund liability and a right to the returned goods are recognised for the products expected to be returned. Accumulated experience is used to estimate such returns at the time of sale at a portfolio level (expected value method). Because the number of products returned has been steady for years, it is highly probable that a significant reversal in the cumulative revenue recognised will not occur. The validity of this assumption and the estimated amount of returns are reassessed at each reporting date.

Critical accounting estimates and assumptions

Revenue – Variable consideration

Where contracts with customers includes variable consideration, the revenue’s transaction price includes an estimate of the variable consideration based on the expected value (the sum of probability-weighted amounts) in a range of possible consideration amounts. The estimation of that variable consideration is based on available historical outcomes of the variability.

Sigma Healthcare Limited
Notes to the consolidated financial statements
30 June 2025

Note 3. Expenses

	2025	2024
	\$'000	\$'000
Profit/(loss) before income tax includes the following specific expenses:		
<i>Depreciation and amortisation</i>		
Depreciation – property, plant and equipment	18,572	16,396
Depreciation – right-of-use assets	27,197	18,875
Amortisation – intangible assets	10,213	-
Total depreciation and amortisation	55,982	35,271
<i>Impairment of assets</i>		
Impairment – right-of-use assets	1,874	-
Impairment – property, plant and equipment	240	-
Total impairment of assets	2,114	-
<i>Merger related costs</i>		
Merger related costs ¹	46,624	8,606
<i>Employee benefits expenses</i>		
Employee benefits expenses	300,032	197,948
Defined contribution superannuation expense	21,903	15,308
Total employee benefits expenses	321,935	213,256
<i>Share-based payments expense</i>		
Share-based payments expense	3,894	15,513

(1) Merger related costs represent the non-recurring costs incurred by the Group in association with the merger between Sigma and Chemist Warehouse. These costs include financial advisory, legal, regulatory, accounting, tax and other costs and do not relate to the ongoing operations of the Group.

Note 4. Finance income and expenses

	2025	2024
	\$'000	\$'000
Interest and finance charges on lease receivables	50,476	44,936
Other net finance income	16,868	11,876
Interest and finance charges paid/payable for lease liabilities	(58,619)	(49,854)
Interest paid/payable on loans and borrowings	(33,116)	(14,373)
Net finance costs	(24,391)	(7,415)

Recognition and measurement

Finance costs attributable to qualifying assets are capitalised as part of the asset. All other finance costs are expensed in the period in which they are incurred.

Interest cost/income is recognised as interest accrues using the effective interest method. This is a method of calculating the amortised cost of a financial asset/liability and allocating the interest income/cost over the relevant period using the effective interest rate, which is the rate that exactly discounts estimated future cash receipts/payments through the expected life of the financial asset/liability to the net carrying amount of the financial asset/liability.

Sigma Healthcare Limited
Notes to the consolidated financial statements
30 June 2025

Note 5. Income tax

This note provides an analysis of the Group's income tax expense, shows what amounts are recognised directly in equity and how the tax expense is affected by non-assessable and non-deductible items.

	2025	2024
	\$'000	\$'000
(a) Income tax expense		
Current tax on profits for the year	213,146	172,377
Adjustment for current tax of prior periods	<u>2,371</u>	<u>(108,879)</u>
Total current tax expense	<u>215,517</u>	<u>63,498</u>
Decrease / (increase) in deferred tax assets	6,615	(2,609)
Adjustment for deferred tax of prior periods	<u>(4,095)</u>	<u>(26,425)</u>
Total deferred tax benefit	<u>2,520</u>	<u>(29,034)</u>
Aggregate income tax expense	<u>218,037</u>	<u>34,464</u>
(b) Numerical reconciliation of income tax expense and tax at the statutory rate		
Profit before income tax expense	<u>743,492</u>	<u>574,121</u>
Tax at the statutory tax rate of 30%	223,047	172,237
Tax effect amounts which are not deductible/(taxable) in calculating taxable income:		
Sundry items	(5,398)	(3,019)
Difference in overseas tax rate	2,112	550
Adjustments for current and deferred tax of prior periods	<u>(1,724)</u>	<u>(135,304)</u>
Income tax expense	<u>218,037</u>	<u>34,464</u>

Sigma Healthcare Limited
Notes to the consolidated financial statements
30 June 2025

Note 5. Income tax (continued)

	2025	2024
	\$'000	\$'000
(c) Deferred income tax		
Deferred tax asset comprises temporary differences attributable to:		
Employee benefits	13,755	7,699
Inventories	23,009	13,217
Contract liabilities	7,654	13,734
Provision for make good	13,628	11,929
Lease liabilities	349,951	295,873
Investments	2,586	5,912
Expenditure subject to 5-year write-off	25,030	29,136
Other	17,671	5,230
	<u>453,284</u>	<u>382,730</u>
Deferred tax liability comprises temporary differences attributable to:		
Lease receivables	(278,128)	(258,875)
Right of use assets	(65,268)	(31,529)
Make good asset	(5,278)	(4,994)
Intangible assets	(62,179)	-
Property, plant and equipment	(13,896)	-
	<u>(424,749)</u>	<u>(295,398)</u>
Deferred tax liability	<u>(424,749)</u>	<u>(295,398)</u>
Net deferred tax asset	<u>28,535</u>	<u>87,332</u>
Movements:		
Opening balance	87,332	56,576
Charged to profit or loss	(2,182)	29,025
Charged to other comprehensive income	(5,688)	9
Charged to equity	1,652	-
Tax losses converted to deferred tax assets	2,272	1,722
Deferred tax liability on acquisition	(54,851)	-
	<u>28,535</u>	<u>87,332</u>

OECD Pillar Two model rules

The Group is within the scope of the OECD Pillar Two model rules as it is an applicable multinational enterprise Group with annual consolidated revenue in excess of €750 million.

Pillar Two legislation has been enacted in Australia, the jurisdiction in which the Company is incorporated, with an effective date of 1 January 2024. Under the legislation, the Group may be liable to pay a top-up tax for the difference between its GloBE effective tax rate in each jurisdiction and the 15% minimum rate. The Group's current exposure to additional taxation under Pillar Two is immaterial.

Recognition and measurement

The income tax expense or credit for the period is the tax payable on the current period's taxable income based on the applicable income tax rate for each jurisdiction adjusted by changes in deferred tax assets and liabilities attributable to temporary differences and to unused tax losses.

The current income tax charge is calculated on the basis of the tax laws enacted or substantively enacted at the end of the reporting period in the countries where the company and its subsidiaries and associates operate and generate taxable income. Management periodically evaluates positions taken in tax returns with respect to situations in which applicable tax regulation is subject to interpretation. It establishes provisions where appropriate on the basis of amounts expected to be paid to the tax authorities.

Sigma Healthcare Limited
Notes to the consolidated financial statements
30 June 2025

Note 5. Income tax (continued)

The carrying amount of recognised and unrecognised deferred tax assets are reviewed at each reporting date. Deferred tax assets recognised are reduced to the extent that it is no longer probable that future taxable profits will be available for the carrying amount to be recovered. Previously unrecognised deferred tax assets are recognised to the extent that it is probable that there are future taxable profits available to recover the asset.

Deferred tax assets and liabilities are offset only where there is a legally enforceable right to offset current tax assets against current tax liabilities and deferred tax assets against deferred tax liabilities; and they relate to the same taxable authority on either the same taxable entity or different taxable entities which intend to settle simultaneously.

Australian tax consolidation

Sigma Healthcare Limited (the 'head entity') and its wholly owned Australian subsidiaries have formed an income tax consolidated Group under the tax consolidation regime. Prior to the merger, CW Group Holdings Limited and its wholly owned Australian subsidiaries were part of a separate consolidated Group. Upon the reverse acquisition, CW Group Holdings Limited joined the Sigma Tax Consolidated Group with effect from 12 February 2025.

The head entity and each subsidiary in the tax consolidated Group continue to account for their own current and deferred tax amounts. The tax consolidated Group has applied the 'separate taxpayer within Group' approach in determining the appropriate amount of taxes to allocate to members of the tax consolidated Group.

In addition to its own current and deferred tax amounts, the head entity also recognises the current tax liabilities (or assets) and the deferred tax assets arising from unused tax losses and unused tax credits assumed from each subsidiary in the tax consolidated Group.

Assets or liabilities arising under tax funding arrangements with the tax consolidated entities are recognised as amounts receivable from or payable to other entities in the tax consolidated Group. The tax funding arrangement ensures that the intercompany charge equals the current tax liability or benefit of each tax consolidated Group member.

Foreign entities are taxed individually within their respective tax jurisdictions.

ATO agreement

During the year ended 30 June 2024, the Group reached an agreement with the ATO that an expense of \$445,292,000 recognised during the year ended 30 June 2021 is deductible over five years. The revised tax treatment has been considered a change in estimate and accordingly, the Group has recognised a total tax benefit of \$133,587,600 in the year ended 30 June 2024. As at 30 June 2025 there is no deferred tax asset balance relating to this agreement (2024: \$26,717,521). Without the impact of this agreement with the ATO the effective tax rate for the year ended 30 June 2024 would have been 29%.

Goods and Services Tax ('GST')

Revenues, expenses and assets are recognised net of the amount of associated GST, unless the GST incurred is not recoverable from the tax authority. In this case it is recognised as part of the cost of the acquisition of the asset or as part of the expense.

Receivables and payables are stated inclusive of the amount of GST receivable or payable. The net amount of GST recoverable from, or payable to, the tax authority is included in other receivables or other payables in the balance sheet.

Cash flows are presented on a gross basis. The GST components of cash flows arising from investing or financing activities which are recoverable from, or payable to the tax authority, are presented as operating cash flows.

Commitments and contingencies are disclosed net of the amount of GST recoverable from, or payable to, the tax authority.

Sigma Healthcare Limited
Notes to the consolidated financial statements
30 June 2025

Note 6. Earnings per share

	2025	2024
	cents	cents
Total basic earnings per share attributable to the ordinary equity holders of the Company	5.1	5.5
Total diluted earnings per share attributable to the ordinary equity holders of the Company	5.1	5.5
Earnings used in calculating earnings per share		
	2025	2024
	\$'000	\$'000
<i>Basic and diluted earnings per share</i>		
Profit attributable to the ordinary equity holders of the Company used in calculating basic and diluted earnings per share	529,914	541,013
	2025	2024
	No.	No.
	(thousands)	(thousands)
Weighted average number of ordinary shares used as the denominator in calculating basic earnings per share	10,477,795	9,826,349
<i>Adjustments for calculation of diluted earnings per share:</i>		
Performance rights/options	4,092	-
Effect of shares held under Sigma Employee Share Plan	3,119	-
Weighted average number of ordinary shares and potential ordinary shares used as the denominator in calculating diluted earnings per share	<u>10,485,006</u>	<u>9,826,349</u>

Information concerning the classification of securities

Performance Rights granted to employees under the share plan are considered to be potential ordinary shares. They have been included in the determination of diluted earnings per share if the relevant performance hurdles have been met based on the Company's performance up to the conversion date, and to the extent to which they are dilutive.

Weighted average number of shares

Under the principles of reverse acquisition accounting (refer Note 25 Business Combinations), the equity structure (including the number of ordinary shares) reflects the equity structure of the legal parent (the accounting acquiree), including the equity interests the legal parent issued to effect the business combination.

Accordingly, the equity structure of the legal subsidiary (the accounting acquirer) in the comparative period has been restated using the exchange ratio (6.3:1) established in the scheme of arrangement (Scheme) to reflect the number of shares of the legal parent (the accounting acquiree) issued in the reverse acquisition, even though the issue of shares did not occur until the time of the reverse acquisition in the current period.

Accounting policy for earnings per share

Basic earnings per share

Basic earnings per share is calculated by dividing the profit attributable to the owners of the Group, excluding any costs of servicing equity other than ordinary shares, by the weighted average number of ordinary shares outstanding during the financial year, adjusted for bonus elements in ordinary shares issued during the financial year.

Diluted earnings per share

Diluted earnings per share adjusts the figures used in the determination of basic earnings per share to take into account the after-income tax effect of interest and other financing costs associated with dilutive potential ordinary shares and the weighted average number of shares assumed to have been issued for no consideration in relation to dilutive potential ordinary shares.

Sigma Healthcare Limited
Notes to the consolidated financial statements
30 June 2025

Group Balance Sheet

Note 7. Trade and other receivables

	2025	2024
	\$'000	\$'000
Trade receivables	1,527,828	673,130
Other receivables	47,308	21,882
	<u>1,575,136</u>	<u>695,012</u>

The following table summarises the ageing of current trade receivable balances, based on individual customer trading terms.

	2025	2024
	\$'000	\$'000
Current	1,472,194	643,025
0 - 30 days overdue	18,402	8,523
31 - 60 days overdue	18,027	8,095
61 - 90 days overdue	8,208	3,986
91 or more days overdue	10,997	9,501
	<u>1,527,828</u>	<u>673,130</u>

Recognition and measurement

Trade and other receivables are initially recognised at transaction price and subsequently measured at amortised cost using the effective interest method, less an allowance for impairment (expected credit loss). They are presented as current assets unless collection is not expected for more than 12 months after the reporting date. Trade receivables are generally due for settlement between 30 to 60 days.

Fair values of trade receivables

Due to the short-term nature of current receivables, their carrying amount is considered to be the same as their fair value.

Expected credit loss

The Group has applied the simplified approach to measuring expected credit losses, which uses a lifetime expected loss allowance. To measure the expected credit losses, trade receivables have been grouped based on days overdue.

The expected loss rates are based on the payment profiles of sales over a period of 12-24 months up to the reporting period. The historical loss rates are adjusted to reflect current and forward-looking information on macroeconomic factors affecting the ability of the customers to settle the receivables. The Group has historically incurred immaterial credit losses.

Note 8. Inventories

	2025	2024
	\$'000	\$'000
Stock on hand	<u>1,019,778</u>	<u>599,903</u>

Inventories recognised as an expense during the year ended 30 June 2025 amounts to \$4,272.3 million (2024: \$2,006.6 million). These were included in cost of sales in the consolidated statement of profit or loss.

Write-downs of inventories to net realisable value amounted to \$9,229,300 (2024: \$2,545,000). These were recognised as an expense during the year ended 30 June 2025 and included in cost of sales in the consolidated statement of profit or loss.

Sigma Healthcare Limited
Notes to the consolidated financial statements
30 June 2025

Note 8. Inventories (continued)

Recognition and measurement

Inventories are stated at the lower of cost and net realisable value. Costs are assigned to individual items of inventory on the basis of weighted average costs. Costs of purchased inventory are determined after deducting rebates and discounts. Net realisable value is the estimated selling price in the ordinary course of business less the estimated costs necessary to make the sale.

Critical accounting estimates and assumptions

Provision for impairment of inventories

The provision for impairment of inventories assessment requires a degree of estimation and judgement. The level of the provision is assessed by taking into account the recent sales history, the ageing of inventories and other factors that affect inventory obsolescence.

Note 9. Financial assets at amortised cost

	2025	2024
	\$'000	\$'000
<i>Current assets</i>		
Loans receivable	512	3,808
<i>Non-current assets</i>		
Loans receivable	22,948	9,693

For loans with related parties refer to Note 32 for details.

Classification of financial assets at amortised cost

The Group classifies its financial asset as at amortised cost only if both of the following conditions are met:

- (i) it is held within a business model whose objective is to hold assets in order to collect contractual cash flows; and
- (ii) the contractual terms of the financial asset represent contractual cash flows that are solely payments of principal and interest.

Recognition and measurement

Loans receivable are initially recognised at transaction price and subsequently measured at amortised cost using the effective interest method, less an allowance for impairment (expected credit loss).

The Group's policy is to recognise an allowance for expected credit losses (ECLs) for financial assets at amortised cost. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Group expects to receive, discounted at an approximation of the original effective interest rate. The expected cash flows will include cash flows from the sale of collateral held or other credit enhancements that are integral to the contractual terms.

The Group measures the loss allowance for loans receivable at an amount equal to 12-month ECL if the credit risk on the financial instrument has not increased significantly since initial recognition.

12-month ECL represents the portion of lifetime ECL that is expected to result from default events on a financial instrument that are possible within 12 months after the reporting date.

The Group has performed this assessment at the reporting dates and concluded no allowance is required based on expected payments.

Sigma Healthcare Limited
Notes to the consolidated financial statements
30 June 2025

Note 10. Other assets

	2025	2024
	\$'000	\$'000
<i>Current assets</i>		
Prepayments	28,065	20,404
Other current assets	6,508	5,740
	<u>34,573</u>	<u>26,144</u>
<i>Non-current assets</i>		
Other non-current assets	6,781	-

Note 11. Property, plant and equipment

	2025	2024
	\$'000	\$'000
Land and buildings - at cost	125,004	-
Less: Accumulated depreciation and impairment	(1,027)	-
	<u>123,977</u>	<u>-</u>
Furniture, fittings and equipment - at cost	254,485	122,980
Less: Accumulated depreciation and impairment	(58,024)	(49,915)
	<u>196,461</u>	<u>73,065</u>
Net book amount	<u>320,438</u>	<u>73,065</u>

Reconciliations

Reconciliations of the written down values at the beginning and end of the current and previous financial year are set out below:

	Land & buildings	Furniture, fittings & equipment	Total
	\$'000	\$'000	\$'000
Balance at 1 July 2023	-	61,265	61,265
Additions	-	41,726	41,726
Transfers to finance lease receivables	-	(13,530)	(13,530)
Depreciation expense	-	(16,396)	(16,396)
	<u>-</u>	<u>73,065</u>	<u>73,065</u>
Balance at 30 June 2024	-	73,065	73,065
Additions	-	43,642	43,642
Business combinations	125,004	125,042	250,046
Disposal	-	(650)	(650)
Transfers to finance lease receivables	-	(26,853)	(26,853)
Impairment expense	-	(240)	(240)
Depreciation expense	(1,027)	(17,545)	(18,572)
	<u>123,977</u>	<u>196,461</u>	<u>320,438</u>
Balance at 30 June 2025	<u>123,977</u>	<u>196,461</u>	<u>320,438</u>

Recognition and measurement

Property, plant and equipment is stated at historic cost less depreciation. Historical cost includes expenditure that is directly attributable to the acquisition of the items.

Sigma Healthcare Limited
Notes to the consolidated financial statements
30 June 2025

Note 11. Property, plant and equipment (continued)

Subsequent costs are included in the asset's carrying amount or recognised as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Group and the cost of the item can be measured reliably. The carrying amount of any component accounted for as a separate asset is derecognised when replaced. All other repairs and maintenance are charged to profit or loss during the reporting period in which they are incurred.

Depreciation is calculated on a diminishing value or straight line basis to allocate the cost of the assets over their expected useful lives, as follows:

Buildings	40 years
Furniture, fittings and equipment	2 - 20 years

The asset's residual values and useful lives are reviewed, and adjusted if appropriate, at the end of each reporting period.

An asset's carrying amount is written down immediately to its recoverable amount if the asset's carrying amount is greater than its estimated recoverable amount.

Gains and losses on disposals are determined by comparing proceeds with carrying amount. These are included in profit or loss.

Sigma Healthcare Limited
Notes to the consolidated financial statements
30 June 2025

Note 12. Intangible assets

	2025	2024
	\$'000	\$'000
Goodwill – at cost	3,617,293	-
Less: Accumulated impairment	-	-
	<u>3,617,293</u>	<u>-</u>
Brand names – at cost	149,604	13,300
Less: Accumulated amortisation and impairment	(1,748)	-
	<u>147,856</u>	<u>13,300</u>
Other intangibles – at cost	103,797	-
Less: Accumulated amortisation and impairment	(8,465)	-
	<u>95,332</u>	<u>-</u>
Net book amount	<u>3,860,481</u>	<u>13,300</u>

Reconciliations

Reconciliations of the written down values at the beginning and end of the current and previous financial year are set out below:

	Goodwill	Brand names	Other	Total
	\$'000	\$'000	intangibles	\$'000
			\$'000	
Balance at 1 July 2023	-	4,800	-	4,800
Additions	-	8,500	-	8,500
	<u>-</u>	<u>8,500</u>	<u>-</u>	<u>8,500</u>
Balance at 30 June 2024	-	13,300	-	13,300
Additions	-	5,000	-	5,000
Business combinations	3,623,450	131,304	103,930	3,858,684
Disposals	(6,157)	-	(133)	(6,290)
Amortisation expense	-	(1,748)	(8,465)	(10,213)
	<u>-</u>	<u>(1,748)</u>	<u>(8,465)</u>	<u>(10,213)</u>
Balance at 30 June 2025	<u>3,617,293</u>	<u>147,856</u>	<u>95,332</u>	<u>3,860,481</u>

Recognition and measurement

Intangible assets are carried at cost less accumulated depreciation and impairment losses where applicable. Intangible assets acquired separately are capitalised at cost or if arising from a business combination at fair value as at the date of acquisition.

Goodwill

Goodwill represents the excess of the cost of an acquisition over the fair value of the Company's share of the net identifiable assets acquired at the date of acquisition. Goodwill is measured at cost and subsequently measured at cost less any impairment losses.

Finite life intangibles

Certain brand names, trademarks, customer contracts and relationships have been assessed to have a finite useful life and are carried at cost less accumulated amortisation. Where acquired in a business combination cost represents the fair value at the date of acquisition. They are amortised over their expected useful lives, which vary for different categories of intangibles, generally ranging between:

- 25 to 40 years for Brand Names
- 3 to 14 years for Other Intangibles

Impairment of goodwill, intangible assets and non-current assets

Assets with finite useful lives are subject to amortisation and are reviewed for impairment at each reporting period and whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. Goodwill and indefinite life intangible assets are tested annually, or more frequently when indicators of impairment are identified.

Note 12. Intangible assets (continued)

These tests are performed by assessing the recoverable amount of each individual asset or, if this is not possible, the recoverable amount of the cash generating unit (CGU) to which the asset belongs. CGUs are the smallest identifiable Group of assets and liabilities that generate cash inflows that are largely independent of the cash inflows from other assets or Groups of assets. An impairment loss is recognised for the amount by which the carrying amount of an asset or a CGU exceeds its recoverable amount.

For the purpose of impairment testing, an intangible asset with an indefinite life is allocated to each CGU that is expected to benefit from the synergies relating to the business combination, reflecting the lowest level for which the assets are monitored for internal management purposes.

The goodwill held by the Group is fully allocated to the Australian Healthcare CGU. Other CGUs which include overseas operations and stores are reviewed for indicators of impairment using both internal and external sources of information. Detailed impairment testing is completed where an indication of impairment is identified.

Impairment calculations

The recoverable amount of the Australian Healthcare CGU has been calculated based on the value in use model, using a discounted cash flow (DCF) approach.

The key assumptions used in the value in use model include the FY26 financial budget, sales growth, gross margin, cost of doing business and the discount rate. These assumptions are based on past experience and the Company's forecast operating and financial performance of the CGU taking into account current market and economic conditions, risks, uncertainties and opportunities for improvement for the CGU.

The DCF uses pre-tax cash flow projections over a 5-year period, extrapolated into perpetuity using a terminal growth rate. The cash flow projection for Years 1 to 3 is based on the most recent Board approved budget and forecast, with the remaining 2 years extrapolated using the long-term growth rate and is discounted at an appropriate after-tax discount rate of 8.5% (2024: n/a), taking into account the Group's weighted average cost of capital (WACC) adjusted for any risks specific to the CGU.

Terminal growth rate of 2.5% (2024: n/a) applied in the DCF are based on estimates of long-term inflation, GDP growth in the country in which the CGU primarily operates and estimates of long-term performance of each CGU.

The Group has conducted sensitivity analysis taking into consideration the current market and macro-economic conditions, which indicated that no reasonably possible change in key assumptions would result in an impairment loss. Accordingly, the Group concluded that no impairment is required based on current market and economic conditions and expected future performance.

Critical accounting estimates and assumptions

Goodwill and indefinite life intangible assets are tested for impairment on an annual basis, or more frequently if there are indicators of impairment. The determination of recoverable amount of the CGU which the assets are allocated to requires significant estimation of forecast future cash flows, discount rates and expected long-term growth rates.

Sigma Healthcare Limited
Notes to the consolidated financial statements
30 June 2025

Note 13. Trade and other payables

	2025	2024
	\$'000	\$'000
<i>Current liabilities</i>		
Trade payables	1,182,195	638,340
Accruals	<u>141,408</u>	<u>107,484</u>
	<u>1,323,603</u>	<u>745,824</u>

Recognition and measurement

These amounts represent liabilities for goods and services provided to the Group prior to the end of the financial year and which are unpaid. The amounts are unsecured and are usually settled within 30 to 60 days of the invoice date. The carrying amounts of trade and other payables are considered to be same as their fair values, due to their short-term nature.

Note 14. Other liabilities

	2025	2024
	\$'000	\$'000
<i>Current liabilities</i>		
Customer liabilities	9,261	12,803
Other liabilities – supplier contracts	<u>7,201</u>	<u>7,208</u>
	<u>16,462</u>	<u>20,011</u>
<i>Non-current liabilities</i>		
Customer liabilities	6,709	2,408
Other liabilities – supplier contracts	<u>10,395</u>	<u>12,369</u>
	<u>17,104</u>	<u>14,777</u>

Recognition and measurement

(a) Customer liabilities

Customer liabilities represent the Group's obligation to transfer goods or services to a customer and are recognised when a customer pays consideration, or when the Group recognises a receivable to reflect its unconditional right to consideration (whichever is earlier) before the Group has transferred the goods or services to the customer.

(b) Other liabilities – Supplier Contracts

Other liabilities – Supplier Contracts represent the Group's obligation to transfer goods or services to a supplier and are recognised when the supplier pays consideration, or when the Group recognises a receivable to reflect its unconditional right to consideration (whichever is earlier) before the Group has transferred the goods or service to the supplier.

Sigma Healthcare Limited
Notes to the consolidated financial statements
30 June 2025

Note 15. Provisions

	2025	2024
	\$'000	\$'000
<i>Current liabilities</i>		
Employee benefit obligations	39,753	22,282
Make good provision	3,921	3,561
Provisions for returns or refunds	124	54
Other	478	-
	<u>44,276</u>	<u>25,897</u>
<i>Non-current liabilities</i>		
Employee benefit obligations	3,233	2,024
Make good provision	25,720	19,688
Other	1,147	-
	<u>30,100</u>	<u>21,712</u>

Employee benefits

Employee benefit obligations cover the Group's liabilities for long service leave and annual leave, and are classified as either long-term benefits or short-term benefits.

Amounts not expected to be settled within the next 12 months

The current portion of employee benefits liability includes all of the accrued annual leave, the unconditional entitlements to long service leave where the employees have completed the required period of service and also for those employees who are entitled to pro-rata payments in certain circumstances. The entire amount of the provision is presented as current, since the Group does not have an unconditional right to defer settlement for any of these obligations. However, based on past experience, the Group does not expect all employees to take the full amount of accrued leave or require payment within the next 12 months.

The following amounts reflect leave that is not expected to be taken within the next 12 months:

	2025	2024
	\$'000	\$'000
Employee benefits obligation expected to be settled after 12 months	<u>13,392</u>	<u>9,007</u>

Make good provision

The Group is required to restore some of the leased premises to their original condition at the end of the respective lease terms. A provision has been recognised for the present value of the estimated expenditure required to remove any leasehold improvements.

Movements in make good provision

Movements in the make good provision for each financial year are set out below:

	2025	2024
	\$'000	\$'000
Carrying amount at the start of the year	23,249	22,628
Business combinations	4,111	-
Additional provisions recognised	3,201	2,701
Amounts used	<u>(920)</u>	<u>(2,080)</u>
Carrying amount at the end of the year	<u>29,641</u>	<u>23,249</u>

Recognition and measurement

Provisions for legal claims and make good obligations are recognised when the Group has a present legal or constructive obligation as a result of past events, it is probable that an outflow of resources will be required to settle the obligation and the amount can be reliably estimated. Provisions are not recognised for future operating losses.

Sigma Healthcare Limited
Notes to the consolidated financial statements
30 June 2025

Note 15. Provisions (continued)

Where there are a number of similar obligations, the likelihood that an outflow will be required in settlement is determined by considering the class of obligations as a whole. A provision is recognised even if the likelihood of an outflow with respect to any one item included in the same class of obligations may be small.

Provisions are measured at the present value of management's best estimate of the expenditure required to settle the present obligation at the end of the reporting period. The discount rate used to determine the present value is a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the liability. The increase in the provision due to the passage of time is recognised as interest expense.

(a) Short-term employee benefits

Liabilities for wages and salaries, including non-monetary benefits, annual leave, long service leave and accumulating sick leave expected to be settled wholly within 12 months of the reporting date are measured at the amounts expected to be paid when the liabilities are settled. Non-accumulating sick leave is expensed to profit or loss when incurred.

(b) Other long-term employee benefits

The liability for annual leave and long service leave not expected to be settled within 12 months of the reporting date are measured at the present value of expected future payments to be made in respect of services provided by employees up to the reporting date using the projected unit credit method. Consideration is given to expected future wage and salary levels, experience of employee departures and periods of service. Expected future payments are discounted using market yields at the reporting date on high quality corporate bonds with terms to maturity and currency that match, as closely as possible, the estimated future cash outflows.

(c) Defined contribution superannuation expense

Contributions to defined contribution superannuation plans are expensed in the period in which they are incurred.

Sigma Healthcare Limited
Notes to the consolidated financial statements
30 June 2025

Note 16. Leases

(a) Right-of-use assets

	2025	2024
	\$'000	\$'000
<i>Non-current assets</i>		
Buildings	544,450	392,580
Less: Accumulated depreciation and impairment	<u>(315,068)</u>	<u>(288,579)</u>
	<u>229,382</u>	<u>104,001</u>
Equipment	20,317	17,119
Less: Accumulated depreciation	<u>(10,970)</u>	<u>(8,100)</u>
	<u>9,347</u>	<u>9,019</u>
	<u>238,729</u>	<u>113,020</u>

Reconciliations

Reconciliations of the written down values at the beginning and end of the current and previous financial year are set out below:

	Buildings	Equipment	Total
	\$'000	\$'000	\$'000
Balance at 1 July 2023	103,729	9,197	112,926
Additions	17,851	3,929	21,780
Remeasurements	(1,601)	(1,210)	(2,811)
Depreciation expense	<u>(15,978)</u>	<u>(2,897)</u>	<u>(18,875)</u>
Balance at 30 June 2024	104,001	9,019	113,020
Additions	22,922	349	23,271
Business combinations	127,884	3,184	131,068
Remeasurements	352	89	441
Impairment expense	(1,874)	-	(1,874)
Depreciation expense	<u>(23,903)</u>	<u>(3,294)</u>	<u>(27,197)</u>
Balance at 30 June 2025	<u>229,382</u>	<u>9,347</u>	<u>238,729</u>

Recognition and measurement

A right-of-use asset is recognised at the commencement date of a lease. The right-of-use asset is measured at cost, which comprises the initial amount of the lease liability, adjusted for, as applicable, any lease payments made at or before the commencement date net of any lease incentives received, any initial direct costs incurred, and, except where included in the cost of inventories, an estimate of costs expected to be incurred for dismantling and removing the underlying asset, and restoring the site or asset.

The Group leases various offices, warehouses, retail stores and equipment. Rental contracts are made for fixed periods of 12 months to 19 years but may have extension option.

Right-of-use assets are depreciated on a straight-line basis over the unexpired period of the lease or the estimated useful life of the asset, whichever is the shorter. Where the Group expects to obtain ownership of the leased asset at the end of the lease term, the depreciation is over its estimated useful life. Right-of-use assets are subject to impairment or adjusted for any remeasurement of lease liabilities.

Right-of-use assets that meet the definition of investment property are measured at cost.

The Group has elected not to recognise a right-of-use asset and corresponding lease liability for short-term leases with terms of 12 months or less and leases of low-value assets. Lease payments on these assets are expensed to profit or loss as incurred.

Sigma Healthcare Limited
Notes to the consolidated financial statements
30 June 2025

Note 16. Leases (continued)

Impairment assessment

The Group tests right-of-use assets for impairment to ensure they are not carried above their recoverable amounts where there is an indication that assets may be impaired (which is assessed at least at each reporting date).

These tests are performed by assessing the recoverable amount of each individual asset or, if this is not possible, the recoverable amount of the cash generating unit (CGU) to which the asset belongs. CGUs are the lowest levels at which assets are Grouped and generate separately identifiable cash inflows and outflows.

The carrying values of the right-of-use assets are reviewed for impairment annually. If an indication of impairment exists, and where the carrying value of the asset exceeds the estimated recoverable amount, the assets or cash-generating units (CGU) are written down to their recoverable amount. The recoverable amount is the greater of fair value less costs of disposal and value-in-use. Value-in-use refers to an asset's value based on the expected future cash flows arising from its continued use, discounted to present value using a post-tax discount rate that reflect current market assessments of the risks specific to the asset. The recoverable amount was estimated on an individual lease basis.

(b) Lease receivables

	2025	2024
	\$'000	\$'000
<i>Current assets</i>		
Lease receivables	<u>139,656</u>	<u>118,628</u>
<i>Non-current assets</i>		
Lease receivables	<u>821,668</u>	<u>741,823</u>

The Group holds the head lease for a number of franchised and other stores. The Group sub-licences under the same terms and conditions as the head lease. The lease payments are considered fixed, and these sub-licence arrangements are classified as finance leases.

	2025	2024
	\$'000	\$'000
Commitments in relation to receivables are as follows:		
Within one year	140,540	118,477
Later than one year but not later than five years	731,884	597,013
Later than five years	381,966	364,413
Minimum lease receivables	<u>1,254,390</u>	<u>1,079,903</u>
Unearned interest income	<u>(293,066)</u>	<u>(219,452)</u>
Total lease receivables	<u>961,324</u>	<u>860,451</u>

(c) Lease liabilities

	2025	2024
	\$'000	\$'000
<i>Current liabilities</i>		
Lease liability	<u>157,975</u>	<u>131,325</u>
<i>Non-current liabilities</i>		
Lease liability	<u>1,021,846</u>	<u>849,598</u>

Sigma Healthcare Limited
Notes to the consolidated financial statements
30 June 2025

Note 16. Leases (continued)

	2025	2024
	\$'000	\$'000
<i>Reconciliation of lease liabilities</i>		
Lease liabilities at beginning of the year	980,923	924,475
Lease remeasurements agreed during the year	59,888	60,902
Additional leases entered into during the year	152,280	120,503
Business combinations	126,514	-
Interest expense	58,619	49,854
Lease payments	<u>(198,403)</u>	<u>(174,811)</u>
Lease liabilities at end of the year	<u>1,179,821</u>	<u>980,923</u>

Recognition and measurement

A lease liability is recognised at the commencement date of a lease. The lease liability is initially recognised at the present value of the lease payments to be made over the term of the lease, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Group's incremental borrowing rate. Lease payments comprise of fixed payments less any lease incentives receivable, variable lease payments that depend on an index or a rate, amounts expected to be paid under residual value guarantees, exercise price of a purchase option when the exercise of the option is reasonably certain to occur, and any anticipated termination penalties. The variable lease payments that do not depend on an index or a rate are expensed in the period in which they are incurred.

Lease liabilities are measured at amortised cost using the effective interest method. The carrying amounts are remeasured if there is a change in the following: future lease payments arising from a change in an index or a rate used; residual guarantee; lease term; certainty of a purchase option and termination penalties. When a lease liability is remeasured, an adjustment is made to the corresponding right-of-use asset or lease receivable, or to profit or loss if the carrying amount of the right-of-use asset is fully written down.

(d) Amounts recognised in the consolidated statement of profit or loss and other comprehensive income

	2025	2024
	\$'000	\$'000
Depreciation expense on right-of-use assets	27,197	18,875
Interest expense on lease liabilities	58,619	49,854
Rent expense of variable and short-term leases	<u>16,613</u>	<u>5,723</u>
	<u>102,429</u>	<u>74,452</u>

Rent expenses on leases

The expenses incurred are for short-term leases and leases of low-value assets (such as tablets and personal computers, small items of office furniture and telephones). The Group recognises the lease payments as an operating expense on a straight-line basis over the term of the lease unless another systematic basis is more representative of the time pattern in which economic benefits from the leased assets are consumed.

These leases are not included in right-of-use assets or corresponding lease liabilities in accordance with AASB 16 *Leases*.

Critical accounting estimates and assumptions

(i) Right-of-use asset impairment

The Group tests right of use assets for impairment to ensure they are not carried above their recoverable amounts where there is an indication that assets may be impaired (which is assessed at least at each reporting date).

Note 16. Leases (continued)

(ii) Lease term

In determining the lease term, management considers all facts and circumstances that create an economic incentive to exercise an extension option, or not exercise a termination option. Extension options (or periods after termination options) are only included in the lease term if the lease is reasonably certain to be extended (or not terminated).

The Group also considers factors including historical lease durations and the costs and business disruption required to replace the leased asset.

The lease term is reassessed if an option is actually exercised (or not exercised) or the Group becomes obliged to exercise (or not exercise) it. The assessment of reasonable certainty is only revised if a significant event or a significant change in circumstances occurs, which affects this assessment, and that is within the control of the lessee.

(iii) Classification of Leases

The Group holds the head lease for the majority of franchised stores and sub-licenses these to franchisees.

Where the Group sub-licenses the location to franchisees under the same terms and conditions as the head lease and the lease payments are considered fixed, the sublease arrangement is classified as a finance lease.

Capital and risk management

Note 17. Notes to the statement of cash flows

(a) Reconciliation of cash and cash equivalents

Cash and cash equivalents include cash balances, demand deposits held at call with financial institutions and highly liquid investments and notes with maturity of three months or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value.

	2025	2024
	\$'000	\$'000
<i>Current assets</i>		
Cash and bank balances	138,774	273,124
	138,774	273,124

(b) Reconciliation of profit after income tax to net cash from operating activities

	2025	2024
	\$'000	\$'000
Profit/(loss) after income tax expense for the year	525,455	539,657
Adjustments for:		
Depreciation and amortisation	55,982	35,271
Share of profits of associates and joint ventures accounted for using the equity method	(30,211)	(23,059)
Share-based payments	1,980	15,513
Fair value loss/(gains) on non-current financial assets at fair value through profit or loss	317	528
Impairment expense	2,114	-
Other non-cash adjustments	(3,830)	(3,830)
Change in operating assets and liabilities, net of effects from business combinations:		
(Increase) in trade and other receivables	(103,752)	(294,321)
(Increase) in inventories	(57,255)	(117,838)
Decrease/(increase) in deferred tax assets	15,395	(30,756)
(Increase)/decrease in other operating assets	(13,693)	22,470
Increase in trade and other payables	99,484	156,267
Increase/(decrease) in other liabilities	10,200	(13,600)
Increase/(decrease) in provision for income tax	111,239	(17,098)
(Decrease)/increase in other provisions	(14,597)	3,973
Net cash from operating activities	598,828	273,177

Note 18. Issued capital

	2025	2024	2025	2024
	No. of shares	No. of shares	\$'000	\$'000
	(thousands)	(thousands)		
Ordinary shares - fully paid	11,543,703	1,557,400	4,391,567	553,699
Treasury shares	(42,440)	-	11,732	-
Total contributed equity	11,501,263	1,557,400	4,403,299	553,699

Sigma Healthcare Limited
Notes to the consolidated financial statements
30 June 2025

Note 18. Issued capital (continued)

Ordinary shares

Ordinary shares entitle the holder to participate in dividends and the proceeds on the winding up of the Company in proportion to the number of and amounts paid on the shares held. The fully paid ordinary shares have no par value and the Company does not have a limited amount of authorised capital.

On a show of hands every member present at a meeting in person or by proxy shall have one vote and upon a poll each share shall have one vote.

Incremental costs directly attributable to the issue of new shares or options are shown in equity as a deduction, net of tax, from the proceeds.

Treasury shares

The shares held by Sigma Employee Share Administration Pty Ltd are treasury shares which are the Company's ordinary shares which, as at the end of the year, have not vested to Group employees, and therefore controlled by the Group.

(a) Movements in ordinary share capital

	2025	2024	2025	2024
	No. of shares	No. of shares	\$'000	\$'000
	(thousands)	(thousands)		
Details				
Opening balance at beginning of financial year	1,557,400	1,553,282	553,699	549,391
Issue of shares pre-acquisition	10,457	4,118	47,900	4,308
Ordinary share capital of CW Group Holdings Limited	1,567,857	1,557,400	601,599	553,699
Exchange of Chemist Warehouse shares for the Company's shares	(1,567,857)	-	-	-
Shares to effect deemed acquisition of Sigma, net of share issuance costs	1,635,539	-	4,489,968	-
Company shares issued to Chemist Warehouse shareholders on acquisition (i)	9,906,181	-	-	-
Capital distribution to Chemist Warehouse shareholders as part of acquisition (ii)	-	-	(700,000)	-
Conversion of performance rights to ordinary shares	1,983	-	-	-
Balance at the end of the financial year	11,543,703	1,557,400	4,391,567	553,699

(i) Issue of 9,906,180,588 shares to the shareholders of CW Group Holdings Limited as consideration for 100% of the shares held in CW Group Holdings Limited – refer to Note 25 Business Combinations.

(ii) \$700.0m cash payment to existing Chemist Warehouse shareholders under the Merger Implementation Agreement. This cash payment is treated as an equity transaction in the form of a distribution as the \$700.0m was paid to the Chemist Warehouse (accounting acquirer) shareholders. Under AASB 132 *Financial Instruments: Presentation*, this cash payment is recognised as a deduction to equity.

Reverse acquisition impact

Under AASB 3 *Business Combinations*, in the event of a reverse acquisition, the amount recognised as issued equity interests in the consolidated financial statements is determined by adding the issued equity interest of the legal subsidiary (the accounting acquirer) outstanding immediately before the business combination to the fair value of the legal parent (accounting acquiree).

However, the equity structure (i.e. the number and type of equity interests issued) reflects the equity structure of the legal parent (the accounting acquiree), including the equity interests the legal parent issued to effect the combination.

Accordingly, the equity structure of the legal subsidiary (the accounting acquirer) is restated using the exchange ratio established in the scheme of arrangement (Scheme) to reflect the number of shares of the legal parent (the accounting acquiree) issued in the reverse acquisition.

Sigma Healthcare Limited
Notes to the consolidated financial statements
30 June 2025

Note 18. Issued capital (continued)

(b) Movements in treasury share capital

	2025 No. of shares (thousands)	2024 No. of shares (thousands)	2025 \$'000	2024 \$'000
Details				
Opening balance at beginning of financial year	-	-	-	-
Treasury shares of the Company	(57,189)	-	-	-
Employee shares exercised	14,749	-	7,182	-
Reclassification of settled and expired share-based transactions	-	-	4,550	-
Balance at the end of the financial year	(42,440)	-	11,732	-

(c) Capital management

Capital of the Group is managed in order to safeguard the ability of the Group to continue as a going concern, to provide returns to shareholders, to provide benefits for other stakeholders and to maintain an optimal capital structure.

In order to maintain or adjust the capital structure, the Group may adjust the amount of dividends paid to shareholders, return capital to shareholders, issue new shares or sell assets.

There are no externally imposed capital requirements.

For information on dividends refer to Note 21.

Note 19. Reserves

	2025 \$'000	2024 \$'000
Financial assets at fair value through other comprehensive income reserve	(5,295)	(8,435)
Foreign currency translation reserve	2,578	(369)
Share-based payments reserve	60,015	17,938
Merger reserve	(63,321)	(63,321)
	<u>(6,023)</u>	<u>(54,187)</u>

Financial assets at fair value through other comprehensive income reserve

The Group has elected to recognise changes in the fair value of certain investments in equity securities in other comprehensive income. These changes are accumulated within the fair value through other comprehensive income reserve within equity. The Group transfers amounts from this reserve to retained earnings when the relevant equity securities are derecognised.

Foreign currency translation reserve

Exchange differences arising on translation of foreign controlled entities are recognised in other comprehensive income and accumulated in a separate reserve within equity. The cumulative amount is reclassified to profit or loss when the net investment is disposed of.

Sigma Healthcare Limited
Notes to the consolidated financial statements
30 June 2025

Note 19. Reserves (continued)

Share-based payments reserve

The reserve is used to recognise the value of equity benefits provided to employees and directors as part of their remuneration.

Merger reserve

Reserve created as a result of common control transactions at book value for accounting purposes with no fair value adjustments.

Common control transactions include the combining of entities which are ultimately controlled by the same party (or parties) both before and after the transaction. Assets and liabilities acquired as part of the common control transactions are recorded at book value and no fair value adjustments are made.

For transactions in which combining entities are controlled by the same party or parties before and after the transaction and where that control is not transitory are referred to as common control transactions. The Group's accounting policy for the acquiring entity is to account for the transaction at book values on a prospective basis as reflected in the consolidated financial statements of the selling entity.

The excess of the cost of the transaction over the acquirer's proportionate share of the net assets value acquired in common control transactions, will be allocated to the merger reserve in equity.

Movements in reserves

Movements in each class of reserve during the current and previous financial years are set out below:

	Financial assets at FVOCI \$'000	Foreign currency translation \$'000	Share- based payments \$'000	Merger \$'000	Total \$'000
Balance at 1 July 2023	(8,413)	432	2,425	(59,196)	(64,752)
Revaluations, net of tax	920	-	-	-	920
Transfer of reserves to retained profits, net of tax	(942)	-	-	-	(942)
Foreign currency translation, net of tax	-	(801)	-	-	(801)
Share-based payments expenses	-	-	15,513	-	15,513
Acquisition of non-controlling interest	-	-	-	(4,125)	(4,125)
Balance at 30 June 2024	(8,435)	(369)	17,938	(63,321)	(54,187)
Revaluations, net of tax	14,182	-	-	-	14,182
Transfer of reserves to retained profits, net of tax	(11,304)	-	-	-	(11,304)
In substance replacement equity-settled employee share awards, arising from reverse acquisition (note 25)	-	-	40,901	-	40,901
Foreign currency translation, net of tax	-	2,651	-	-	2,651
Share-based payments expenses	-	-	1,980	-	1,980
Other	262	296	(804)	-	(246)
Balance at 30 June 2025	(5,295)	2,578	60,015	(63,321)	(6,023)

Sigma Healthcare Limited
Notes to the consolidated financial statements
30 June 2025

Note 20. Retained earnings

	2025	2024
	\$'000	\$'000
Retained earnings at the beginning of the financial year	222,906	(101,348)
Profit after income tax expense for the year	529,914	541,013
Transfer of gain on disposal of equity investments at FV through OCI to retained profits, net of tax	11,304	942
Transfer from share-based payments reserve	21	-
Transfer from treasury shares to retained earnings for shares settled or forfeited	(4,551)	-
Transfer between foreign currency translation reserve	(295)	-
Dividends provided for or paid (note 21)	<u>(486,036)</u>	<u>(217,701)</u>
Retained profits at the end of the financial year	<u>273,263</u>	<u>222,906</u>

Note 21. Dividends

Dividends provided for or paid during the financial year were as follows:

	2025		2024	
	Cents per share	\$'000	Cents per share	\$'000
Final dividend – prior year	9.5	148,946	6.5	100,963
Interim dividend – current year	21.5	337,090	7.5	116,738
Dividends recognised	31.0	486,036	14.0	217,701
Dividends provided for or paid by the Group	31.0	486,036	14.0	217,701

The above disclosure represents the dividends recognised by Chemist Warehouse (pre-merger) only.

All dividends declared and subsequently paid have been franked to 100% at the 30% company income tax rate.

Franking credits

	2025	2024
	\$'000	\$'000
Franking credits available for subsequent financial years based on a tax rate of 30% (2024: 30%)	<u>186,453</u>	<u>161,640</u>

The above amounts are calculated from the balance of the franking account as at the end of the reporting period, adjusted for franking credits and debits that will arise from the settlement of liabilities or receivables for income tax and dividends after the end of the year.

Recognition and measurement

Dividends are recognised when declared during the financial year and no longer at the discretion of the Company.

Provision is made for the amount of any dividend declared, being appropriately authorised and no longer at the discretion of the Company, on or before the end of the financial year but not distributed at the reporting date.

Sigma Healthcare Limited
Notes to the consolidated financial statements
30 June 2025

Note 22. Borrowings

	2025	2024
	\$'000	\$'000
Current		
Secured – Bank facilities	-	-
Unsecured – Other loans*	35,643	32,776
	<u>35,643</u>	<u>32,776</u>
Non-current		
Secured – Bank facilities	855,292	-
Unsecured – Other loans*	-	300,000
	<u>855,292</u>	<u>300,000</u>
	<u><u>890,935</u></u>	<u><u>332,776</u></u>

* Further information relating to loans from related parties is set out in Note 32.

Senior Secured Syndicated Facility Agreement

The Group has a Senior Secured Syndicated Facility Agreement with its lenders, which includes:

- Facility A – revolving cash advance facility of \$940 million
- Facility C – re-drawable multi-option facility of \$60 million¹
- Facility D – revolving cash advance facility of \$500 million

¹ Facility C is for the issuance of bank guarantees – refer to Note 34 for further details.

All three facilities expire on 10 February 2028. Refer to Note 23 for further details on the Group's financing facilities.

Loan covenant

Under the terms of the Senior Secured Syndicated Facility Agreement, the Group is required to comply with a fixed charge cover ratio (FCCR) covenant where the Cover Ratio is not less than 2.0x at the end of each annual and interim reporting period. The ratio is a measure of how the Group's earnings can be used to cover its interest and other financing costs and certain other charges.

The Group has complied with the financial covenant throughout the reporting period. There are no indications that the Group would have difficulties complying with the covenants when they will be next tested as at the 31 December 2025 interim reporting date and for the next financial year ending 30 June 2026.

Recognition and measurement

Borrowings are recognised initially at fair value less attributable transaction costs. Subsequently borrowings are stated at amortised cost. Borrowings are classified as current liabilities unless the Group has an unconditional right to defer settlement of the liability for at least twelve months from balance date and intends to do so.

Borrowing costs capitalised

The amount of borrowing costs capitalised for the year ended 30 June 2025 relating to the borrowings was \$9,708,000 (2024: nil). The interest rate applicable to the debt facilities is variable, and the Group does not hedge the interest rate. The costs associated with the debt facilities are recorded in "Finance costs" in the consolidated statement of profit or loss and other comprehensive income.

Note 23. Financial risk management

This note explains the Group's exposure to financial risks and how these risks could affect the Group's future financial performance. Current year profit or loss information has been included where relevant to add further context.

The Group's activities expose it to a variety of financial risks, including market risk (including foreign currency risk and interest rate risk), credit risk and liquidity risk. The Group's risk management is predominantly controlled and carried out by senior finance executives under policies approved by the Board of Directors ('the Board').

These policies include identification and analysis of the risk exposure of the Group and appropriate procedures, controls and risk limits. These policies require periodic reporting to the Board.

The Group does not enter into or trade financial instruments, including derivative financial instruments, for speculative purposes.

Sigma Healthcare Limited
Notes to the consolidated financial statements
30 June 2025

Note 23. Financial risk management (continued)

(a) Market risk

(i) Foreign currency risk

The Group undertakes certain transactions denominated in foreign currency and is exposed to foreign currency risk through foreign exchange rate fluctuations.

Foreign exchange risk arises from future commercial transactions and recognised financial assets and financial liabilities denominated in a currency that is not the entity's functional currency. The risk is measured using sensitivity analysis and cash flow forecasting.

The Group's exposure to foreign currency risk at the end of the reporting period, expressed in Australian dollar, was as follows:

	CNY \$'000	USD \$'000	NZD \$'000	GBP \$'000	EUR \$'000	AED \$'000
2025						
Trade and other payables	(422)	(2,346)	(13,409)	(122)	(11,204)	(567)
Trade and other receivables	2,463	1,240	38,821	1	-	-
2024						
Trade and other payables	-	(7,467)	(8,316)	(692)	(992)	-
Trade and other receivables	4,174	-	-	-	-	-

(ii) Cash flow and fair value interest rate risk

The Group's main interest rate risk arises from long-term borrowings with variable rates, which expose the Group to cash flow interest rate risk.

The Group may seek to mitigate its exposure to fluctuations in interest rates by entering into interest rate hedging contracts for a portion of forecast interest rate exposures. The Group did not enter into any interest rate hedge contracts during the year ended 30 June 2025 (2024: nil).

Holding all other variables constant at the reporting date, applying a sensitivity of 100 basis points to the weighted average interest rate for the Group's long-term borrowings results in an impact of +/- \$6.1 million on post tax profit.

(b) Credit risk

Credit risk arises from cash and cash equivalents as well as credit exposures to wholesale and retail customers, including outstanding receivables.

Risk management

Credit risk is managed on a Group basis. For banks and financial institutions, only independently rated parties with a minimum rating of 'A' are accepted.

Risk control assesses the credit quality of the customer, taking into account its financial position, past experience and other factors. Individual risk limits are set based on internal or external ratings in accordance with limits set by the board. The compliance with credit limits by wholesale customers is regularly monitored by line management.

Sales to retail customers are required to be settled in cash or using major credit cards, mitigating credit risk. There are no significant concentrations of credit risk, whether through exposure to individual customers, specific industry sectors and/or regions.

The Group's trade receivables are subject to the expected credit loss model. Refer to Note 7 for the Group's assessment of expected losses. While cash and cash equivalents are also subject to the impairment requirements of AASB 9, the identified impairment loss was immaterial.

(c) Liquidity risk

Vigilant liquidity risk management requires the Group to maintain sufficient liquid assets (mainly cash and cash equivalents).

Sigma Healthcare Limited
Notes to the consolidated financial statements
30 June 2025

Note 23. Financial risk management (continued)

The Group manages liquidity risk by maintaining adequate cash reserves by continuously monitoring actual and forecast cash flows and matching the maturity profiles of financial assets and liabilities.

Financing arrangements

The Group had access to the following borrowing facilities at the end of the reporting period:

	2025	2024
	\$'000	\$'000
Secured bank loan facilities:		
Amount used	865,000	-
Amount unused	575,000	100,000
	<u>1,440,000</u>	<u>100,000</u>

The above does not include the bank guarantee facility of \$60.0 million – refer to Note 34.

The weighted average term to maturity of committed bank facilities and rolling cash flow forecasts are periodically provided to management and the Board.

Revolving Facility Agreement

During the current financial year, the Group terminated its existing Revolving Facilities with Westpac Banking Corporation (\$50.0 million) and National Australia Bank (\$50.0 million).

Refer to Note 22 Borrowings for further details on the Group's current financing facilities.

Maturities of financial liabilities

The tables below analyse the Group's financial liabilities into relevant maturity groupings based on their contractual maturities.

The amounts disclosed in the table are the contractual cash flows. Balances due within 12 months equal their carrying balances as the impact of discounting is not significant.

The following tables detail the Group's remaining contractual maturity for its financial instrument liabilities. The tables have been drawn up based on the cash flows of financial liabilities based on the earliest date on which the financial liabilities are required to be paid. The tables include both interest and principal cash flows disclosed as remaining contractual maturities and therefore these totals may differ from their carrying amount in the balance sheet.

2025	1 year or less	Between 1	Over 5 years	Remaining
	\$'000	and 5 years	\$'000	contractual
		\$'000	\$'000	maturities
				\$'000
Non-derivatives				
<i>Non-interest bearing</i>				
Trade payables	1,182,195	-	-	1,182,195
<i>Interest-bearing - fixed</i>				
Lease liability	156,180	803,967	527,081	1,487,228
Loans payable	901,860	-	-	901,860
Total non-derivatives	<u>2,240,235</u>	<u>803,967</u>	<u>527,081</u>	<u>3,571,283</u>

Sigma Healthcare Limited
Notes to the consolidated financial statements
30 June 2025

Note 23. Financial risk management (continued)

2024	1 year or less \$'000	Between 1 and 5 years \$'000	Over 5 years \$'000	Remaining contractual maturities \$'000
Non-derivatives				
<i>Non-interest bearing</i>				
Trade payables	638,340	-	-	638,340
<i>Interest-bearing - fixed</i>				
Lease liability	124,026	615,815	379,379	1,119,220
Loans payable	32,776	-	302,386	335,162
Total non-derivatives	<u>795,142</u>	<u>615,815</u>	<u>681,765</u>	<u>2,092,722</u>

The cash flows in the maturity analysis above are not expected to occur significantly earlier than contractually disclosed above.

Note 24. Fair value measurement

The following tables detail the Group's assets and liabilities, measured or disclosed at fair value, using a three-level hierarchy, based on the lowest level of input that is significant to the entire fair value measurement, being:

- **Level 1:** The fair value of financial instruments traded in active markets (such as publicly equity securities) is based on quoted market prices at the end of the reporting period. The quoted market prices used for financial assets held by the Group is the current price. These instruments are included in level 1.
- **Level 2:** The fair value of financial instruments that are not traded in an active market (e.g., over-the-counter derivatives) is determined using valuation techniques which maximise use of observable market data and rely as little as possible on entity-specific estimates. If all significant inputs required to fair value an instrument are observable, the instrument is included in level 2.
- **Level 3:** If one or more of the significant inputs is not based on observable market data, the instrument is included in level 3. This is the case of unlisted equity securities.

2025	Level 1 \$'000	Level 2 \$'000	Level 3 \$'000	Total \$'000
<i>Assets</i>				
Investments at fair value through other comprehensive income	5,245	-	26,741	31,986
Investments at fair value through profit or loss	100	-	4,608	4,708
Total assets	<u>5,345</u>	<u>-</u>	<u>31,349</u>	<u>36,694</u>

2024	Level 1 \$'000	Level 2 \$'000	Level 3 \$'000	Total \$'000
<i>Assets</i>				
Investments at fair value through other comprehensive income	40,588	-	18,866	59,454
Investments at fair value through profit or loss	472	-	1,790	2,262
Total assets	<u>41,060</u>	<u>-</u>	<u>20,656</u>	<u>61,716</u>

During the year, the following gains/(losses) were recognised in profit or loss and other comprehensive income:

	2025 \$000	2024 \$000
Gains / (losses) on equity investments, net of tax	14,182	920

Note 24. Fair value measurement (continued)

Financial assets at fair value through other comprehensive income

Financial assets at FVOCI comprise equity securities which are not held for trading, and which the Group has irrevocably elected at initial recognition to recognise in this category. These are strategic investments, and the Group considers this classification to be more relevant.

Recognition and measurement

When an asset or liability, financial or non-financial, is measured at fair value for recognition or disclosure purposes, the fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date; and assumes that the transaction will take place either: in the principal market; or in the absence of a principal market, in the most advantageous market.

Fair value is measured using the assumptions that market participants would use when pricing the asset or liability, assuming they act in their economic best interests. For non-financial assets, the fair value measurement is based on its highest and best use. Valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, are used, maximising the use of relevant observable inputs and minimising the use of unobservable inputs.

Assets and liabilities measured at fair value are classified into three levels, using a fair value hierarchy that reflects the significance of the inputs used in making the measurements. Classifications are reviewed at each reporting date and transfers between levels are determined based on a reassessment of the lowest level of input that is significant to the fair value measurement.

For recurring and non-recurring fair value measurements, external valuers may be used when internal expertise is either not available or when the valuation is deemed to be significant. External valuers are selected based on market knowledge and reputation. Where there is a significant change in fair value of an asset or liability from one period to another, an analysis is undertaken, which includes a verification of the major inputs applied in the latest valuation and a comparison, where applicable, with external sources of data.

Sigma Healthcare Limited
Notes to the consolidated financial statements
30 June 2025

Group structure

Note 25. Business combinations

(a) Sigma Healthcare Limited

On 12 February 2025, the implementation of the scheme of arrangement (“Scheme”), under which Sigma Healthcare Limited (“Sigma”) would acquire 100% of the issued shares in CW Group Holdings Limited (“Chemist Warehouse”), was completed. The merger creates a leading Australian retail pharmacy franchisor and a full-line pharmaceutical wholesaler and distributor, and delivers significant growth opportunities in Australia and internationally.

Under the Scheme, Sigma Healthcare Limited acquired all the shares in Chemist Warehouse. The transaction resulted in the previous Chemist Warehouse shareholders receiving \$700.0 million cash and 9,906,180,588 Sigma shares.

Sigma is the legal acquirer of Chemist Warehouse. For financial reporting purposes, Chemist Warehouse will be identified as the accounting acquirer, known as a reverse acquisition, when applying AASB 3 *Business Combinations*. Chemist Warehouse is identified as the accounting acquirer, and Sigma the accounting acquiree, because the shareholders of Chemist Warehouse obtained control of the combined Group (85.8% shareholdings), the change in Board composition with four Chemist Warehouse shareholders appointed as directors and the relative size of the two businesses.

Under AASB 3, the purchase consideration is determined with reference to the value of shares that Chemist Warehouse would have needed to issue in order to acquire Sigma at the acquisition date, being \$4,494.5 million. The \$700.0 million cash payment is a capital distribution to the previous Chemist Warehouse shareholders, and therefore is accounted for separately to the business combination.

AASB 3 *Business Combinations* requires that the consolidated financial statements prepared following a reverse acquisition to be issued under the name of the legal parent (Sigma) but be a continuation of the financial statements of the legal subsidiary (Chemist Warehouse, which is the acquirer for accounting purposes).

Details of the purchase consideration, the net assets acquired and goodwill are as follows:

	\$'000
Purchase consideration:	
Ordinary shares issued	4,494,460
In-substance replacement employee share awards	<u>55,824</u>
	4,550,284

The fair value of the consideration transferred by Chemist Warehouse has been determined based on the fair value of equity interest that Chemist Warehouse would have had to issue at the date of acquisition to give the owners of Sigma the same ownership in the Consolidated Group. The fair value of equity interest was determined with reference to the published share price of Sigma Healthcare Limited on acquisition date.

The in-substance replacement employee share awards represent the fair value of Sigma’s employee share plans issued pre-merger, attributed services rendered by employees pre-merger and remains on foot at acquisition date.

In accordance with AASB 3, purchase consideration includes replacement employee share awards issued by the accounting acquirer for existing awards issued by the acquiree to its employees, to the extent that the market-based measure of the replacement awards is attributed to pre-merger services rendered by the employees. Whilst Chemist Warehouse did not issue replacement awards to Sigma’s employees, the effects of the merger resulting in modification to the employee share awards are assessed to be in substance replacements issued by the Merged Group.

The cash distribution of \$700.0m under the Scheme is deemed to be a capital distribution and has been accounted for as a reduction to issued capital – refer to Note 18 Issued Capital.

Sigma Healthcare Limited
Notes to the consolidated financial statements
30 June 2025

Note 25. Business combinations (continued)

The provisionally determined fair values of the assets and liabilities recognised as a result of the acquisition are as follows:

	\$'000
Cash and cash equivalents	157,761
Trade receivables	1,124,050
Inventories	355,756
Land and buildings	125,004
Furniture, fittings and equipment	124,745
Right-of-use assets	131,068
Other assets	47,200
Intangible assets	224,734
Trade payables	(852,614)
Other liabilities	(6,078)
Provisions	(10,255)
Lease liabilities	(126,514)
Borrowings	(271,114)
Deferred tax liability	(51,128)
Non-controlling interests	(1,477)
Net identifiable assets acquired	<u>971,138</u>
Add: provisional goodwill arising on acquisition	<u>3,579,146</u>
Net assets acquired	<u>4,550,284</u>

Certain items within the accounting for the reverse acquisition of Sigma Healthcare Limited remain provisional as at 30 June 2025 due to ongoing work finalising valuations which may impact acquisition accounting entries. The Group will finalise its accounting for the reverse acquisition in the financial statements of the Group for the year ending 30 June 2026.

The provisional goodwill arising on acquisition is attributable to various factors, including workforce in place, cost synergies and distribution network and geographic presence. It will not be deductible for tax purposes. As at 30 June 2025, the provisional goodwill is allocated to the Australian Healthcare CGU.

Acquired receivables

The fair value of acquired trade receivables is \$1,124.1m. The gross contractual amount for trade receivables due is \$1,131.4m, with a loss allowance of \$7.3m recognised on acquisition.

Revenue and profit contribution

The acquired business contributed revenues of \$2,428.2m and earnings before interest and tax (EBIT) of \$18.8m to the Group for the period from 12 February to 30 June 2025.

If the acquisition had occurred on 1 July 2024, consolidated pro-forma revenue and EBIT for the year ended 30 June 2025 would have been \$9,584.6m and \$879.2m respectively. These amounts have been calculated using the acquiree's results and adjusting them for:

- differences in the accounting policies;
- elimination in intercompany transactions;
- merger related costs which represent the non-recurring costs incurred by both the acquirer and acquiree in association with the merger. These costs include financial advisory, legal, regulatory, accounting, tax and other costs and do not relate to the ongoing operations of the Merged Group;
- integration costs incurred to integrate the Sigma and Chemist Warehouse businesses, post-merger; and
- the additional depreciation and amortisation that would have been charged on the assumption that the fair value adjustments to PPE and intangible assets had applied from 1 July 2024, together with consequential tax effects.

The calculation does not account for any changes in business operations or strategy.

Sigma Healthcare Limited
Notes to the consolidated financial statements
30 June 2025

Note 25. Business combinations (continued)

Acquisition related costs

Acquisition related costs of \$46.6m that were not directly attributable to the issue of shares are included in general and administrative expenses in the statement of profit or loss and other comprehensive income and in operating cash flows in the statement of cash flows.

(b) DPP Pharmaceuticals Pty Limited

On 1 July 2024, the Group completed the acquisition of 100% of the issued units of DPP Pharmaceuticals Unit Trust and 100% of the shares in DPP Pharmaceuticals Pty Ltd (DPP), a developer and seller of healthcare products for a consideration of \$47.9 million. The acquisition provides the Group with control of additional healthcare brands that will complement the offerings that the Group provides its customers.

Details of the purchase consideration, the net assets acquired and goodwill are as follows:

	\$'000
Ordinary shares issued	47,900

The assets and liabilities recognised as a result of the acquisition are as follows:

	Fair value
	\$'000
Cash and cash equivalents	4,205
Trade and other receivables	4,271
Inventories	5,600
Other current assets	1,034
Intangible assets	10,500
Other non-current assets	96
Trade and other payables	(1,632)
Financial liabilities at amortised cost	(12,195)
Deferred tax liability	(3,561)
Net identifiable assets acquired	8,318
	<hr/>
Add: Goodwill	39,582
Net assets acquired	47,900
	<hr/>

Goodwill is attributable to DPP's strong position and profitability as well as synergies expected to arise as a result of the acquisition. Goodwill is not tax deductible.

Acquired trade receivables

The fair value of trade and other receivables is \$4.3m. The gross contractual amount for trade receivables due is \$4.3m, of which no amount is expected to be uncollectible.

Recognition and measurement

Business combinations are accounted for using the acquisition method. Identifiable assets, liabilities and contingent liabilities acquired are measured at fair value at the acquisition date.

If the initial accounting for a business combination is incomplete by the end of the reporting period in which the combination occurs, the Group reports provisional amounts for the items for which the accounting is incomplete. Those provisional amounts are adjusted during the measurement period (no more than 12 months from the acquisition date), or additional assets or liabilities are recognised, to reflect new information obtained about facts and circumstances that existed as of the acquisition date that, if known, would have affected the amounts recognised as of that date.

Sigma Healthcare Limited
Notes to the consolidated financial statements
30 June 2025

Note 26. Results of Sigma Consolidated Group pre-transaction

The following represents the pre-transaction summarised results for the consolidated Group of Sigma Healthcare Limited between the period 1 February 2025 and the day before the transaction close date of 12 February 2025. This is provided for information purposes only and does not reflect the position of the Group going forward.

This is as a result of the reverse acquisition accounting being applied as of 12 February 2025, where Chemist Warehouse has been identified as the accounting acquirer of the existing Sigma Group.

This disclosure has been included to provide the users of the financial statements with relevant information for the period from the last audited financial results of Sigma (year ended 31 January 2025) to the Merger Implementation date (12 February 2025), as a result of the reverse acquisition.

	1 Feb 25 – 11 Feb 25¹ 11 days \$'000	1 Feb 24 – 31 Jan 25² 12 months \$'000
Results of the pre-transaction consolidated Group		
Loss for the period	(1,181)	(12,918)
Other comprehensive income	61	1,822
Total comprehensive loss for the period	<u>(1,120)</u>	<u>(11,096)</u>
	As at 11 Feb 25¹	As at 31 Jan 25²
Financial position of the pre-transaction Group at period end		
Current assets	<u>1,985,331</u>	<u>1,376,791</u>
Total assets	<u>3,136,989</u>	<u>1,830,567</u>
Current liabilities	<u>900,789</u>	<u>864,967</u>
Total liabilities	<u>2,297,881</u>	<u>991,289</u>
Total equity of the pre-transaction Group comprising of:		
Share capital	1,641,069	1,641,069
Revaluation reserve	(2)	(280)
Reserve for own shares	(2,456)	(3,400)
Non-controlling interest	1,477	1,418
Retained earnings/(Accumulated losses)	<u>(800,980)</u>	<u>(799,529)</u>
Total equity	<u>839,108</u>	<u>839,278</u>

- (1) The results and financial position of the pre-transaction Group does not include elimination entries or fair value adjustments arising from implementation for the merger.
- (2) The comparatives in this Note are included in the audited Sigma Healthcare Limited financial statements for the year ended 31 January 2025.

Sigma Healthcare Limited
Notes to the consolidated financial statements
30 June 2025

Note 27. Interests in other entities

(a) Subsidiaries

The consolidated financial statements include the assets, liabilities and results of the following controlled entities:

Name	Ownership interest		Name	Ownership interest	
	2025 %	2024 %		2025 %	2024 %
Sigma entities²					
Sigma Healthcare Limited ^{1,4}	n/a	-	Sigma Company Limited ¹	100	-
Chemist Club Pty Ltd	100	-	Guardian Pharmacies Australia Pty Ltd	100	-
Allied Master Chemists of Australia Limited ¹	100	-	Pharmacy Wholesalers (Wellington) Limited	#	100
Sigma Employee Share Administration Pty Ltd	100	-	QDL Limited ¹	100	-
Sigma NZ Limited	#	100	Medical Industries Australia Hold Co. Pty Ltd	100	-
Sigma (W.A.) Pty Ltd	100	-	PriceSave Pty Ltd	100	-
Sigma Healthcare Logistics Pty Ltd ¹	100	-	Discount Drugstores Pty Ltd	100	-
Linton Street Pty Ltd	100	-	Crucible Health Pty Ltd	100	-
PharmaSave Australia Pty Ltd	100	-	ACN 133 432 096 Pty Ltd	100	-
MPS Hold Co. Pty Ltd ¹	100	-	ACN 141 734 723 Pty Ltd	100	-
Tromax Pty Ltd	100	-			
Sigma Healthcare Hospital Services Pty Ltd	100	-			
Chemist Warehouse entities³					
CW Group Holdings Limited ^{1,5}	100	n/a	The Trustee for Socialized Unit Trust	100	100
CW Retail Pty Ltd	100	100	Chemist Warehouse Limited	#	100
CW Retail Holdings Pty Ltd	100	100	CW Retail Services (NZ) Pty Ltd	#	100
CW Management Pty Ltd	100	100	CWIRE Retail Holdings Limited	&	70
CW Media Pty Ltd	100	100	CWIRE Retail 1 Limited	&	70
CW Leasing Services Pty Ltd	100	100	CWIRE Retail 2 Limited	&	70
CW China Pty Ltd	100	100	CWIRE Retail 3 Limited	&	70
CW Retail Services Pty Ltd	100	100	CWIRE Retail 4 Limited	&	70
CW NZ Pharmacy Pty Ltd ¹	100	100	CWIRE Retail 5 Limited	&	70
CW Leasing NZ Pty Ltd	100	100	CWIRE Retail 6 Limited	&	70
CW Treasury Services Pty Ltd	100	100	CWIRE Retail 7 Limited	&	70
ePharmacy Holdings Pty Ltd ¹	100	100	CWIRE Retail 8 Limited	&	70
ePharmacy Group Pty Limited ¹	100	100	CWIRE Retail 9 Limited	&	70
ePharmacy Internet Sales Pty Ltd	100	100	CWIRE Retail 10 Limited	&	70
Game-On Product Group Pty Ltd	100	100	CWIRE Retail 11 Limited	&	70
BSAP Solutions Pty Ltd	100	100	CWIRE Retail 12 Limited	&	70
CW IP Pty Ltd	100	100	CWIRE Retail 13 Limited	&	70
Socialized Pty Ltd	100	100	CWIRE Retail 14 Limited	&	70
Market Reach Pty Ltd	100	100	CWIRE Retail 15 Limited	&	70
Bondi Perfume Company Pty Ltd	100	100	CWIRE Retail 16 Limited	&	70
CW Hospital Services Pty Ltd	100	100	CWIRE Retail 17 Limited	&	70
CW Macau Pty Ltd	100	100	CWIRE Retail 18 Limited	&	70
CW Retail Asia Pty Ltd	100	100	CWIRE Retail 19 Limited	&	70
Wagner Pharmaceuticals Pty Ltd ¹	100	100	CWIRE Retail 20 Limited	&	70
Instant Consult Pty Ltd	60	60	CWIRE Retail 21 Limited	&	70
Optometrist Warehouse Pty Ltd	70	70	CWIRE Retail 22 Limited	&	70
CW Account Services Pty Ltd	100	100	CWIRE Retail 23 Limited	&	70
CW Retail Trust	100	100	CWIRE Retail 24 Limited	&	70
CW Retail Holdings Trust	100	100	CWIRE Retail 25 Limited	&	70
CW Management Trust	100	100	CWIRE Retail 26 Limited	&	70
CW Media Trust	100	100	CWIRE Retail 27 Limited	&	70

Sigma Healthcare Limited
Notes to the consolidated financial statements
30 June 2025

Note 27. Interests in other entities (continued)

Name	Ownership interest		Name	Ownership interest	
	2025	2024		2025	2024
	%	%		%	%
CW Leasing Services Trust	100	100	CWIRE Retail 28 Limited	& 70	70
CW China Trust	100	100	CWIRE Retail 29 Limited	& 70	70
CW Retail Services Trust	100	100	CWIRE Retail 30 Limited	& 70	70
CW Leasing NZ Unit Trust	100	100	Chemist Warehouse Ireland Limited	& 100	100
Stratosphere Media Agency Pty Ltd	100	100	CWH Pharmacy LLC	^ 60	-
Stratosphere NZ Limited	# 100	100	DPP Pharmaceuticals Trust	100	-
CW IP Unit Trust	100	100	DPP Pharmaceutical Pty Limited	100	-
ePharmacy Unit Trust	100	100	GM Pharma International Pty Ltd	100	-

- (1) These companies are subject to a deed of cross guarantee (note 30).
- (2) Chemist Warehouse completed the reverse acquisition of Sigma on 12 February 2025.
- (3) In the year ended 30 June 2024 the Group comprised only of Chemist Warehouse group entities.
- (4) For accounting purposes considered a subsidiary, however, for legal purposes considered the parent entity.
- (5) At 30 June 2024 CW Group Holdings Limited was the legal parent entity.

All subsidiaries are incorporated in Australia unless identified by one of the following symbols:

#	New Zealand
&	Ireland
^	UAE

(b) Interests in associates and joint ventures

The Group does not have any individual material associates or joint ventures. Throughout the Group's international store network, the Group accounts for 61 entities that operate Chemist Warehouse stores as joint ventures. Refer to Note 28 Investments accounted for using the equity method.

During the current financial year, the Group acquired a minority interest in a number of entities. The Group has assessed that it has significant influence over these entities and therefore, has accounted for its investments using the equity method – refer to Note 28.

NostraData Pty Ltd (NostraData)

On 12 February 2025, the Group disposed of 5.1% interest in NostraData Pty Ltd, such that the Group's total shareholding has decreased from 51.0% in FY24 to 45.9%.

Consequently, from 12 February 2025, the Group reclassified the accounting for its investment in NostraData from being a consolidated subsidiary to equity method for investment in associates under AASB 128 *Investments in Associates and Joint Ventures* as the Group no longer has control over NostraData.

Changes in ownership interests

The Group treats transactions with non-controlling interests that do not result in a loss of control as transactions with equity owners of the Group. A change in ownership interests results in an adjustment between the carrying amounts of the controlling and non-controlling interests to reflect their relative interests in the subsidiary. Any difference between the amount of the adjustment to non-controlling interests and any consideration paid or received is recognised a separate reserve within equity attributable to the owners of the Group.

When the Group ceases to consolidate or equity account for an investment because of loss of control, joint control or significant influence, any retained interest in the entity is remeasured to its fair value with the change in carrying amount recognised in profit or loss. This fair value becomes the initial carrying amount for the purposes of subsequently accounting for the retained interest as an associate, joint venture or financial asset. In addition, any amounts previously recognised in other comprehensive income in respect of that entity are accounted for as if the Group had directly disposed of the related assets or liabilities. This may mean that amounts previously recognised in other comprehensive income are reclassified to profit or loss where appropriate.

Sigma Healthcare Limited
Notes to the consolidated financial statements
30 June 2025

Note 27. Interests in other entities (continued)

Critical accounting estimates and assumptions

Consolidation assessment of franchisees

In determining whether the franchisees require to be consolidated with the Group an assessment of control was made. For a number of reasons, including consideration of equity interest, voting rights and decision-making authority, it was determined that the Group does not have substantive power over the Australian franchisees and therefore does not control them. Australian franchisees are therefore not consolidated with the Group.

Note 28. Investments accounted for using the equity method

	2025	2024
	\$'000	\$'000
<i>Non-current assets</i>		
Investments in associates	11,862	159
Investments in joint ventures	31,237	44,861
	<u>43,099</u>	<u>45,020</u>

Movements in investments in joint ventures for the period are set out below:

	2025	2024
	\$'000	\$'000
Opening balance at the start of the period	44,861	22,311
Profit for the period	29,514	22,550
Dividends paid/payable	(43,138)	-
	<u>31,237</u>	<u>44,861</u>

Movements in investments in associates for the period are set out below:

	2025	2024
	\$'000	\$'000
Opening balance at the start of the period	159	498
Additions to investments in associates during the period	11,006	-
Distributions from investments in associates during the period	-	(847)
Profit for the period	697	508
	<u>11,862</u>	<u>159</u>

Recognition and measurement

Associates

Associates are all entities over which the Group has significant influence but not control or joint control. This is generally the case where the Group holds between 20% and 50% of the voting rights. Investments in associates are accounted for using the equity method of accounting after initially being recognised at cost in the consolidated balance sheet.

Joint Ventures

Interests in joint ventures are accounted for using the equity method, after initially being recognised at cost in the consolidated balance sheet.

Equity method of accounting

Under the equity method of accounting, the investments are initially recognised at cost and adjusted thereafter to recognise the Group's share of post-acquisition profits or losses of the investee in profit or loss, and the Group's share of movements in other comprehensive income of the investee in other comprehensive income. Dividends received or receivable from equity accounted investments are recognised as a reduction in the carrying value of the investment.

Sigma Healthcare Limited
Notes to the consolidated financial statements
30 June 2025

Note 28. Investments accounted for using the equity method (continued)

Where the Group's share of losses in an equity-accounted investment equals or exceeds its interest in the entity, including any other unsecured long-term receivables, the Group does not recognise further losses, until it has incurred obligations or made payments on behalf of the other entity.

Unrealised gains on transactions between the Group and its equity accounted investments are eliminated to the extent of the Group's interest in these entities. Unrealised losses are also eliminated unless the transaction provides evidence of an impairment of the asset transferred. Accounting policies of equity-accounted investees have been changed where necessary to ensure consistency with the Group.

Critical accounting estimates and assumptions

Investments accounted for using the equity method

The Group accounts for its investment in New Zealand entities that operate Chemist Warehouse stores as joint ventures. This is on the basis that the Group's contractual arrangements with these entities result in them meeting the definition of a joint venture.

Note 29. Non-controlling interests

	2025	2024
	\$'000	\$'000
Balance at beginning of the year	(5,527)	(3,578)
Share of loss for the year	(4,459)	(1,356)
Transactions with NCI	42	-
Acquisition of NCI	-	(183)
Dividends paid	-	(410)
	<u>(9,944)</u>	<u>(5,527)</u>

Note 30. Deed of cross guarantee

Pursuant to *ASIC Instrument 25/0078 (Sigma ASIC Instrument)*, (read together with *ASIC Corporations (Wholly-owned Companies) Instrument 2016/785 (Wholly Owned ASIC Instrument)*), the wholly owned Australian controlled entities identified in Note 27 footnote (1) are relieved from the *Corporations Act 2001* requirements for the preparation, audit and lodgement of financial reports for their statutory financial years ending after 31 January 2025.

The Sigma ASIC Instrument was obtained by the Group in connection with the merger transaction as a consequence of separate relief granted by ASIC which allow Sigma (and certain of its subsidiaries) to meet their financial reporting obligations based on a notional financial year that runs to 30 June each year, enabling the Merged Group to report in accordance with Chemist Warehouse's financial year end of 30 June.

As a result of receiving this relief, Sigma will meet its financial reporting obligations under Part 2M.3 of the *Corporations Act 2001* in relation to notional financial years ending 30 June and notional half-years ending 31 December, as if those were Sigma's statutory financial years and half-years. Although the Sigma ASIC Instrument provides the relevant relief from the preparation, audit and lodgement of financial reports for Sigma's subsidiaries which have financial reporting obligations, it must be read together with the Wholly Owned ASIC Instrument.

These entities which are also referred to in the Directors' declaration are, together with the Company, all members of the 'extended closed group' as defined under the Wholly Owned ASIC Instrument.

As disclosed in Sigma Healthcare Limited's Financial Report for the period ended 31 January 2025, Sigma Healthcare Limited and certain of its wholly-owned subsidiaries were party to a Deed of Cross Guarantee dated 20 January 2006 (as amended), as defined in the Wholly Owned ASIC Instrument (**Previous Deed**).

Sigma Healthcare Limited
Notes to the consolidated financial statements
30 June 2025

Note 30. Deed of cross guarantee (continued)

In connection with the implementation of the merger between Sigma and Chemist Warehouse, the following changes occurred in relation to the Previous Deed:

- On 19 May 2025, a revocation deed was lodged with ASIC to revoke the Previous Deed. The revocation deed will take effect on 20 November 2025;
- On 19 May 2025, Sigma Healthcare Limited entered into a Deed of Cross Guarantee (New Deed) with the entities below, under which each member of the extended closed Group guarantees the debts of the others; and
- On 21 August 2025, Sigma Company Limited and QDL Limited entered into deeds of accession so that they became party to the New Deed as group entities.

The following entities are parties to the New Deed (and comprise the closed Group and the extended closed Group):

- Sigma Healthcare Limited
- Sigma Company Limited (this entity is an alternative trustee and is also a Group Entity, as defined in the New Deed)
- QDL Limited
- Allied Master Chemists of Australia Limited
- MPS Hold Co. Pty Limited
- Sigma Healthcare Logistics Pty Limited
- CW Group Holdings Limited
- ePharmacy Holdings Pty Limited
- ePharmacy Group Pty Limited
- CW NZ Pharmacy Pty Limited
- Wagner Pharmaceuticals Pty Limited

The extended closed Group's consolidated statement of profit or loss and balance sheet have been prepared in accordance with the Group's accounting policy and are set out below.

The comparatives which would apply pursuant to the Wholly Owned ASIC Instrument relate to the Sigma extended closed Group under the Previous Deed, for the preceding financial year end (being the 12 months ended 31 January 2025). This information is required to be included as the Sigma ASIC Instrument incorporates by reference certain conditions of relief contained in the Wholly Owned ASIC Instrument.

The Previous Deed has been revoked during the current financial period ended 30 June 2025 which revocation will take effect from 20 November 2025.

Sigma Healthcare Limited
Notes to the consolidated financial statements
30 June 2025

Note 30. Deed of cross guarantee (continued)

(a) Consolidated statement of profit or loss and other comprehensive income

Set out below is a consolidated statement of profit or loss and other comprehensive income for the year ended 30 June 2025 of the extended closed Group, after eliminating all transactions between parties to the Deed of Cross Guarantee. The prior year comparatives are for the Sigma extended closed Group under the Previous Deed for the year ended 31 January 2025.

	Financial year ended 30 Jun 2025	Financial year ended 31 Jan 2025
	\$'000	\$'000
Statement of profit or loss and other comprehensive income		
Revenue	2,575,781	4,935,146
Cost of sales	(2,334,940)	(4,574,887)
Share of profits of associates and joint ventures accounted for using the equity method	722	-
Other income	501,103	5,939
Warehousing and distribution expenses	(81,414)	(187,243)
Marketing and sales expenses	(16,996)	(37,615)
Administration and general expenses	(70,130)	(121,179)
Net finance costs	(23,421)	(10,524)
	<u>550,705</u>	<u>9,637</u>
Profit / (loss) before income tax (expense)/benefit		
Income tax (expense)/benefit	(14,934)	(23,305)
	<u>535,771</u>	<u>(13,668)</u>
Profit / (loss) after income tax (expense)/benefit		
Other comprehensive income for the year, net of tax	(452)	1,822
	<u>535,319</u>	<u>(11,846)</u>
Total comprehensive income / (loss) for the year		

Sigma Healthcare Limited
Notes to the consolidated financial statements
30 June 2025

Note 30. Deed of cross guarantee (continued)

(b) Consolidated balance sheet and summary of movements in consolidated retained earnings

Set out below is a consolidated balance sheet and a summary of movements in consolidated retained earnings for the year ended 30 June 2025 of the extended closed Group. The prior year comparatives are for the Sigma extended closed Group under the Previous Deed for the year ended 31 January 2025.

Balance sheet	30 Jun 2025	31 Jan 2025
	\$'000	\$'000
Current assets		
Cash and cash equivalents	68,842	11,679
Trade and other receivables	1,296,784	956,534
Inventories	460,560	383,437
Financial assets at amortised cost	-	-
Current tax asset	-	3,456
Other assets	15,485	5,182
Total current assets	1,841,671	1,360,288
Non-current assets		
Investments	621,805	7,812
Trade and other receivables	29,111	22,329
Financial assets at fair value through other comprehensive income	8,667	8,524
Property, plant and equipment	183,345	180,699
Right-of-use assets	68,177	73,769
Intangible assets	58,181	110,477
Other assets	14,400	16,400
Deferred tax assets	43,067	39,182
Total non-current assets	1,026,753	459,192
Total assets	2,868,424	1,819,480
Current liabilities		
Trade and other payables	697,902	808,734
Other liabilities	4,474	190
Borrowings	109,532	-
Lease liabilities	11,742	10,640
Current tax liabilities	124,466	-
Provisions	10,274	9,858
	958,390	829,422
Non-current liabilities		
Other liabilities	109,021	-
Borrowings	855,292	-
Lease liabilities	119,150	121,446
Provisions	4,880	4,876
	1,088,343	126,322
Total liabilities	2,046,733	955,744
Net assets	821,691	863,736
Equity		
Issued capital	1,578,339	1,682,372
Issued capital held by equity compensation plan	(2,921)	(14,654)
Reserves	16,402	(3,876)
Retained earnings	(770,129)	(800,106)
Total equity	821,691	863,736

Sigma Healthcare Limited
Notes to the consolidated financial statements
30 June 2025

Note 30. Deed of cross guarantee (continued)

	30 Jun 2025	31 Jan 2025
	\$'000	\$'000
Summary of movements in consolidated retained earnings		
Retained earnings/(accumulated losses) at the beginning of the financial year	(815,334)	(769,922)
Profit/(loss) for the period	535,771	(13,668)
Reclassification of settled and expired share-based transactions	(4,551)	(826)
Dividends paid	(486,036)	(15,938)
Transfers	21	248
Retained earnings/(accumulated losses) at the end of the financial year	(770,129)	(800,106)

Note 31. Parent entity financial information

As at, and throughout the financial year ended 30 June 2025, the parent entity of the Group was Sigma Healthcare Limited.

The individual financial statements for the parent entity, Sigma Healthcare Limited, show the following aggregate amounts:

	As at	As at
	30 Jun 25	31 Jan 25
	\$'000	\$'000
Balance sheet		
Current assets	381,156	320,213
Total assets ¹	<u>28,678,401</u>	<u>685,880</u>
Current liabilities	108,762	23,344
Total liabilities	<u>108,762</u>	<u>23,344</u>
Total equity		
Issued capital	28,595,432	677,739
Reserves	456	1,678
Retained earnings	<u>(26,249)</u>	<u>(16,881)</u>
Total equity	<u>28,569,639</u>	<u>662,536</u>
	1 Feb 25 –	1 Feb 24 –
	30 Jun 25	31 Jan 25
	5 months	12 months
	\$'000	\$'000
Financial results		
Loss for the period	(8,685)	(3,369)
Other comprehensive income	-	-
Total comprehensive income / (loss)	<u>(8,685)</u>	<u>(3,369)</u>

¹ Total assets includes Sigma Healthcare Limited's investment in Chemist Warehouse of \$27.9 billion which represents the fair value of Sigma shares issued to Chemist Warehouse and the \$700.0 million cash consideration transferred.

Sigma Healthcare Limited
Notes to the consolidated financial statements
30 June 2025

Note 31. Parent entity financial information (continued)

Contingent liabilities

The parent entity did not have any contingent liabilities as at 30 June 2025. (2024: nil)

Guarantees

Under the terms of the Deed of Cross Guarantee dated 16 May 2025 (and lodged with ASIC on 19 May 2025), entered in accordance with the Sigma ASIC Instrument (read together with the Wholly Owned ASIC Instrument) (in each case as defined in Note 30), the Company has undertaken to meet any shortfall which might arise on the winding up of controlled entities which are party to the Deed (see Note 30). No deficiencies of assets exist in any of these entities. No liability was recognised by the parent entity or the Group in relation to these cross guarantees, as the fair value of the guarantees is immaterial.

Parent company investment in subsidiary companies

Investments in subsidiaries are carried at cost in the individual financial statements of Sigma Healthcare Limited. An impairment loss is recognised whenever the carrying amount of the investment exceeds its recoverable amount. Recoverable amount is the higher of value in use and fair value less costs of disposal. The carrying value of the parent's investment in subsidiaries as at 30 June 2025 was \$28,285,695,000 (2024: \$363,511,000).

Receivables from controlled entities

The parent entity did not have any impairment in respect of any intercompany loan receivable during the current period (2024: nil). The parent loan receivables are not overdue and eliminate on consolidation.

Contractual commitments for the acquisition of property, plant or equipment

The parent entity did not have any contractual commitments for the acquisition of property, plant and equipment as at 30 June 2025 (2024: nil).

Determining the parent entity financial information

The financial information for the parent entity has been prepared on the same basis as the consolidated financial statements, except as set out below.

Investments in subsidiaries, associates and joint ventures

Investments in subsidiaries, associates and joint venture entities are accounted for at cost in the financial statements of the parent entity. Dividends received from associates are recognised in the parent entity's profit or loss when its right to receive the dividend is established.

Note 32. Related party transactions

Transactions with related parties are disclosed in this note based on the recognition and measurement principles applied in the consolidated statement of profit or loss and other comprehensive income.

Difference between related parties disclosure in Remuneration Report and Financial Statements

The related party disclosures included in the Consolidated Financial Statements differ to the disclosures included in the Remuneration Report due to application of different reporting requirements as a result of the reverse acquisition in the current financial year.

As the merger between Chemist Warehouse and Sigma is accounted for as a reverse acquisition under AASB 3 *Business Combinations*, the Consolidated Financial Statements represent the continuing accounts of Chemist Warehouse.

Sigma Healthcare Limited
Notes to the consolidated financial statements
30 June 2025

Note 32. Related party transactions (continued)

This note disclosure has been prepared on the below basis, in accordance with AASB 124 *Related Party Disclosures*:

- From 1 July 2024 to 11 February 2025 (pre-merger), Related Parties have been identified as:
 - KMPs of Chemist Warehouse;
 - Close family members of Chemist Warehouse's KMPs;
 - Entities Chemist Warehouse's KMPs control (either directly, indirectly or jointly); and
 - Entities subject to significant influence or joint control by Chemist Warehouse.
- From the merger date of 12 February 2025 to 30 June 2025, Related Parties have been identified as:
 - KMPs of the Merged Group;
 - Close family members of the Merged Group's KMPs;
 - Entities the Merged Group's KMPs control (either directly, indirectly or jointly); and
 - Entities subject to significant influence or joint control by the Merged Group.

The related party disclosures in the Remuneration Report have been prepared on the basis of Sigma Healthcare Limited being the legal entity required to report in accordance with the *Corporations Act* and *Corporations Regulations*, where:

- From 1 July 2024 to 11 February 2025 (pre-merger), Related Parties refer to:
 - KMPs of Sigma Healthcare Limited;
 - Close family members of Sigma Healthcare Limited's KMPs;
 - Entities Sigma Healthcare Limited's KMPs control (either directly, indirectly or jointly); and
 - Entities subject to significant influence or joint control by Sigma Healthcare Limited.
- From the merger date of 12 February 2025 to 30 June 2025, the Related Parties are the Related Parties of the Merged Group as defined above.

As a result of the above, the Remuneration Report and Consolidated Financial Statements are required by the relevant legislation and accounting standards to capture different persons (for example, related parties of either Chemist Warehouse or Sigma measured either before, or after, implementation of the merger for different periods). Refer to the Remuneration Report for further information.

For the purposes of this note disclosure, Mr S Gance is not assessed to be a Related Party of the Group subsequent to the completion of the merger on 12 February 2025, in accordance with AASB 124 *Related Party Disclosures*. Disclosures regarding his transactions post-merger are included in the Remuneration Report to comply with the ASX Confirmation Conditions in relation to the merger.

Due to the differences in basis of preparation between Remuneration Report and Consolidated Financial Statement, the Related Party disclosures in these two reports will differ.

Subsidiaries

Interests in subsidiaries are set out in Note 27.

Key Management Personnel

Disclosures relating to Key Management Personnel are set out in Note 35.

Key Management Personnel refers to directors of Chemist Warehouse prior to the implementation of the merger on 12 February 2025. Subsequent to the merger, Key Management Personnel refers to persons set out in the Remuneration Report (being the Key Management Personnel of the Merged Group).

Entities exercising control over the Group

Sigma Healthcare Limited represents the highest controlling entity upon which one entity has control.

Entities subject to significant influence or joint control by the Group and are equity accounted for

An entity that has the power to participate in the financial and operating policy decisions of a second entity, but does not have control over those policies, is an entity which holds significant influence or joint control over the second entity. Significant influence or joint control may be gained by share ownership, statute or agreement.

The Group also transacts with the entities in the capacity of an Agent where costs incurred by the Group are reimbursed by the entities. These transactions are presented on a net basis.

Sigma Healthcare Limited
Notes to the consolidated financial statements
30 June 2025

Note 32. Related party transactions (continued)

Transactions with related parties disclosed below are based on normal commercial terms and conditions that would be available to third parties.

	2025	2024
	\$'000	\$'000
<i>Transactions with associates</i>		
Revenue from sales of goods to entities	345	268
Purchases and other charges from entities	(8,302)	(6,349)
<i>Outstanding balances with associates</i>		
Trade receivables from entities	1,639	649
Trade payables from entities	(1,235)	-
	2025	2024
	\$'000	\$'000
<i>Transactions with joint ventures</i>		
Revenue from sales of goods to entities	28,533	43,539
Rendering of services to entities	30,783	25,923
Leases income received from entities	18,725	14,262
<i>Outstanding balances with joint ventures</i>		
Trade receivables from entities	8,551	17,295
Lease receivables	105,171	75,145
Trade payables to entities	(5,234)	(4,701)
Loans payable to entities	(28,557)	(30,753)

Entities over which the Key Management Personnel have control or joint control

Entities which the Key Management Personnel have control or joint control over include:

- **East Yarra Friendly Society Pty Ltd ("EYFS"):** At 30 June 2025 the Group has no outstanding loan owing to EYFS (30 June 2024: \$300.0 million).
- **Franchised stores:** There are franchised stores which are operated and owned by Key Management Personnel of the Group (including any franchised stores owned by EYFS) either wholly or in partnership with other parties. The terms of the franchise agreements with related party franchised stores are on agreed terms and conditions.
- **Properties:** Properties controlled or jointly controlled by the Key Management Personnel and leased to the Group.
- **Other related parties:** Entities outside the Group over which Key Management Personnel have control or joint control.

The Group also transacts with the entities in the capacity of an Agent where costs incurred by the Group are reimbursed by the entities. These transactions are presented on a net basis.

Transactions with related parties disclosed below are based on normal commercial terms and conditions that would be available to third parties.

As disclosed above, Key Management Personnel refer to directors of Chemist Warehouse prior to the implementation of the merger on 12 February 2025. Subsequent to the merger, Key Management Personnel refers to persons set out in the Remuneration Report.

	2025	2024
	\$'000	\$'000
<i>Transactions with entities which Key Management Personnel have control or joint control over</i>		
Revenue from sales of goods to the entities	1,242,073	934,198
Rendering of services to the entities	63,664	61,674
Fees revenue	71,789	88,199
Lease income received from entities	70,734	78,697
Lease charges	(46,903)	(39,893)
Purchases and other charges from entities	(8,414)	(21,954)

Sigma Healthcare Limited
Notes to the consolidated financial statements
30 June 2025

Note 32. Related party transactions (continued)

	2025	2024
	\$'000	\$'000
<i>Outstanding balances with entities which Key Management Personnel have control or joint control over</i>		
Trade receivables from entities	260,682	178,806
Trade payables to entities	(16,881)	(43,179)
Lease receivable	221,541	334,605
Lease liability	(240,229)	(222,343)
Make good provision	(3,479)	(2,800)
<i>Movement of loans and interest payable to related parties</i>		
Carrying amount at the start of the year	(302,386)	(246,037)
Loan recognised as a result of business combination	(12,190)	-
Loan repayments to related parties	333,201	291,517
Loan proceeds from related parties	(21,297)	(347,174)
Interest repayments to related parties	12,581	13,681
Interest incurred from related parties	(9,909)	(14,373)
Carrying amount at the end of the year	<u>-</u>	<u>(302,386)</u>

The Group provides loans to related party franchised stores to fund the purchase or establishment of the franchise business. As at 30 June 2025, the Group has a loan balance owing from related party franchised stores of \$1.7 million and has earned interest income of \$0.2 million during the financial year. The difference between the \$0.2 million interest income here and the figures provided in the Remuneration Report is because these accounts represent the continuing accounts of Chemist Warehouse (while the Remuneration Report is prepared on the basis that Sigma is the disclosing entity).

During the financial year ended 30 June 2025, the Group acquired 100% of the issued units of DPP Pharmaceutical Unit Trust and 100% of the shares in DPP Pharmaceuticals Pty Ltd ("DPP"), a developer and seller of healthcare products, for consideration of \$47,900,000. Related parties had a minority shareholding in the acquired Group.

Refer to Note 25 Business Combinations for further details.

During the financial year ended 30 June 2025, the Group acquired a 39% interest in Tilley Soaps Australia Pty Ltd from a Related Party. Tilley Soaps Australia Pty Ltd is a manufacturer and supplier of hygiene and beauty products. The Group has assessed that it has significant influence over this entity and therefore, has accounted for its investment using the equity method – refer to Note 28.

Sigma Healthcare Limited
Notes to the consolidated financial statements
30 June 2025

Close family members of Key Management Personnel

Close family members (CFM) of the Key Management Personnel are related parties to the Group. Close family members are defined in accordance with AASB 124 *Related Party Transactions* and include the Key Management Personnel's children, spouse and/or domestic partner.

Transactions with CFM include transactions with entities over which the CFM have control or joint control. The Group also transacts with the entities in the capacity of an Agent where costs incurred by the Group are reimbursed by the entities. These transactions are presented on a net basis. Transactions with CFM disclosed below are based on normal commercial terms and conditions that would be available to third parties.

	2025	2024
	\$'000	\$'000
<i>Transactions with close family members</i>		
Sales of goods to the entities	204,573	166,180
Rendering of services to the entities	13,411	12,598
Fees revenue	15,885	19,682
Lease income received from entities	12,404	13,212
Lease charges	-	(460)
Purchases and other charges from entities	(376)	-
Employee benefits	(321)	(525)
	2025	2024
	\$'000	\$'000
<i>Outstanding balances with close family members</i>		
Trade receivables from entities	39,931	37,952
Trade payables from entities	(1,934)	(9,268)
Lease receivable	27,820	59,354

Guarantees with related parties

For details on guarantees see note 34.

Sigma Healthcare Limited
Notes to the consolidated financial statements
30 June 2025

Other disclosures

Note 33. Remuneration of auditors

During the financial year the following fees were paid or payable for services provided by PricewaterhouseCoopers, the auditor of the Group and by non-related audit firms:

	2025	2024
	\$	\$
<i>Services provided by PricewaterhouseCoopers</i>		
Audit services	1,100,000	849,876
Other assurance services ¹	750,313	9,000
Other services		
Risk consulting services	53,850	-
	<u>1,904,163</u>	<u>858,876</u>
<i>Services provided by other accounting firms</i>		
Audit services	<u>253,251</u>	<u>191,998</u>

¹ PwC was engaged as the Investigating Accountant, prior to completion of the merger, to report on the historical financial information of Sigma and Chemist Warehouse and the pro forma historical financial information of the Merged Group for inclusion in the Merged Group Prospectus.

Note 34. Commitments

The Group has the following contractual purchase commitments with its suppliers:

	2025	2024
	\$'000	\$'000
Within one year	-	3,000,000
One to five years	-	13,576,894
More than five years	-	-
	<u>-</u>	<u>16,576,894</u>

The contractual purchase commitments at 30 June 2024 related to the Supply Agreement between Sigma and Chemist Warehouse. As a result of the merger between Sigma and Chemist Warehouse, the contractual purchase commitments relating to this Supply Agreement has reduced to nil at 30 June 2025.

Guarantees

In the year ended 30 June 2024, the Group together with a related party, had guaranteed the payment obligation to an external supplier of amounts owed by the franchised store network to the supplier. The Group had 565 franchised stores within the network that owed an average amount of \$735,820 per franchised store to the supplier as at 30 June 2024. As at 30 June 2025, the Group no longer has contractual arrangements with the external supplier.

The Group has guaranteed certain payment obligations to landlords of leased premises. As at 30 June 2025, the Group has a bank guarantee facility of \$60,000,000 (2024: \$35,000,000), of which \$41,098,107 (2024: \$34,145,808) is utilised.

Contingent liabilities

The Group did not have any contingent liabilities as at 30 June 2025. (2024: nil)

Sigma Healthcare Limited
Notes to the consolidated financial statements
30 June 2025

Note 35. Key management personnel disclosures

The compensation paid or payable to key management personnel of the Group is set out below:

	2025	2024
	\$'000	\$'000
Short-term employee benefits	5,213	-
Post-employment benefits	218	-
Long-term benefits	30	-
Share-based payments	1,276	-
Total key management personnel compensation	6,737	-

Prior to the implementation of merger between Sigma and Chemist Warehouse, key management personnel (KMPs) referred to the directors of Chemist Warehouse.

During the year ended 30 June 2024, the directors of Chemist Warehouse worked in an executive capacity and drew no remuneration.

During the period 1 July 2024 to 11 February 2025, remuneration was paid to the directors of Chemist Warehouse and is included in the compensation paid to key management personnel for the current financial year.

Subsequent to the implementation of merger on 12 February 2025, remuneration for KMPs for the consolidated Group have been disclosed above. KMPs for the consolidated Group post-merger are listed in the Remuneration Report at page 21.

Disclosures relating to related party transactions with Directors or key management personnel are set out in Note 32.

Note 36. Share-based payments

The Group has an employee share plan and share-based remuneration schemes for executive and non-executive management (excluding non-executive Directors).

Expenses arising from share-based payment transactions attributable to employees recognised during the period were as follows:

	2025	2024
	\$'000	\$'000
Shares issued - employees	-	10,950
Shares issued - other	48	3,755
Performance rights expense	-	808
Performance rights under short-term incentive plan	329	-
Rights issued under the executive long-term incentive plan	1,917	-
Cash settled performance rights under long-term incentive plan	1,600	-
Total share-based payment expense	3,894	15,513

(a) Performance rights plan

Performance rights were granted to certain key executives at Chemist Warehouse in July 2022, to provide incentives to deliver long term shareholder returns.

The rights vest upon certain milestone events being met.

Rights are granted under the plan for no consideration and carry no dividend or voting rights.

Sigma Healthcare Limited
Notes to the consolidated financial statements
30 June 2025

Note 36. Share-based payments (continued)

Set out below are summaries of performance rights granted under the plan:

	Number of options	
	2025	2024
Outstanding at the beginning of the financial year	446,765	446,765
Granted during the year	-	-
Exercised during the year	(446,765)	-
	<u>-</u>	<u>446,765</u>
Outstanding at the end of the financial year	-	446,765
Vested and exercisable at the end of the financial year	<u>-</u>	<u>-</u>

There are no outstanding Chemist Warehouse performance rights at the end of the financial year.

(b) Employee share plan

Up until the financial year 2021/22, Sigma's Employee Share Plan periodically offered ordinary shares to all full or part time employees of the Group. The ordinary shares issued under the plan rank equally with all other fully paid ordinary shares on issue. Interest free loans are offered to acquire the shares. The price at which shares are issued is determined by the weighted average price of ordinary shares over the five trading days prior to and including the date of issue of shares. The Employee Share Plan is administered by Sigma Employee Share Administration Pty Ltd (SESA), a controlled entity. At balance date 3,262,500 shares are on issue.

Interest free loans from SESA to employees are for a period of 10 years and are secured by the shares issued. The loans are repayable from dividends received on the shares and from voluntary loan repayments. If an employee leaves employment within the Group, they can repay the loan in full and acquire unrestricted ownership of the shares. If the employee does not wish to acquire the shares and repay the loan, the shares are transferred to SESA for later sale on market to repay the remaining balance of the loan.

Post-merger between Sigma and Chemist Warehouse, all existing loan funded plans from previous years remain on foot, however no loan funded employee share scheme offerings were provided during the current financial year.

Dividends paid by Sigma Healthcare Limited on shares held under loan funded share plans not issued to employees are eliminated in full on consolidation. Any Dividends applied to repay loan balances are recorded in a separate reserve account as they represent part of the exercise price "paid" by the employee. Dividends of forfeited shares are subsequently transferred back to retained earnings / accumulated losses.

(c) Share-based remuneration schemes

Prior to the merger between Sigma and Chemist Warehouse, Sigma has in place several equity-based incentive plans under which eligible participants have been granted equity securities in Sigma Healthcare Limited. The incentive plans were established by Sigma with the purpose of aligning the interest of eligible participants more closely with the interests of shareholders.

Upon merger, the Group has retained the Sigma incentive plans which remain on foot, being the 2023/2024 "One-off" Executive Equity Grant and the 2024/2025 Executive long-term incentive plan. These incentive plans were modified as a result of the merger – refer to below sections for further details.

Details of the features of each share-based remuneration scheme are provided on pages 31 to 33 of the Remuneration Report.

Executive long-term incentive plan – rights issue (zero exercise price)

For the year ended 31 January 2025 (grant date: 1 February 2024), Sigma implemented a rights issue for the executive long-term incentive plan. Participants were issued rights with a three-year performance period subject to service and forfeiture conditions.

Subsequent to the merger, the performance period for this plan was extended by 5 months (exercise date changed from 31 January 2027 to 30 June 2027 to align with the financial year-end of the Merged Group. The Merged Group Board may review targets associated with the performance measures to ensure these are appropriate for the merged entity.

Sigma Healthcare Limited
Notes to the consolidated financial statements
30 June 2025

Note 36. Share-based payments (continued)

Outstanding rights issue

	Balance at 12 February 2025	Granted during the year	Exercised during the year	Forfeited during the year	Balance at 30 June 2025
Number of outstanding performance rights	2,455,802	-	-	(89,852)	2,365,950
Total	2,455,802	-	-	(89,852)	2,365,950

Executive short-term incentive plans – rights issue (zero exercise price)

Prior to merger, the Company implemented a short-term incentive (STI) deferred rights plan which was used for the years ended 31 January 2023, 31 January 2024 and 31 January 2025. During the year ended 31 January 2023, the Company also provided a sign on rights issue to the CEO (grant date: 1 February 2022) covering the 24-month period to 31 January 2024. In the context of the merger, the Board approved payment of the 25% deferred equity component to be delivered in cash for the financial year ended 31 January 2025.

From the merger date (12 February 2025) to 30 June 2025, there have been no short-term incentive rights granted by the Company.

For the 2025/2026 financial year commencing 1 July 2025, the Board has approved an increase to the deferred equity component from 25% to 50% (with 50% of these ordinary shares deferred for 12 months and the remaining 50% deferred for 24 months) with 50% of the STI being delivered in cash. Due to the financial year end change associated with the merger, the CEO's STI opportunity for the 2025/2026 financial year will be 141.67% 'at target' and 70.83% 'at stretch' (for a total maximum STI benefit of 212.50%) based on a 17-month period (being 1 February 2025 to 30 June 2026).

In accordance with the provisions of these share-based remuneration schemes, executives and non-executive managers within the Group are granted options to acquire shares at a zero-exercise price (rights issues).

Outstanding rights issue

	Balance at 12 February 2025	Granted during the year	Exercised during the year	Forfeited during the year	Balance at 30 June 2025
Number of outstanding performance rights	1,965,878	-	(1,965,878)	-	-
Total	1,965,878	-	(1,965,878)	-	-

2023/2024 “One-off” Executive Equity Grant

A “one-off” 2023/2024 Executive Equity Grant Rights Plan (EEG) was granted by Sigma to its CEO, CFO and certain executive team members on 1 February 2023, with a vesting period of 3 years. During Sigma's standalone financial year end of 31 January 2025 (pre-merger), the Board considered the continued employment of executives both during the period of, and following approval of, the merger, the significant value delivered to Sigma Shareholders through the merger and the key roles executives have performed in relation to the merger. The Board determined the rights under the 2023/2024 EEG are subject to the following treatment:

- (i) a cash payment equal to the value of 25% of the EEG Rights (being the service-based component of the grant) be made upon the 'normal' retention date in the EEG (being 31 January 2026) and the corresponding EEG Rights lapsing;
- (ii) a cash payment equal to the value of 37.5% of the EEG Rights be made upon the merger completing and the corresponding EEG rights lapsing, and
- (iii) 37.5% of the EEG Rights converting to ordinary shares in Sigma as at completion of the merger (12 February 2025) that are then held in escrow until 31 January 2026.

Sigma Healthcare Limited
Notes to the consolidated financial statements
30 June 2025

Note 36. Share-based payments (continued)

If a participant gives notice of termination of employment prior to a settlement event as detailed above, their entitlements under the EEG (as modified) will be forfeited.

As required pursuant to ASX listing rules, Shareholder approval was obtained to convert 37.5% of the EEG Rights to ordinary shares, and to cancel the remaining EEG Rights and replace these with cash payments to participants at the Extraordinary General Meeting held in January 2025.

(d) Fair value of options granted

The fair value of options granted are independently determined by an external consultant engaged by the Company. The fair value of each performance rights granted was determined on the date of grant using the Black-Scholes option pricing model that considers the terms and components on the option for those rights with non-market based vesting conditions and using the Monte Carlo methods for those rights with market-based vesting conditions.

There were no new share rights granted by the Group between the implementation of the merger on 12 February 2025 and financial year-end 30 June 2025.

Recognition and measurement

Equity-settled transactions are awards of shares, or options over shares, that are provided to employees in exchange for the rendering of services. Equity-settled share-based payments to employees are measured at the fair value of the equity instruments at the grant date. The fair value determined at the grant date of the equity-settled share-based payments is expensed on a straight-line basis over the vesting period, based on the Group's estimate of equity instruments that will eventually vest, with a corresponding increase in equity. At the end of each reporting period, the Group revises its estimate of the number of equity instruments expected to vest. The impact of the revision of the original estimates, if any, is recognised in profit or loss such that the cumulative expense reflects the revised estimate, with a corresponding adjustment to the options / performance rights reserve.

Where an equity-settled share-based payment scheme is modified during the vesting period, an additional charge is recognised over the remainder of that vesting period to the extent that the fair value of the revised scheme at the modification date exceeds the fair value of the original scheme at the modification date. Where the fair value of the revised scheme does not exceed the fair value of the original scheme, the Group continues to recognise the charge required under the conditions of the original scheme. Where an equity-settled share-based payment scheme is modified to cash-settled and the fair value of the original scheme at the date of modification exceeds the grant date fair value of the scheme, the excess is recognised as a reduction to equity. Individuals must be employed by the Group at the time of vesting, and not in their notice period, to be entitled to the equity incentives.

The amount payable to team members in respects of cash-settled share-based payments is recognised as an expense, with a corresponding increase in liabilities, over the period which the team members become unconditionally entitled to the payment. The liability is measured at each reporting date and at settlement date based on the fair value, with any changes in the liability being recognised in profit or loss.

Note 37. Events after the reporting period

Subsequent to 30 June 2025, the Directors have resolved to pay a fully franked final dividend of 1.3 cents per share. Accordingly, this dividend is not provided for in the balance sheet at 30 June 2025. The ex-dividend date is 2 September 2025, the record date is 3 September 2025 and the dividend is expected to be paid on 18 September 2025. The total amount expected to be payable is \$150.1 million.

In August 2025, the Group has also made the decision to close three distribution centres in Australia, following a comprehensive review.

Other than the matters discussed above, there have not been any other matters or circumstances that have arisen since 30 June 2025 that have significantly affected, or may significantly affect the operations of the Group, the results of those operations or the state of affairs of the Group in subsequent years not otherwise disclosed.

Sigma Healthcare Limited
Consolidated entity disclosure statement
As at 30 June 2025

Name of entity	Type of entity	Trustee, partner or participant in JV	% of share capital	Country of incorporation	Australian resident or foreign resident	Foreign jurisdiction(s) of foreign residents
Sigma Healthcare Limited	Body Corporate	-	N/A	Australia	Australian	N/A
Chemist Club Pty Limited	Body Corporate	-	100%	Australia	Australian	N/A
Sigma Company Limited	Body Corporate	-	100%	Australia	Australian	N/A
Allied Master Chemists of Australia Limited	Body Corporate	-	100%	Australia	Australian	N/A
Guardian Pharmacies Australia Pty Ltd	Body Corporate	-	100%	Australia	Australian	N/A
Sigma Employee Share Administration Pty Ltd	Body Corporate	-	100%	Australia	Australian	N/A
Sigma NZ Limited	Body Corporate	-	100%	New Zealand	Australian and Foreign	New Zealand
Pharmacy Wholesalers (Wellington) Limited	Body Corporate	-	100%	New Zealand	Foreign	New Zealand
QDL Limited	Body Corporate	-	100%	Australia	Australian	N/A
Sigma (W.A.) Pty Ltd	Body Corporate	-	100%	Australia	Australian	N/A
ACN 141 734 723 Pty Ltd	Body Corporate	-	100%	Australia	Australian	N/A
Sigma Healthcare Logistics Pty Ltd	Body Corporate	-	100%	Australia	Australian	N/A
Linton Street Pty Ltd	Body Corporate	-	100%	Australia	Australian	N/A
PriceSave Pty Ltd	Body Corporate	-	100%	Australia	Australian	N/A
PharmaSave Australia Pty Ltd	Body Corporate	-	100%	Australia	Australian	N/A
Discount Drugstores Pty Ltd	Body Corporate	-	100%	Australia	Australian	N/A
MPS Hold Co. Pty Ltd	Body Corporate	-	100%	Australia	Australian	N/A
Medical Industries Australia Hold Co. Pty Ltd	Body Corporate	-	100%	Australia	Australian	N/A
Crucible Health Pty Ltd	Body Corporate	-	100%	Australia	Australian	N/A
Sigma Healthcare Hospital Services Pty Ltd	Body Corporate	-	100%	Australia	Australian	N/A
Tromax Pty Ltd	Body Corporate	-	100%	Australia	Australian	N/A
ACN 133 432 096 Pty Ltd	Body Corporate	-	100%	Australia	Australian	N/A
CW Group Holdings Ltd	Body Corporate	-	100%	Australia	Australian	N/A
CW Retail Pty Ltd	Body Corporate	Trustee	100%	Australia	Australian	N/A
CW Retail Holdings Pty Ltd	Body Corporate	Trustee	100%	Australia	Australian	N/A
CW Management Pty Ltd	Body Corporate	Trustee	100%	Australia	Australian	N/A
CW Media Pty Ltd	Body Corporate	Trustee	100%	Australia	Australian	N/A
CW Leasing Services Pty Ltd	Body Corporate	Trustee	100%	Australia	Australian	N/A
CW China Pty Ltd	Body Corporate	Trustee	100%	Australia	Australian	N/A
CW Retail Services Pty Ltd	Body Corporate	Trustee	100%	Australia	Australian	N/A
CW NZ Pharmacy Pty Ltd	Body Corporate	-	100%	Australia	Australian	N/A
CW Leasing NZ Pty Ltd	Body Corporate	Trustee	100%	Australia	Australian	N/A
CW Treasury Services Pty Ltd	Body Corporate	-	100%	Australia	Australian	N/A
ePharmacy Holdings Pty Ltd	Body Corporate	-	100%	Australia	Australian	N/A
ePharmacy Group Pty Limited	Body Corporate	-	100%	Australia	Australian	N/A
ePharmacy Internet Sales Pty Ltd	Body Corporate	-	100%	Australia	Australian	N/A
Game-On Product Group Pty Ltd	Body Corporate	-	100%	Australia	Australian	N/A
BSAP Solutions Pty Ltd	Body Corporate	-	100%	Australia	Australian	N/A
CW IP Pty Ltd	Body Corporate	Trustee	100%	Australia	Australian	N/A
Socialized Pty Ltd	Body Corporate	Trustee	100%	Australia	Australian	N/A
Market Reach Pty Ltd	Body Corporate	-	100%	Australia	Australian	N/A
Bondi Perfume Company Pty Ltd	Body Corporate	-	100%	Australia	Australian	N/A
CW Hospital Services Pty Ltd	Body Corporate	-	100%	Australia	Australian	N/A
CW Macau Pty Ltd	Body Corporate	-	100%	Australia	Australian	N/A
CW Retail Asia Pty Ltd	Body Corporate	-	100%	Australia	Australian	N/A
Wagner Pharmaceuticals Pty Ltd	Body Corporate	-	100%	Australia	Australian	N/A
Instant Consult Pty Ltd	Body Corporate	-	60%	Australia	Australian	N/A
Optometrist Warehouse Pty Ltd	Body Corporate	-	70%	Australia	Australian	N/A

Sigma Healthcare Limited
Consolidated entity disclosure statement
As at 30 June 2025

Name of entity	Type of entity	Trustee, partner or participant in JV	% of share capital	Country of incorporation	Australian resident or foreign resident	Foreign jurisdiction(s) of foreign residents
Stratosphere Media Agency Pty Ltd	Body Corporate	-	100%	Australia	Australian	N/A
Stratosphere NZ Limited	Body Corporate	-	100%	New Zealand	Australian and Foreign	New Zealand
CW Account Services Pty Ltd	Body Corporate	-	100%	Australia	Australian	N/A
CW Retail Trust	Trust	-	N/A	N/A	Australian	N/A
CW Retail Holdings Trust	Trust	-	N/A	N/A	Australian	N/A
CW Management Trust	Trust	-	N/A	N/A	Australian	N/A
CW Media Trust	Trust	-	N/A	N/A	Australian	N/A
CW Leasing Services Trust	Trust	-	N/A	N/A	Australian	N/A
CW China Trust	Trust	-	N/A	N/A	Australian	N/A
CW Retail Services Trust	Trust	-	N/A	N/A	Australian	N/A
CW Leasing NZ Unit Trust	Trust	-	N/A	N/A	Australian	N/A
CW IP Unit Trust	Trust	-	N/A	N/A	Australian	N/A
ePharmacy Unit Trust	Trust	-	N/A	N/A	Australian	N/A
The Trustee for Socialized Unit Trust	Trust	-	N/A	N/A	Australian	N/A
Chemist Warehouse Limited	Body Corporate	-	100%	New Zealand	Foreign	New Zealand
CW Retail Services (NZ) Pty Ltd	Body Corporate	-	100%	New Zealand	Foreign	New Zealand
Chemist Warehouse Ireland Limited	Body Corporate	-	100%	Ireland	Foreign	Ireland
CWIRE Retail Holdings Limited	Body Corporate	-	70%	Ireland	Foreign	Ireland
CWIRE Retail 1 Limited	Body Corporate	-	70%	Ireland	Foreign	Ireland
CWIRE Retail 2 Limited	Body Corporate	-	70%	Ireland	Foreign	Ireland
CWIRE Retail 3 Limited	Body Corporate	-	70%	Ireland	Foreign	Ireland
CWIRE Retail 4 Limited	Body Corporate	-	70%	Ireland	Foreign	Ireland
CWIRE Retail 5 Limited	Body Corporate	-	70%	Ireland	Foreign	Ireland
CWIRE Retail 6 Limited	Body Corporate	-	70%	Ireland	Foreign	Ireland
CWIRE Retail 7 Limited	Body Corporate	-	70%	Ireland	Foreign	Ireland
CWIRE Retail 8 Limited	Body Corporate	-	70%	Ireland	Foreign	Ireland
CWIRE Retail 9 Limited	Body Corporate	-	70%	Ireland	Foreign	Ireland
CWIRE Retail 10 Limited	Body Corporate	-	70%	Ireland	Foreign	Ireland
CWIRE Retail 11 Limited	Body Corporate	-	70%	Ireland	Foreign	Ireland
CWIRE Retail 12 Limited	Body Corporate	-	70%	Ireland	Foreign	Ireland
CWIRE Retail 13 Limited	Body Corporate	-	70%	Ireland	Foreign	Ireland
CWIRE Retail 14 Limited	Body Corporate	-	70%	Ireland	Foreign	Ireland
CWIRE Retail 15 Limited	Body Corporate	-	70%	Ireland	Foreign	Ireland
CWIRE Retail 16 Limited	Body Corporate	-	70%	Ireland	Foreign	Ireland
CWIRE Retail 17 Limited	Body Corporate	-	70%	Ireland	Foreign	Ireland
CWIRE Retail 18 Limited	Body Corporate	-	70%	Ireland	Foreign	Ireland
CWIRE Retail 19 Limited	Body Corporate	-	70%	Ireland	Foreign	Ireland
CWIRE Retail 20 Limited	Body Corporate	-	70%	Ireland	Foreign	Ireland
CWIRE Retail 21 Limited	Body Corporate	-	70%	Ireland	Foreign	Ireland
CWIRE Retail 22 Limited	Body Corporate	-	70%	Ireland	Foreign	Ireland
CWIRE Retail 23 Limited	Body Corporate	-	70%	Ireland	Foreign	Ireland
CWIRE Retail 24 Limited	Body Corporate	-	70%	Ireland	Foreign	Ireland
CWIRE Retail 25 Limited	Body Corporate	-	70%	Ireland	Foreign	Ireland
CWIRE Retail 26 Limited	Body Corporate	-	70%	Ireland	Foreign	Ireland
CWIRE Retail 27 Limited	Body Corporate	-	70%	Ireland	Foreign	Ireland
CWIRE Retail 28 Limited	Body Corporate	-	70%	Ireland	Foreign	Ireland
CWIRE Retail 29 Limited	Body Corporate	-	70%	Ireland	Foreign	Ireland
CWIRE Retail 30 Limited	Body Corporate	-	70%	Ireland	Foreign	Ireland
CWH Pharmacy LLC	Body Corporate	-	60%	UAE	Foreign	UAE
DPP Pharmaceuticals Trust	Trust	-	N/A	N/A	Australian	N/A
DPP Pharmaceutical Pty Limited	Body Corporate	-	100%	Australia	Australian	N/A
GM Pharma International Pty Limited	Body Corporate	-	100%	Australia	Australian	N/A

Sigma Healthcare Limited
Directors' declaration
30 June 2025

In the directors' opinion:

- (a) the attached financial statements and notes comply with the *Corporations Act 2001*, including:
 - (i) complying with Accounting Standards, the *Corporations Regulations 2001* and other mandatory professional reporting requirements, and
 - (ii) giving a true and fair view of the consolidated entity's financial position as at 30 June 2025 and of its performance for the financial year ended on that date, and
- (b) the financial statements also comply with International Financial Reporting Standards as issued by the International Accounting Standards Board as described in note to the financial statements;
- (c) there are reasonable grounds to believe that the company will be able to pay its debts as and when they become due and payable;
- (d) the consolidated entity disclosure statement is true and correct; and
- (e) at the date of this declaration, there are reasonable grounds to believe that the members of the extended closed Group will be able to meet any liabilities to which they are, or may become, subject by virtue of the deed of cross guarantee described in Note 30 to the financial statements.

This declaration is made in accordance with a resolution of the directors.

On behalf of the directors



Michael Sammells
Chairman



Vikesh Ramsunder
CEO and Managing Director

27 August 2025
Melbourne



Independent auditor's report

To the members of Sigma Healthcare Limited

Report on the audit of the financial report

Our opinion

In our opinion:

The accompanying financial report of Sigma Healthcare Limited (the Company) and its controlled entities (together the Group) is in accordance with the *Corporations Act 2001*, including:

- a. giving a true and fair view of the Group's financial position as at 30 June 2025 and of its financial performance for the year then ended
- b. complying with Australian Accounting Standards and the *Corporations Regulations 2001*.

What we have audited

The financial report comprises:

- the consolidated balance sheet as at 30 June 2025
- the consolidated statement of profit or loss and other comprehensive income for the year then ended
- the consolidated statement of changes in equity for the year then ended
- the consolidated statement of cash flows for the year then ended
- the notes to the consolidated financial statements, including material accounting policy information and other explanatory information
- the consolidated entity disclosure statement as at 30 June 2025
- the directors' declaration.

PricewaterhouseCoopers, ABN 52 780 433 757
2 Riverside Quay, SOUTHBANK VIC 3006,
GPO Box 1331, MELBOURNE VIC 3001
T: 61 3 8603 1000, F: 61 3 8603 1999, www.pwc.com.au



Basis for opinion

We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those standards are further described in the *Auditor's responsibilities for the audit of the financial report* section of our report.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Independence

We are independent of the Group in accordance with the auditor independence requirements of the *Corporations Act 2001* and the ethical requirements of the Accounting Professional & Ethical Standards Board's APES 110 *Code of Ethics for Professional Accountants (including Independence Standards)* (the Code) that are relevant to our audit of the financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

Our audit approach

An audit is designed to provide reasonable assurance about whether the financial report is free from material misstatement. Misstatements may arise due to fraud or error. They are considered material if individually or in aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the financial report.

We tailored the scope of our audit to ensure that we performed enough work to be able to give an opinion on the financial report as a whole, taking into account the geographic and management structure of the Group, its accounting processes and controls and the industry in which it operates.

Audit Scope

Our audit focused on where the Group made subjective judgements; for example, significant accounting estimates involving assumptions and inherently uncertain future events.

In establishing the overall approach to the group audit, we determined the type of work that needed to be performed by us, as the group auditor.

Key audit matters

Key audit matters are those matters that, in our professional judgement, were of most significance in our audit of the financial report for the current period. The key audit matters were addressed in the context of our audit of the financial report as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. Further, any commentary on the outcomes of a particular audit procedure is made in that context. We communicated the key audit matters to the Audit Committee.

<i>Key audit matter</i>	<i>How our audit addressed the key audit matter</i>
<p>Business combination accounting for Sigma Healthcare Limited</p> <p>(Refer to note 25(a))</p> <p>On 12 February 2025, Sigma Healthcare Limited (“Sigma”) acquired 100% of the issued shares in CW Group Holdings Limited (“Chemist Warehouse”) with the implementation of the scheme of arrangement being completed.</p> <p>The legal acquisition by Sigma of Chemist Warehouse is a reverse acquisition under AASB 3 <i>Business Combinations</i>.</p> <p>We considered this a key audit matter because it was a significant transaction in the year and there is judgement involved in determining the fair value of assets acquired.</p>	<p>We performed the following procedures, amongst others:</p> <ul style="list-style-type: none"> • Developed an understanding of the transaction by reading the Prospectus issued to the shareholders of Sigma. • Assessed the appropriateness of the criteria used to determine the accounting acquirer and evaluated the Group’s accounting treatment as a reverse acquisition against Australian Accounting Standards. • Tested the fair value of the purchase consideration with reference to the share price for Sigma at the acquisition date. • Evaluated the identification of the assets acquired and liabilities assumed against the requirements of Australian Accounting Standards. • Assessed the fair values of brand names recognised, with the support of PwC Valuation experts, by considering the appropriateness of the valuation methodology and assessing the significant assumptions, including royalty rates used in estimating the fair values. • Evaluated the reasonableness of disclosures in the financial report in light of the requirements of Australian Accounting Standards.

Key audit matter

How our audit addressed the key audit matter

Carrying value of goodwill and intangible assets

(Refer to note 12)

At 30 June 2025, the Group has recognised goodwill and intangible assets.

The goodwill and intangibles assets are allocated to the Australian Healthcare cash generating unit (“CGU”).

The Group performed an impairment assessment for the CGU, by preparing a value-in-use impairment model to determine if the carrying amount of the CGU is supported.

We considered this a key matter given the financial significance of the balance and significant level of judgement and estimate involved in determining the value in use for the CGU.

We performed the following procedures, amongst others:

- Assessed whether the allocation of the Group’s goodwill and intangible assets to the Australian Healthcare CGU was consistent with our knowledge of the Group’s operations and internal Group reporting.
- Assessed whether the CGU appropriately included the assets, liabilities and cash flows directly attributable to the CGU.
- Assessed significant assumptions within the model for appropriateness, with reference to the board approved budget for FY26 and historical growth rates.
- Tested the mathematical accuracy of key data included in the impairment model calculation.
- Evaluated the appropriateness of the discount rate and long-term growth rate assumptions in the model, with the support of PwC Valuation experts, by comparing them to market observable inputs.
- Evaluated the reasonableness of disclosures in the financial report in light of the requirements of Australian Accounting Standards.

Related Party transactions

(Refer to note 32)

The Group engaged in significant transactions with related parties, including the sale of goods and services, purchases, and lease arrangements during the year ended 30 June 2025.

This was considered a key audit matter due to the significance of related party transactions to the financial report, including the relevant disclosures required by Australian Accounting Standards.

We performed the following procedures, amongst others:

- Assessed the design and implementation of key controls for identifying related parties and related party transactions, including review of board minutes for the Related Party Independent Board Committee.
- Assessed the identification of related parties by understanding the nature of related parties, the Group’s structure and the Group’s assessment of Key Management Personnel.

Key audit matter**How our audit addressed the key audit matter**

- Considered third party external information to assess the completeness of related parties and the identification of all entities and franchisee agreements with related parties.
- On a sample basis, tested the accuracy and completeness of the underlying related party transactions to supporting documentation, including sales invoices.
- On a sample basis, reviewed lease agreements to assess the completeness of related party transactions.
- Evaluated the reasonableness of the disclosures in the financial report in light of the requirements of Australian Accounting Standards.

Other information

The directors are responsible for the other information. The other information comprises the information included in the annual report for the year ended 30 June 2025, but does not include the financial report and our auditor's report thereon. Prior to the date of this auditor's report, the other information we obtained included the Directors report. We expect the remaining other information to be made available to us after the date of this auditor's report.

Our opinion on the financial report does not cover the other information and we do not and will not express an opinion or any form of assurance conclusion thereon through our opinion on the financial report. We have issued a separate opinion on the remuneration report.

In connection with our audit of the financial report, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial report or our knowledge obtained in the audit, or otherwise appears to be materially misstated.

If, based on the work we have performed on the other information that we obtained prior to the date of this auditor's report, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.



When we read the other information not yet received, if we conclude that there is a material misstatement therein, we are required to communicate the matter to the directors and use our professional judgement to determine the appropriate action to take.

Responsibilities of the directors for the financial report

The directors of the Company are responsible for the preparation of the financial report in accordance with Australian Accounting Standards and the *Corporations Act 2001*, including giving a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of the financial report that is free from material misstatement, whether due to fraud or error.

In preparing the financial report, the directors are responsible for assessing the ability of the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the Group or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial report

Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Australian Auditing Standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the financial report.

A further description of our responsibilities for the audit of the financial report is located at the Auditing and Assurance Standards Board website at: https://auasb.gov.au/media/bwvjcgre/ar1_2024.pdf. This description forms part of our auditor's report.

Report on the remuneration report

Our opinion on the remuneration report

We have audited the remuneration report included in the directors' report for the year ended 30 June 2025.



In our opinion, the remuneration report of Sigma Healthcare Limited for the year ended 30 June 2025 complies with section 300A of the *Corporations Act 2001*.

Responsibilities

The directors of the Company are responsible for the preparation and presentation of the remuneration report in accordance with section 300A of the *Corporations Act 2001*. Our responsibility is to express an opinion on the remuneration report, based on our audit conducted in accordance with Australian Auditing Standards.

Emphasis of matter: Basis of preparation of the Remuneration Report

We draw attention to Section 1 of the Remuneration Report, which describes the Basis of Preparation for the disclosures of Key Management Personnel included in the Remuneration Report. Our opinion is not modified in respect of this matter

A handwritten signature in black ink that reads 'PricewaterhouseCoopers'.

PricewaterhouseCoopers

A handwritten signature in black ink that reads 'Alison Tait Milner'.

Alison Tait Milner
Partner

Melbourne
27 August 2025